Naphthyl-substituted pyrido[4,3-d]pyrimidines and related compounds and their use in treating medical conditions

Naphthyl-substituted pyrido[4,3-d]pyrimidines and related compounds are developed to inhibit K-Ras activity, addressing the ineffectiveness of current cancer treatments by targeting mutant K-Ras proteins, providing a therapeutic benefit for cancer treatment with potential reduced side effects.

WO2024243025A1PCT designated stage expired Publication Date: 2024-11-28IKENA ONCOLOGY INC

Patent Information

Application Number
PCT/US2024/029910
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-09-21
Filing Date
2024-05-17
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current cancer treatments for solid tumors, such as breast, lung, and pancreatic cancer, are not effective for all patients and often come with significant adverse side effects, and there is a need for new therapies that can inhibit K-Ras activity to address the progression of these cancers.

Method used

Development of naphthyl-substituted pyrido[4,3-d]pyrimidines and related compounds that can inhibit K-Ras activity, including specific compounds represented by Formulas (I) and (I-1), which can be used in pharmaceutical compositions to treat medical disorders like cancer by administering a therapeutically effective amount to a subject in need.

Benefits of technology

The compounds effectively inhibit K-Ras activity, providing a therapeutic benefit for cancer treatment by targeting mutant forms of K-Ras proteins, such as K-Ras G12V, G12D, G12A, G12C, G12R, G12S, and Q61H, potentially offering a more effective and less toxic alternative to existing cancer therapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000003_0001
    Figure IMGF000003_0001
  • Figure IMGF000003_0002
    Figure IMGF000003_0002
  • Figure IMGF000006_0001
    Figure IMGF000006_0001
Patent Text Reader

Abstract

The disclosure provides naphthyl-substituted pyrido[4,3-d]pyrimidines and related compounds, pharmaceutical compositions, their use for inhibiting K-Ras activity and their use in the treatment of medical disorders, such as cancer.
Need to check novelty before this filing date? Find Prior Art

Description

NAPHTHYL-SUBSTITUTED PYRIDO[4,3-D]PYRIMIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONSCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of and priority to United States Provisional Patent Application serial number 63 / 467,764, filed May 19, 2023 and United States Provisional Patent Application serial number 63 / 539,701, filed September 21, 2023; the contents of each of which are hereby incorporated by reference in their entirety.FIELD

[0002] The disclosure provides naphthyl-substituted pyrido[4,3-d]pyrimidines and related compounds, pharmaceutical compositions, their use for inhibiting K-Ras activity and their use in the treatment of medical disorders, such as cancer.BACKGROUND

[0003] Cancer continues to be a significant health problem despite the substantial research efforts and scientific advances reported in the literature for treating this disease. Solid tumors, including breast cancer, lung cancer, and pancreatic cancer remain prevalent among the world population. Current treatment options for these cancers are not effective for all patients and / or can have substantial adverse side effects. New therapies are needed to address this unmet need in cancer therapy.

[0004] Kirsten rat sarcoma 2 Viral Oncogene Homolog (K-Ras) is a GTPase that has been reported to impact cell survival, proliferation, migration, and differentiation. Evidence suggests that activating mutations of K-Ras (for example, K-Ras G12D or K-Ras G12V) may be involved in the onset and progression of multiple cancers, and that inhibition of such mutant K-Ras proteins may provide a therapeutic benefit for cancer.

[0005] New compounds having inhibitory activity toward K-Ras are therefore needed as therapeutic agents for the treatment of medical disorders, such as cancer. The present disclosure addresses the foregoing needs and provides other related advantages.SUMMARY

[0006] The disclosure provides naphthyl-substituted pyrido[4,3-d]pyrimidines and related compounds, pharmaceutical compositions, their use for inhibiting K-Ras activity and their use in the treatment of medical disorders, such as cancer. In particular, one aspect of the disclosure provides a collection of naphthyl-substituted pyrido[4,3-d ]pyrimidines and related compounds, such as a compound represented by Formula (I):or a pharmaceutically acceptable salt thereof, where the variables are as defined in the detailed description. Another aspect of the disclosure provides a collection of naphthyl-substituted pyrido[4,3-d ]pyrimidines and related compounds, such as a compound represented by Formula (I- 1):or a pharmaceutically acceptable salt thereof, where the variables are as defined in the detailed description. Further description of additional collections of naphthyl-substituted pyrido[4,3- d]pyrimidines and related compounds are described in the detailed description. The compounds may be part of a pharmaceutical composition comprising a pharmaceutically acceptable carrier.

[0007] Another aspect of the disclosure provides a method of treating a disorder mediated by K-Ras. The method comprises administering a therapeutically effective amount of a compound described herein, such as a compound of Formula (I) or Formula (1-1), to a subject in need thereof to treat the disorder, as further described in the detailed description. In certain embodiments, theK-Ras is K-Ras G12V, K-Ras G12D, K-Ras G12A, K-Ras G12C, K-Ras G12R, K-Ras G12S, and / or K-Ras Q61H.

[0008] Another aspect of the disclosure provides a method of inhibiting K-Ras activity. The method comprises contacting K-Ras with an effective amount of a compound described herein, such as a compound of Formula (I) or Formula (I- 1 ), to inhibit K-Ras activity, as further described in the detailed description. In certain embodiments, the K-Ras is K-Ras G12V, K-Ras G12D, K- Ras G12A, K-Ras G12C, K-Ras G12R, K-Ras G12S, and / or K-Ras Q61H.DETAILED DESCRIPTION

[0009] The disclosure provides naphthyl-substituted pyrido[4,3-d]pyrimidines and related compounds, pharmaceutical compositions, their use for inhibiting K-Ras activity (such as wild type K-Ras or mutated forms of K-Ras, for example, K-Ras G12V, K-Ras G12D, K-Ras G12A, K-Ras G12C, K-Ras G12R, K-Ras G12S, and / or K-Ras Q61H) and their use in the treatment of medical disorders, such as cancer. The practice of the present disclosure employs, unless otherwise indicated, conventional techniques of organic chemistry, pharmacology, molecular biology (including recombinant techniques), cell biology, biochemistry, and immunology. Such techniques are explained in the literature, such as in “Comprehensive Organic Synthesis” (B.M. Trost & I. Fleming, eds., 1991-1992); “Handbook of experimental immunology” (D.M. Weir & C.C. Blackwell, eds.); “Current protocols in molecular biology” (F.M. Ausubel etal., eds., 1987, and periodic updates); and “Current protocols in immunology” (J.E. Coligan et al., eds., 1991), each of which is herein incorporated by reference in its entirety.

[0010] Various aspects of the disclosure are set forth below in sections; however, aspects of the disclosure described in one particular section are not to be limited to any particular section. Further, when a variable is not accompanied by a definition, the previous definition of the variable controls.Definitions

[0011] Compounds of the present disclosure include those described generally herein, and are further illustrated by the classes, subclasses, and species disclosed herein. As used herein, the following definitions shall apply unless otherwise indicated. These definitions apply regardless of whether a term is used by itself or in combination with other terms, unless otherwise indicated.Hence, the definition of “alkyl” applies to “alkyl” as well as the “alkyl” portions of “-O-alkyl” etc. For purposes of this disclosure, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75thEd. Additionally, general principles of organic chemistry are described in “Organic Chemistry”, Thomas Sorrell, University Science Books, Sausalito: 1999, and “March’s Advanced Organic Chemistry”, 5thEd., Ed.: Smith, M.B. and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.

[0012] The term “aliphatic” or “aliphatic group”, as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as “cycloaliphatic”), that has a single point of attachment to the rest of the molecule. Unless otherwise specified, aliphatic groups contain 1-6 aliphatic carbon atoms. In certain embodiments, aliphatic groups contain 1-5 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms. In certain embodiments, “cycloaliphatic” refers to a monocyclic C3-6 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.

[0013] As used herein, the term “bicyclic ring” or “bicyclic ring system” refers to any bicyclic ring system, i.e., carbocyclic or heterocyclic, saturated or having one or more units of unsaturation, having one or more atoms in common between the two rings of the ring system. Thus, the term includes any permissible ring fusion, such as ortho -fused or spirocyclic. As used herein, the term “heterobicyclic” is a subset of “bicyclic” that requires that one or more heteroatoms are present in one or both rings of the bicycle. Such heteroatoms may be present at ring junctions and are optionally substituted, and may be selected from nitrogen (including N-oxides), oxygen, sulfur (including oxidized forms such as sulfones and sulfonates), phosphorus (including oxidized forms such as phosphates), boron, etc. In certain embodiments, a bicyclic group has 7-12 ring membersand 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. As used herein, the term “bridged bicyclic” refers to any bicyclic ring system, i.e., carbocyclic or heterocyclic, saturated or partially unsaturated, having at least one bridge. As defined by IUPAC, a “bridge” is an unbranched chain of atoms or an atom or a valence bond connecting two bridgeheads, where a “bridgehead” is any skeletal atom of the ring system which is bonded to three or more skeletal atoms (excluding hydrogen). In certain embodiments, a bridged bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Such bridged bicyclic groups are well known in the art and include those groups set forth below where each group is attached to the rest of the molecule at any substitutable carbon or nitrogen atom. Unless otherwise specified, a bridged bicyclic group is optionally substituted with one or more substituents as set forth for aliphatic groups. Additionally or alternatively, any substitutable nitrogen of a bridged bicyclic group is optionally substituted. Exemplary bicyclic rings include:

[0014] Exemplary bridged bicyclics include:

[0015] The term “lower alkyl” refers to a C1-4straight or branched alkyl group. Exemplary lower alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl.

[0016] The term “lower haloalkyl” refers to a C1-4straight or branched alkyl group that is substituted with one or more halogen atoms.

[0017] The term “heteroatom” means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2H -pyrrolyl), NH (as in pyrrolidinyl) or NR+(as in N-substituted pyrrolidinyl)).

[0018] The term “unsaturated,” as used herein, means that a moiety has one or more units of unsaturation.

[0019] As used herein, the term “bivalent C1-8(or C1-6) saturated or unsaturated, straight or branched, hydrocarbon chain”, refers to bivalent alkylene, alkenylene, and alkynylene chains that are straight or branched as defined herein.

[0020] The term “alkylene” refers to a bivalent alkyl group. An “alkylene chain” is a polymethylene group, i.e., -(CH2)n- wherein n is a positive integer, preferably from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3. A substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.

[0021] The term “-(Co alkylene)-" refers to a bond. Accordingly, the term “-(C0-3 alkylene)-” encompasses a bond (i.e., Co) and a -(C1.3 alkylene)- group.

[0022] The term “alkenylene” refers to a bivalent alkenyl group. A substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.

[0023] The terms “halogen” or “halo” means F, Cl, Br, or I.

[0024] The term “aryl” used alone or as part of a larger moiety as in “aralkyl,” “aralkoxy,” or “aryloxyalkyl,” refers to monocyclic or bicyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. The term “aryl” may be used interchangeably with the term “aryl ring.” In certain embodiments of the present disclosure, “aryl” refers to an aromatic ring system which includes, but not limited to, phenyl, biphenyl, naphthyl, anthracyl and the like, which may bear one or more substituents. Also included within the scope of the term “aryl,” as it is used herein, is a group in which an aromatic ring is fused to one or more non-aromatic rings, such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, and the like. The term “phenylene” refers to a multivalent phenyl group having the appropriate number of open valences to account for groups attached to it. For example, “phenylene” is a bivalent phenyl group

[0025] The terms “heteroaryl” and “heteroar-,” used alone or as part of a larger moiety, e.g., “heteroaralkyl,” or “heteroaralkoxy,” refer to groups having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 π electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms. The term “heteroatom” refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen. Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. The terms “heteroaryl” and “heteroar-”, as used herein, also include groups in which aheteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where unless otherwise specified, the radical or point of attachment is on the heteroaromatic ring or on one of the rings to which the heteroaromatic ring is fused. Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H- quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, and tetrahydroisoquinolinyl. A heteroaryl group may be mono- or bicyclic. The term “heteroaryl” may be used interchangeably with the terms “heteroaryl ring,” “heteroaryl group,” or “heteroaromatic,” any of which terms include rings that are optionally substituted. The term “heteroaralkyl” refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted.

[0026] The term “heteroarylene” refers to a multivalent heteroaryl group having the appropriate number of open valences to account for groups attached to it. For example, “heteroarylene” is a bivalent heteroaryl group when it has two groups attached to it; “heteroarylene” is a trivalent heteroaryl group when it has three groups attached to it. The term “pyridinylene” refers to a multivalent pyridine radical having the appropriate number of open valences to account for groups attached to it. For example, “pyridinylene” is a bivalent pyridine radical when it has two groups attached to it (e.g., “pyridinylene” is a trivalent pyridine radical when it has three groups attached t

[0027] As used herein, the terms “heterocycle,” “heterocyclyl,” “heterocyclic radical,” and “heterocyclic ring” are used interchangeably and refer to a stable 5- to 7-membered monocyclic or 7-10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above. When used in reference to a ring atom of a heterocycle, the term "nitrogen" includes a substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro- 2H- pyrrol y I), NH (as in pyrrolidinyl), or+NR (as in N substituted pyrrolidinyl).

[0028] A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, 2-oxa-6- azaspiro[3.3]heptane, and quinuclidinyl. The terms “heterocycle,” “heterocyclyl,” “heterocyclyl ring,” “heterocyclic group,” “heterocyclic moiety,” and “heterocyclic radical,” are used interchangeably herein, and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl, 3H indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl. A heterocyclyl group may be mono- or bicyclic. The term “heterocyclyl alkyl” refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted. The term “oxo-heterocyclyl” refers to a heterocyclyl substituted by an oxo group. The term “heterocyclylene” refers to a multivalent heterocyclyl group having the appropriate number of open valences to account for groups attached to it. For example, “heterocyclylene” is a bivalent heterocyclyl group when it has two groups attached to it; “heterocyclylene” is a trivalent heterocyclyl group when it has three groups attached to it.

[0029] As used herein, the term “partially unsaturated” refers to a ring moiety that includes at least one double or triple bond. The term “partially unsaturated” is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined.

[0030] As described herein, compounds of the disclosure may contain “optionally substituted” moieties. In general, the term “substituted,” whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. Unless otherwise indicated, an “optionally substituted” group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned by this disclosure are preferably those that result in the formation of stable or chemically feasible compounds. The term “stable,” as used herein, refers to compounds that are not substantiallyaltered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.

[0031] Each optional substituent on a substitutable carbon is a monovalent substituent independently selected from halogen; -(CH2)0-4R°; -(CH2)0-4OR°; -O(CH2)0-4R°, -O-(CH2)0-44C(O)OR°; -(CH2)0-4CH(OR°)2; -(CH2)0-4SR°; -(CH2)0-4Ph, which may be substituted with R°; -(CH2)0-4O(CH2)0-1Ph which may be substituted with R°; -CH=CHPh, which may be substituted with R°; -(CH2)0-4O(CH2)0-1-pyridyl which may be substituted with R°; -NO2; -CN; - N3; -(CH2)0-4N(R°)2; -(CH2)0-4N(R°)C(O)R°; -N(R°)C(S)R°; -(CH2)0-4N(R°)C(O)NR°2; -N(R°)C(S)NRº2; -(CH2)0-4N(R°)C(O)OR°; -N(R°)N(R°)C(O)R°; -N(R°)N(R°)C(0)NR°2; -N(R°)N(R°)C(O)OR°; -(CH2)0-4C(O)R°; -C(S)R°; -(CH2)0-4C(O)OR°; -(CH2)0-4C(O)SR°; -(CH2)o 4C(O)OSiR°3; -(CH2)0-4OC(O)R°; -OC(0)(CH2)0-4SR- SC(S)SR°; -(CH2)0-4SC(O)R°; -(CH2)0-4C(O)NR°2; -C(S)NR°2; -C(S)SR°; -SC(S)SR°, -(CH2)0-4OC(O)NR°2; -C(O)N(OR°)R°; -C(O)C(O)R°; -C(O)CH2C(O)R°; -C(NOR°)R°; -(CH2)0-4SSR°; -(CH2)o-4S(O)2R°; -(CH2)0-4S(O)2OR°; -(CH2)0-4OS(O)2R°; -S(O)2NR°2; -S(O)(NR°)R°; - S(O)2N=C(NR°2)2; -(CH2)0-4S(O)R°; -N(R°)S(O)2NR°2; -N(R°)S(O)2R°; -N(OR°)R°; - C(NH)NR°2; -P(O)2R°; -P(O)R°2; -OP(O)R°2; -OP(O)(OR°)2; SiR°3; -(C1-4straight or branched alkylene)O-N(R°)2; or -(C1-4 straight or branched alkylene)C(O)O-N(R°)2.

[0032] Each R° is independently hydrogen, C1-6 aliphatic, -CH2PI1, -0(CH2)o iPh, -CH2-(5-6 membered heteroaryl ring), or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R°, taken together with their intervening atom(s), form a 3-12-membered saturated, partially unsaturated, or aryl mono- or bicyclic ring having 0- 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, which may be substituted by a divalent substituent on a saturated carbon atom of R° selected from =0 and =S; or each R° is optionally substituted with a monovalent substituent independently selected from halogen, - (CH2)0-2R., -(haloR*), -(CH2)0-2OH, -(CH2)0-2OR*, -(CH2)0-2CH(OR*)2; -O(haloR*), -CN, -N3, -(CH2)0-2C(O)R*, -(CH2)0-2C(O)OH, -(CH2)0-2C(O)OR*, -(CH2)0-2SR*, -(CH2)0-2SH, -(CH2)0-2NH2, -(CH2)0-2NHR", -(CH2)0-2NR*2, -NO2, -SiR’3, -OSiR’3, -C(O)SR* -(C1-4straight or branched alkylene)C(O)OR*, or -SSR*.

[0033] Each R" is independently selected from C1-4 aliphatic, -CH2Ph, -0(CH2)o-iPh, or a 5- 6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein each R" is unsubstituted or where preceded by halo is substituted only with one or more halogens; or wherein an optional substituent on a saturated carbon is a divalent substituent independently selected from =0, =S, =NNR*2, =NNHC(0)R*, =NNHC(0)0R*, =NNHS(O)2R*, =NR*, =N0R*, -O(C(R*2))2-3O-, or - S(C(R*2))2-3S-, or a divalent substituent bound to vicinal substitutable carbons of an “optionally substituted” group is -O(CR*2)2-3O-, wherein each independent occurrence of R is selected from hydrogen, C1-6 aliphatic or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0034] When R* is C1-6 aliphatic, R* is optionally substituted with halogen, - R", -(haloR"), -OH, -OR", -O(haloR"), -CN, -C(O)OH, -C(O)OR", -NH2, -NHR", -NR"2, or - NO2, wherein each R" is independently selected from C1-4aliphatic, -CH2Ph, -0(CH2)o iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein each R" is unsubstituted or where preceded by halo is substituted only with one or more halogens.

[0035] An optional substituent on a substitutable nitrogen is independently -R\ -NR'2, -C(NH)NR'2, or -N(R^)S(O)2R^; wherein each R' is independently hydrogen, C1-6 aliphatic, unsubstituted -OPh, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, two independent occurrences of R+, taken together with their intervening atom(s) form an unsubstituted 3-12-membered saturated, partially unsaturated, or aryl mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein when R1” is C1-6 aliphatic, R:is optionally substituted with halogen, -R", -(haloR*), -OH, -OR", -O(haloR"), - CN, -C(O)OH, -C(O)OR", -NH2, -NHR", -NR*2, or -NO2, wherein each R" is independently selected from C1-4aliphatic, -CH2Ph, -0(CH2)0-1Ph, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein each R" is unsubstituted or where preceded by halo is substituted only with one or more halogens.

[0036] As used herein, the term "pharmaceutically acceptable salt" refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in Journal of Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of this disclosure include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphor sulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2- hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like.

[0037] Further, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl et al., Camille G. (eds.) Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley-VCH; S. Berge et al. , Journal of Pharmaceutical Sciences (1977) 66(1) 1-19; P. Gould, International Journal of Pharmaceutics (1986) 33 201-217; Anderson et al., The Practice of Medicinal Chemistry (1996), Academic Press, New York; and in The Orange Book (Food & Drug Administration, Washington, D.C. on their website). These disclosures are incorporated herein by reference.

[0038] Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N (C1-4al k yl )4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceuticallyacceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.

[0039] Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the disclosure. Unless otherwise stated, all tautomeric forms of the compounds of the disclosure are within the scope of the disclosure. The invention includes compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures including the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a13C- or14C-enriched carbon are within the scope of this disclosure. Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents in accordance with the present disclosure.

[0040] Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known to those skilled in the art, such as, for example, by chromatography and / or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher’s acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Alternatively, a particular enantiomer of a compound of the present disclosure may be prepared by asymmetric synthesis. Still further, where the molecule contains a basic functional group (such as amino) or an acidic functional group (such as carboxylic acid) diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means known in the art, and subsequent recovery of the pure enantiomers.

[0041] Individual stereoisomers of the compounds of the disclosure may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. Chiral center(s) in a compound of the present disclosure can havethe S or R configuration as defined by the IUPAC 1974 Recommendations. Further, to the extent a compound described herein may exist as an atropisomer (e.g., substituted biaryls), all forms of such atropisomer are considered part of this disclosure.

[0042] Chemical names, common names, and chemical structures may be used interchangeably to describe the same structure. If a chemical compound is referred to using both a chemical structure and a chemical name, and an ambiguity exists between the structure and the name, the structure predominates. It should also be noted that any carbon as well as heteroatom with unsatisfied valences in the text, schemes, examples and tables herein is assumed to have the sufficient number of hydrogen atom(s) to satisfy the valences.

[0043] The terms “a” and “an” as used herein mean “one or more” and include the plural unless the context is inappropriate.

[0044] The term “alkyl” refers to a saturated straight or branched hydrocarbon, such as a straight or branched group of 1-12, 1-10, or 1-6 carbon atoms, referred to herein as C1-12 alkyl, C1- 10 alkyl, and C1-6 alkyl, respectively. Exemplary alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl-l -propyl, 2-methyl-2-propyl, 2-methyl-l -butyl, 3- m ethyl- 1 -butyl, 2-methyl-3 -butyl, 2,2-dimethyl-l -propyl, 2-methyl-l -pentyl, 3 -methyl- 1 -pentyl, 4-methyl-l -pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-l- butyl, 3,3-dimethyl-l -butyl, 2-ethyl-l -butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, etc.

[0045] The term “cycloalkyl” refers to a monovalent saturated cyclic, bicyclic, or bridged cyclic (e.g., adamantyl) hydrocarbon group of 3-12, 3-8, 4-8, or 4-6 carbons, referred to herein, e.g., as “C3-C6 cycloalkyl,” derived from a cycloalkane. Exemplary cycloalkyl groups include cyclohexyl, cyclopentyl, cyclobutyl, and cyclopropyl. The term “cycloalkylene” refers to a bivalent cycloalkyl group.

[0046] The term “haloalkyl” refers to an alkyl group that is substituted with at least one halogen. Exemplary haloalkyl groups include -CH2F, -CHF2, -CF3, -CH2CF3, -CF2CF3, and the like. The term “haloalkylene” refers to a bivalent haloalkyl group.

[0047] The term “hydroxy alkyl” refers to an alkyl group that is substituted with at least one hydroxyl. Exemplary hydroxyalkyl groups include -CH2CH2OH, -C(H)(OH)CH3, -CH2C(H)(OH)CH2CH2OH, and the like.

[0048] The terms “alkenyl” and “alkynyl” are art-recognized and refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond respectively.

[0049] The term “carbocyclylene” refers to a multivalent carbocyclyl group having the appropriate number of open valences to account for groups attached to it. For example, “carbocyclylene” is a bivalent carbocyclyl group when it has two groups attached to it; “carbocyclylene” is a trivalent carbocyclyl group when it has three groups attached to it.

[0050] The terms “alkoxyl” or “alkoxy” are art-recognized and refer to an alkyl group, as defined above, having an oxygen radical attached thereto. Representative alkoxyl groups include methoxy, ethoxy, propyloxy, tery-butoxy and the like. The term “haloalkoxyl” refers to an alkoxyl group that is substituted with at least one halogen. Exemplary haloalkoxyl groups include - OCH2F, -OCHF2, -OCF3, -OCH2CF3, -OCF2CF3, and the like. The term “hydroxyalkoxyl” refers to an alkoxyl group that is substituted with at least one hydroxyl. Exemplary hydroxyalkoxyl groups include -OCH2CH2OH, -OCH2C(H)(OH)CH2CH2OH, and the like. The term “alkoxyl ene” refers to a bivalent alkoxyl group.

[0051] The term “oxo” is art-recognized and refers to a “=O” substituent. For example, a cyclopentane susbsituted with an oxo group is cyclopentanone.

[0052] The symbol “ '≈ ” indicates a point of attachment.

[0053] When a chemical structure containing a ring is depicted with a substituent having a bond that crosses a ring bond, the substituent may be attached at any available position on the ring. For example, the chemical structure encompasses , andIn the context of a polycyclic fused ring, when a chemical structure containing a polycyclic fused ring is depicted with one or more substituent(s) having a bond that crosses multiple rings, the one or more substituent(s) may be independently attached to any of the ringscrossed by the bond. To illustrate, the chemical structureencompasses, for

[0054] When any substituent or variable occurs more than one time in any constituent or the compound of the disclosure, its definition on each occurrence is independent of its definition at every other occurrence, unless otherwise indicated.

[0055] One or more compounds of the disclosure may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the disclosure embrace both solvated and unsolvated forms. “Solvate” means a physical association of a compound of this disclosure with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances, the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. “Solvate” encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. “Hydrate” is a solvate wherein the solvent molecule is H2O.

[0056] As used herein, the terms “subject” and “patient” are used interchangeably and refer to organisms to be treated by the methods of the present disclosure. Such organisms preferably include, but are not limited to, mammals (e.g., murines, simians, equines, bovines, porcines, canines, felines, and the like), and, most preferably, includes humans.

[0057] The term “IC50” is art-recognized and refers to the concentration of a compound that is required to achieve 50% inhibition of the target. The potency of an inhibitor is usually defined by its IC50 value. The lower the IC50 value the greater the potency of the antagonist and the lower the concentration that is required to inhibit the maximum biological response. In certain embodiments, an inhibitor has an IC50 and / or binding constant of less than about 100 μM, less than about 50 μM, less than about 1 μM, less than about 500 nM, less than about 100 nM, less than about 10 nM, or less than about 1 nM.

[0058] As used herein, “K-Ras” refers to a mammalian K-Ras protein. The assignment of amino acid codon and residue positions for human K-Ras is based on the amino acid sequence identified by UniProtKB / Swiss-Prot P01116.

[0059] As used herein, “K-Ras G12V” refers to a mutant form of a mammalian K-Ras protein that contains an amino acid substitution of a valine, instead of a glycine, at amino acid position 12. The assignment of amino acid codon and residue positions for human K-Ras is based on the amino acid sequence identified by UniProtKB / Swiss-Prot P01116: Variantp.Gly 12Val.

[0060] As used herein, “K-Ras G12D” refers to a mutant form of a mammalian K-Ras protein that contains an amino acid substitution of an aspartic acid, instead of a glycine, at amino acid position 12. The assignment of amino acid codon and residue positions for human K-Ras is based on the amino acid sequence identified by UniProtKB / Swiss-Prot P01116: Variantp.Gly 12 Asp.

[0061] As used herein, “K-Ras G12A” refers to a mutant form of a mammalian K-Ras protein that contains an amino acid substitution of an alanine, instead of a glycine, at amino acid position 12. The assignment of amino acid codon and residue positions for human K-Ras is based on the amino acid sequence identified by UniProtKB / Swiss-Prot P01116: Variantp.Gly 12Ala.

[0062] As used herein, “K-Ras G12C” refers to a mutant form of a mammalian K-Ras protein that contains an amino acid substitution of a cysteine, instead of a glycine, at amino acid position 12. The assignment of amino acid codon and residue positions for human K-Ras is based on the amino acid sequence identified by UniProtKB / Swiss-Prot P01116: Variantp.Gly 12Cys.

[0063] As used herein, “K-Ras G12R” refers to a mutant form of a mammalian K-Ras protein that contains an amino acid substitution of an arginine, instead of a glycine, at amino acid position 12. The assignment of amino acid codon and residue positions for human K-Ras is based on the amino acid sequence identified by UniProtKB / Swiss-Prot P01116: Variantp.Gly 12Arg.

[0064] As used herein, “K-Ras G12S” refers to a mutant form of a mammalian K-Ras protein that contains an amino acid substitution of a serine, instead of a glycine, at amino acid position 12. The assignment of amino acid codon and residue positions for human K-Ras is based on the amino acid sequence identified by UniProtKB / Swiss-Prot P01116: Variantp.Gly 12 Ser.

[0065] As used herein, “K-Ras S61H” refers to a mutant form of a mammalian K-Ras protein that contains an amino acid substitution of an histidine, instead of a serine, at amino acid position61. The assignment of amino acid codon and residue positions for human K-Ras is based on the amino acid sequence identified by UniProtKB / Swiss-Prot P01116: Variantp.Ser61His.

[0066] As used herein, the terms “K-Ras inhibitor” or “K-Ras antagonist” are defined as a compound that binds to and / or inhibits K-Ras with measurable affinity. In certain embodiments, inhibition in the presence of the inhibitor is observed in a dose-dependent manner. In certain embodiments, the measured signal (e.g., signaling activity or biological activity) is at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% lower than the signal measured with a negative control under comparable conditions.

[0067] The terms “measurable affinity” and “measurably inhibit,” as used herein, means a measurable change or inhibiting wild type K-Ras or mutated forms of K-Ras, for example, K-Ras G12V, K-Ras G12D, K-Ras G12A, K-Ras G12C, K-Ras G12R, K-Ras G12S, and / or K-Ras Q61H activity between a sample comprising a compound of the present disclosure, or composition thereof, and K-Ras, such as wild type K-Ras or mutated forms of K-Ras, for example, K-Ras G12V, K-Ras G12D, K-Ras G12A, K-Ras G12C, K-Ras G12R, K-Ras G12S, and / or K-Ras Q61H, and an equivalent sample comprising K-Ras, such as wild type K-Ras or mutated forms of K-Ras, for example, K-Ras G12V, K-Ras G12D, K-Ras G12A, K-Ras G12C, K-Ras G12R, K-Ras G12S, and / or K-Ras Q61H, in the absence of said compound, or composition thereof.

[0068] As used herein, the term “effective amount” refers to the amount of a compound sufficient to effect beneficial or desired results (e.g., a therapeutic, ameliorative, inhibitory, or preventative result). An effective amount can be administered in one or more administrations, applications, or dosages and is not intended to be limited to a particular formulation or administration route.

[0069] As used herein, the term “treating” includes any effect, e.g., lessening, reducing, modulating, ameliorating or eliminating, that results in the improvement of the condition, disease, disorder, and the like, or ameliorating a symptom thereof. In certain embodiments, treatment can be administered after one or more symptoms have developed. In other embodiments, treatmentcan be administered in the absence of symptoms. For example, treatment can be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and / or in light of genetic or other susceptibility factors). Treatment can also be continued after symptoms have resolved, for example, to prevent or delay their recurrence.

[0070] The phrases “disorder mediated by K-Ras” or “disease mediated by K-Ras” or "K-Ras- associated disease or disorder," as used herein, means any disease or other deleterious condition in which K-Ras, or a variant or mutant thereof, is known to play a role. A non-limiting example of a K-Ras-associated disease or disorder is a K-Ras-associated cancer.

[0071] The phrases “disorder mediated by K-Ras G12D” or “disease mediated by K-Ras G12D” or "K-Ras G12D-associated disease or disorder," as used herein, refer to diseases or disorders associated with, or mediated by, or having a K-Ras G12D mutation. A non-limiting example of a K-Ras G12D-associated disease or disorder is a K-Ras G12D-associated cancer.

[0072] The phrases “disorder mediated by K-Ras G12V” or “disease mediated by K-Ras G12V” or "K-Ras G12V-associated disease or disorder," as used herein, refer to diseases or disorders associated with, or mediated by, or having a K-Ras G12V mutation. A non-limiting example of a K-Ras G12V-associated disease or disorder is a K-Ras G12V-associated cancer.

[0073] The phrases “disorder mediated by K-Ras G12A” or “disease mediated by K-Ras G12A” or "K-Ras G12A-associated disease or disorder," as used herein, refer to diseases or disorders associated with, or mediated by, or having a K-Ras G12A mutation. A non-limiting example of a K-Ras G12A-associated disease or disorder is a K-Ras G12A-associated cancer.

[0074] The phrases “disorder mediated by K-Ras G12C” or “disease mediated by K-Ras G12C” or "K-Ras G12C-associated disease or disorder," as used herein, refer to diseases or disorders associated with, or mediated by, or having a K-Ras G12C mutation. A non-limiting example of a K-Ras G12C-associated disease or disorder is a K-Ras G12C-associated cancer.

[0075] The phrases “disorder mediated by K-Ras G12R” or “disease mediated by K-Ras G12R” or "K-Ras G12R-associated disease or disorder," as used herein, refer to diseases or disorders associated with, or mediated by, or having a K-Ras G12R mutation. A non-limiting example of a K-Ras G12R-associated disease or disorder is a K-Ras G12R-associated cancer.

[0076] The phrases “disorder mediated by K-Ras G12S” or “disease mediated by K-Ras G12S” or "K-Ras G12S-associated disease or disorder," as used herein, refer to diseases or disorders associated with, or mediated by, or having a K-Ras G12S mutation. A non-limiting example of a K-Ras G12S-associated disease or disorder is a K-Ras G12S-associated cancer.

[0077] The phrases “disorder mediated by K-Ras Q61H” or “disease mediated by K-Ras Q61H” or "K-Ras Q61H -associated disease or disorder," as used herein, refer to diseases or disorders associated with, or mediated by, or having a K-Ras Q61H mutation. A non-limiting example of a K-Ras Q61H -associated disease or disorder is a K-Ras Q61H -associated cancer.

[0078] As used herein, the term “pharmaceutical composition” refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use in vivo or ex vivo.

[0079] As used herein, the term “pharmaceutically acceptable carrier” refers to any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions (e.g., such as an oil / water or water / oil emulsions), and various types of wetting agents. The compositions also can include stabilizers and preservatives. For examples of carriers, stabilizers and adjuvants, see e.g., Martin, Remington’s Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton, PA

[1975] ,

[0080] For therapeutic use, salts of the compounds of the present disclosure are contemplated as being pharmaceutically acceptable. However, salts of acids and bases that are non- pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound.

[0081] In addition, when a compound of the disclosure contains both a basic moiety (such as, but not limited to, a pyridine or imidazole) and an acidic moiety (such as, but not limited to, a carboxylic acid) zwitterions (“inner salts”) may be formed. Such acidic and basic salts used within the scope of the disclosure are pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts. Such salts of the compounds of the disclosure may be formed, for example, by reacting a compound of the disclosure with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.

[0082] Throughout the description, where compositions are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that, additionally, there are compositions of the present disclosure that consist essentially of, or consist of, the recited components, and that there are processes and methods according to the present disclosure that consist essentially of, or consist of, the recited processing steps.

[0083] As a general matter, compositions specifying a percentage are by weight unless otherwise specified.I. Naphthyl-substituted Pyrido[4,3-d ]pyrimidines and Related Compounds

[0084] The disclosure provides naphthyl-substituted pyrido[4,3-d]pyrimidines and related compounds. The compounds may be used in the pharmaceutical compositions and therapeutic methods described herein. Exemplary compounds are described in the following sections, along with exemplary procedures for making the compounds.

[0085] One aspect of the disclosure provides a compound represented by Formula (I):or a pharmaceutically acceptable salt thereof; wherein:R1is naphthyl; an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl or oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or phenyl; each of which is substituted with m occurrences of R5;R2is a 6-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; phenyl; or C1-6 aliphatic; each of which is substituted with n occurrences of R6; or R2is - N(R8)2or -OR8;R3represents independently for each occurrence hydrogen, halo, or C1-4 alkyl;R5represents independently for each occurrence a 3-6 membered saturated or partially unsaturated heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, C2-6 alkynyl, C2-6 alkenyl, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, hydroxyl, C1-6 alkoxyl, C1-6 haloalkoxyl, halo, -N(R8)2, cyano, - (Co-6 alkylene)-C(O)N(R9)2, -OC(O)-(C1-6 aliphatic substituted with 0 or 1 -N(R9)2), -OC(O)-(3-6 membered heterocycle substituted with 0, 1, or 2 C1-6 alkyl), -S(O)2N(R9)2, -N(R8)C(O)-(CI-6 alkyl), or -N(R8)S(O)2-(C1-6alkyl); wherein said C2-6 alkynyl is substituted with 0 or 1 phenyl or 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and wherein said 5-6 membered heteroaryl is substituted with 0, 1, or 2 C1-6 alkyl;R6and R7each represent independently for each occurrence halo, hydroxyl, C1-6 alkoxyl, C1-6 haloalkoxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, -(C1-6 alkylene)-C1-6 alkoxyl, -(Co- 6 alkylene)-(C3-6 cycloalkyl substituted with 0 or 1 -OR8), -(Co-4 alkylene)-cyano, -(C0-4 alkylene)-S(O)2-(halo), -(Co-4 alkylene)-S(O)2-(C1-6 alkyl), -C(O)OR8, -C(O)R8, -C(O)N(R9)2, optionally substituted 3-6 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or -N(R9)2;R8and R9each represent independently for each occurrence hydrogen, optionally substituted C1-6 alkyl, optionally substituted C3-5 cycloalkyl, optionally substituted 3-6 membered saturated or partially unsaturated heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, aryl, -C(O)H, or -C(O)(C1-4 alkyl); or twooccurrences of R9attached to the same nitrogen atom are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring;A1is one of the following: a. a 3-8 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 6-11 membered saturated or partially unsaturated polycyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein each heterocyclyl is substituted with (i) p occurrences of R7, and (ii) 0, 1, or 2 oxo; and wherein said monocyclic heterocyclyl is substituted with 0 or 1 occurrence of -(C0-4 alkylene)-(5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur) or - (Co-4 alkylene)-phenyl, each of which is optionally substituted; b. C3-10 cycloaliphatic, phenyl, indanyl, a 5- or 6-membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-, 9-, or 10-membered bicyclic heteroaryl having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with p occurrences of R7; and wherein said monocyclic heteroaryl is substituted with 0 or 1 occurrence of -(Co-4 alkylene)-(5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur) or -(Co-4 alkylene)-phenyl, each of which is optionally substituted; c. -CN, -N(R8)2, or hydroxyl; orL1, L2, and L3are independently a covalent bond or a C1-4 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -O-, -N(R9)-, -C(O)-, optionally substitutedC3-5 cycloalkylene, or a 3-6 membered saturated monocyclic heterocyclyl having 1 heteroatom selected from nitrogen, oxygen, and sulfur;X1, X2, X3, X4, and X5each represent independently N or CR3;Y1and Y2represent independently a C1-3 bivalent saturated or unsaturated, straight hydrocarbon chain which is substituted with q occurrences of R7; and m, n, p, and q are each independently 0, 1, 2, 3, or 4.

[0086] The definitions of variables in Formula (I) above encompass multiple chemical groups. The application contemplates embodiments where, for example, i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, ii) the definition of a variable is a collection of two or more of the chemical groups selected from those set forth above, and iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii).

[0087] In certain embodiments, the compound is a compound of Formula (I).

[0088] The definitions of variables in Formula (I) above encompass multiple chemical groups. The application contemplates embodiments where, for example, i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, ii) the definition of a variable is a collection of two or more of the chemical groups selected from those set forth above, and iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii).

[0089] In certain embodiments, the compound is a compound of Formula (I).

[0090] As defined generally above, R1is naphthyl; an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl or oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or phenyl; each of which is substituted with m occurrences of R5.

[0091] In certain embodiments, R1is naphthyl; an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatomsindependently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or phenyl; each of which is substituted with m occurrences of R5.

[0092] In certain embodiments, R1is naphthyl, an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R5. In certain embodiments, R1is phenyl or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R5.

[0093] In certain embodiments, R1is naphthyl or phenyl; each of which is substituted with m occurrences of R5. In certain embodiments, R1is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R5.

[0094] In certain embodiments, R1is naphthyl or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R5. In certain embodiments, R1is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R5.

[0095] In certain embodiments, R1is naphthyl substituted with m occurrences of R5. In certain embodiments, R1is 1 -naphthyl substituted with m occurrences of R5In certain embodiments, R1

[0099] In certain embodiments, R1is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl or oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R5. In certain embodiments, R1is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with m occurrences of R5. In certain embodiments, R1is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen and oxygen; wherein said heterocyclyl is substituted with m occurrences of R5. In certain embodiments, R1is an 8-10 membered saturated or partially unsaturated bicyclic oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said oxo-heterocyclyl is substituted with m occurrences of R5.

[0101] In certain embodiments, R1is an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with m occurrences of R5. In certain embodiments, R1is an 8-10 membered bicyclic heteroaryl having 1 or 2 heteroatoms independently selected from nitrogen and oxygen, and sulfur; wherein said heteroaryl is substituted with m occurrences of R5.

[0102] In certain embodiments, R1is quinolinyl, isoquinolinyl, or indazolyl; each of which is substituted with m occurrences of R5. In certain embodiments, R1is quinolinyl substituted with m occurrences of R In certain embodiments, R1is quinoline-4-yl substituted with m occurrences of R5. In certain embodiments, R1is isoquinolinyl substituted with m occurrences of R5. In certain embodiments, R1is isoquinolin- 1-yl substituted with m occurrences of R5. In certain embodiments, R1is indazolyl substituted with m occurrences of R5.

[0103] In certain embodiments, R1is phenyl substituted with m occurrences of R5. In certain embodiments,certain embodiments,

[0104] In certain embodiments, R1is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with m occurrences of R5. In certain embodiments, R1is a 6-membered monocyclic heteroaryl having 1, 2, or 3 nitrogen atoms; wherein said heteroaryl is substituted with m occurrences of R5In certain embodiments, R1is a 5-membered monocyclic heteroaryl having 1,2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with m occurrences of R5. In certain embodiments, R1is selected from those depicted in the compounds in Table 1, below.

[0105] As defined generally above, R2is a 6-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; phenyl; or C1-6 aliphatic; each of which is substituted with n occurrences of R6; or R2is -N(R8)2or -OR8.

[0106] In certain embodiments, R2is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; phenyl; or C1-6 aliphatic; each of which is substituted with n occurrences of R6.

[0107] In certain embodiments, R2is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with n occurrences of R6. In certain embodiments, R2is phenyl or C1-6 aliphatic; each of which is substituted with n occurrences of R6.

[0108] In certain embodiments, R2is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with n occurrences of R6; or R2is -N(R8)2. In certain embodiments, R2is an 8-10 membered saturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 3-7 membered saturated monocyclic heterocyclyl having1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with n occurrences of R6; or R2is -N(R8)2.

[0109] In certain embodiments, R2is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with n occurrences of R6. In certain embodiments, R2is an 8-10 membered saturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 3-7 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with n occurrences of R6. In certain embodiments, R2is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with n occurrences of R6.

[0110] In certain embodiments, R2is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; phenyl; or C1-6 aliphatic; each of which is substituted with n occurrences of R6. In certain embodiments, R2is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or C1-6 aliphatic; each of which is substituted with n occurrences of R6. In certain embodiments, R2is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or phenyl; each of which is substituted with n occurrences of R6.

[0111] In certain embodiments, R2is a 6-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R6. In certain embodiments, R2is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R6. In certain embodiments, R2is an 8-10 membered saturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selectedfrom nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R6. In certain embodiments, R2is an 8-10 membered partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R6.

[0112] In certain embodiments, R2is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen and oxygen; wherein said heterocyclyl is substituted with n occurrences of R6. In certain embodiments, R2is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1 nitrogen atom; wherein said heterocyclyl is substituted with n occurrences of R6. In certain embodiments, R2is an 8-10 membered saturated bicyclic heterocyclyl having 1 nitrogen atom; wherein said heterocyclyl is substituted with n occurrences of R6.

[0113] In certain embodiments, R2issubstituted with n occurrences of R6. Incertain embodiments, R2isIn certain embodiments, R2is or a 3-7 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selectedfrom nitrogen, oxygen, and sulfur. In certain embodiments, R2is, -N(R8)2, or a 3-7 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0114] In certain embodiments, R2is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R2is an 8-10 membered saturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R2is an 8-10 membered partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0115] In certain embodiments, R2is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen and oxygen. In certain embodiments, R2is an 8-10 membered saturated or partially unsaturated bicyclicheterocyclyl having 1 nitrogen atom. In certain embodiments, R2is an 8-10 membered saturated bicyclic heterocyclyl having 1 nitrogen atom. In certain embodiments, R2is

[0116] In certain embodiments, R2is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R6; or R2is -N(R8)2. In certain embodiments, R2is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R6. In certain embodiments, R2is a 4-6 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R6. In certain embodiments, R2is a 5-6 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R6. In certain embodiments, R2is a 5-membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R6. In certain embodiments, R2is a 6-membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R6.

[0117] In certain embodiments, R2is a 3-7 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R6. In certain embodiments, R2is a 5-6 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R6. In certain embodiments, R2is a 3-7 membered partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R6. In certain embodiments, R2is a 5-6 membered partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R6.

[0118] In certain embodiments, R2is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R6. In certain embodiments, R2is a 5-6 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen and oxygen; wherein said heterocyclyl is substituted with n occurrences of R6. In certain embodiments, R2is a 5-6 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen and oxygen; wherein said heterocyclyl is substituted with n occurrences of R6.

[0119] In certain embodiments, R2is -N(R8)2 or a 3-7 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R2is a 3-7 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0120] In certain embodiments, R2is azetidinyl, pyrrolidinyl, piperidinyl, or morpholinyl; each of which is substituted with n occurrences of R6. In certain embodiments, R2is azetidinyl substituted with n occurrences of R6. In certain embodiments, R2is pyrrolidinyl substituted with n occurrences of R6. In certain embodiments, R2is pyrrolidin-2-yl substituted with n occurrences of R6. In certain embodiments, R2is pyrrolidin-2-yl substituted with a single occurrence of R6at the 1-position. In certain embodiments, R2is piperidinyl substituted with n occurrences of R6. In certain embodiments, R2is morpholinyl substituted with n occurrences of R6.

[0121] In certain embodiments, R2is azetidinyl, pyrrolidinyl, piperidinyl, or morpholinyl. In certain embodiments, R2is azetidinyl. In certain embodiments, R2is pyrrolidinyl. In certain embodiments, R2is pyrrolidin-2-yl. In certain embodiments, R2is l-methyl-pyrrolidin-2-yl. In certain embodiments, R2is piperidinyl. In certain embodiments, R2is morpholinyl.

[0122] In certain embodiments, R2is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with n occurrences of R6.

[0123] In certain embodiments, R2is phenyl substituted with n occurrences of R6. In certain embodiments, R2is phenyl.

[0124] In certain embodiments, R2is C1-6 aliphatic substituted with n occurrences of R6. In certain embodiments, R2is C3-6 cycloaliphatic substituted with n occurrences of R6. In certain embodiments, R2is a C1-6 aliphatic chain substituted with n occurrences of R6. In certainembodiments, R2is C3-6 cycloalkyl substituted with n occurrences of R6. In certain embodiments, R2is C1-6 alkyl substituted with n occurrences of R6.

[0125] In certain embodiments, R2is C1-6 aliphatic. In certain embodiments, R2is C3-6 cycloaliphatic. In certain embodiments, R2is a C1-6 aliphatic chain. In certain embodiments, R2is C3-6 cycloalkyl. In certain embodiments, R2is C1-6 alkyl.

[0126] In certain embodiments, R2is -N(R8)2 or -OR8. In certain embodiments, R2is -N(R8)2. In certain embodiments, R2is -N(H or C1-6 alkyl)(optionally substituted C1-6 alkyl). In certain embodiments, R2is -N(CH3)2. In certain embodiments, R2is -OR8. In certain embodiments, R2is selected from those depicted in the compounds in Table 1, below.

[0128] As defined generally above, R3represents independently for each occurrence hydrogen, halo, or C1-4 alkyl. In certain embodiments, R3is hydrogen. In certain embodiments, R3represents independently for each occurrence halo or C1-4 alkyl. In certain embodiments, R3represents independently for each occurrence halo. In certain embodiments, R3is fluoro. In certain embodiments, R3represents independently for each occurrence C1-4 alkyl. In certain embodiments, R3is methyl. In certain embodiments, R3represents independently for each occurrence hydrogen or fluoro. In certain embodiments, R3is hydrogen or fluoro. In certain embodiments, R3is selected from those depicted in the compounds in Table 1, below.

[0129] As defined generally above, R5represents independently for each occurrence a 3-6 membered saturated or partially unsaturated heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, C2-6 alkynyl, C2-6 alkenyl, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, hydroxyl, C1-6 alkoxyl, C1-6 haloalkoxyl, halo, -N(R8)2, cyano, -(Co-6 alkylene)-C(O)N(R9)2, -OC(O)-(C1-6 aliphatic substituted with 0 or 1 -N(R9)2), -OC(O)-(3-6 membered heterocycle substituted with 0, 1, or 2 C1-6 alkyl), - S(O)2N(R9)2, -N(R8)C(O)-(CI-6 alkyl), or -N(R8)S(O)2-(C1-6 alkyl); wherein said C2-6 alkynyl is substituted with 0 or 1 phenyl or 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and wherein said 5-6 membered heteroaryl is substituted with 0, 1, or 2 C1-6 alkyl.

[0130] In certain embodiments, R5represents independently for each occurrence a 3-6 membered saturated or partially unsaturated heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, C2-6 alkynyl, C2-6 alkenyl, C1-6 alkyl, hydroxyl, C1-6 alkoxyl, halo, -N(R8)2, or cyano; wherein said C2-6 alkynyl is substituted with 0 or 1 phenyl or 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0131] In certain embodiments, R5represents independently for each occurrence a 3-6 membered saturated or partially unsaturated heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said 5-6 membered heteroaryl is substituted with 0, 1, or 2 C1-6 alkyl.

[0132] In certain embodiments, R5represents independently for each occurrence C2-6 alkynyl, C2-6 alkenyl, C1-6 alkyl, hydroxyl, C1-6 alkoxyl, halo, or cyano; wherein said C2-6 alkynyl is substituted with phenyl or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0133] In certain embodiments, R5represents independently for each occurrence C2-6 alkynyl, C2-6 alkenyl, C1-6 alkyl, hydroxyl, C1-6 alkoxyl, halo, or cyano.

[0134] In certain embodiments, R5represents independently for each occurrence C2-6 alkynyl, C2-6 alkenyl, C1-6 alkyl, or hydroxyl. In certain embodiments, R5represents independently for each occurrence ethynyl, ethenyl, C1.3 alkyl, or hydroxyl. In certain embodiments, R5representsindependently for each occurrence C2-6 alkynyl or hydroxyl . In certain embodiments, R represents independently for each occurrence ethynyl or hydroxyl. In certain embodiments, one occurrence of R5is ethynyl. In certain embodiments, one occurrence of R5is hydroxyl.

[0135] In certain embodiments, R represents independently for each occurrence C2-6 alkynyl, C1-6 alkyl, C1-6 haloalkyl, hydroxyl, halo, or -N(R8)2. In certain embodiments, R5represents independently for each occurrence C2-6 alkynyl, C1-6 alkyl, hydroxyl, or halo. In certain embodiments, R5represents independently for each occurrence C1-6 alkyl, C1-6 haloalkyl, halo, or -N(R8)2.

[0136] In certain embodiments, R5represents independently for each occurrence -C=CH, methyl, trifluoromethyl, hydroxyl, fluoro, chloro, or -N(R8)2. In certain embodiments, R5represents independently for each occurrence -C=CH, methyl, hydroxyl, fluoro, or chloro. In certain embodiments, R5represents independently for each occurrence -C=CH, hydroxyl, or fluoro. In certain embodiments, R5represents independently for each occurrence methyl, trifluoromethyl, fluoro, chloro, or -NH2.

[0137] In certain embodiments, R represents independently for each occurrence C2-6 alkynyl, hydroxyl, halo, -N(R8)2, -(Co-6 alkylene)-C(O)N(R9)2, -OC(O)-(C1-6 aliphatic substituted with 0 or 1 -N(R9)2), -OC(O)-(3-6 membered heterocycle substituted with 0, 1, or 2 C1-6 alkyl), - S(O)2N(R9)2, -N(R8)C(O)-(CI-6 alkyl), or -N(R8)S(O)2-(CI-6 alkyl). In certain embodiments, R5represents independently for each occurrence hydroxyl, -N(R8)2, -(Co-6 alkylene)-C(O)N(R9)2, - OC(O)-(C1-6 aliphatic substituted with 0 or 1 -N(R9)2), -OC(O)-(3-6 membered heterocycle substituted with 0, 1, or 2 C1-6alkyl), -S(O)2N(R9)2, -N(R8)C(O)-(C1-6alkyl), or -N(R8)S(O)2-(C1- 6 alkyl).

[0138] In certain embodiments, R represents independently for each occurrence C2-6 alkynyl, C2-6 alkenyl, or C1-6 alkyl. In certain embodiments, R5represents independently for each occurrence ethynyl, ethenyl, or C1-3 alkyl. In certain embodiments, R5represents independently for each occurrence hydroxyl or C1-6 alkoxyl. In certain embodiments, R5represents independently for each occurrence halo or cyano.

[0139] In certain embodiments, R5represents independently for each occurrence a 3-6 membered saturated or partially unsaturated heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R5represents independently for each occurrence a 5-6 membered monocyclic heteroaryl having 1, 2, or 3heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said 5-6 membered heteroaryl is substituted with 0, 1, or 2 C1-6 alkyl. In certain embodiments, R5represents independently for each occurrence C2-6 alkynyl. In certain embodiments, R5is ethynyl. In certain embodiments, R5represents C2-6 alkynyl substituted with phenyl or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R5represents independently for each occurrence C2-6 alkenyl. In certain embodiments, R5is ethenyl. In certain embodiments, R5represents independently for each occurrence C1-6 alkyl. In certain embodiments, R5represents independently for each occurrence C1-3 alkyl. In certain embodiments, R5is methyl. In certain embodiments, R5represents independently for each occurrence C1-6 haloalkyl. In certain embodiments, R5is trifluoromethyl. In certain embodiments, R5represents independently for each occurrence C3-6 cycloalkyl. In certain embodiments, R5is hydroxyl. In certain embodiments, R5represents independently for each occurrence C1-6 alkoxyl. In certain embodiments, R5represents independently for each occurrence C1-6 haloalkoxyl. In certain embodiments, R5represents independently for each occurrence halo. In certain embodiments, R5represents independently for each occurrence fluoro or chloro. In certain embodiments, R5is fluoro. In certain embodiments, R5is chloro. In certain embodiments, R5represents independently for each occurrence -N(R8)2. In certain embodiments, R5is -NH2. In certain embodiments, R5is cyano. In certain embodiments, R5represents independently for each occurrence -(C0-6 alkylene)-C(O)N(R9)2. In certain embodiments, R5represents independently for each occurrence -OC(O)-(C1-6 aliphatic substituted with 0 or 1 - N(R9)2). In certain embodiments, R5represents independently for each occurrence -OC(O)-(3-6 membered heterocycle substituted with 0, 1, or 2 C1-6 alkyl). In certain embodiments, R5represents independently for each occurrence -S(O)2N(R9)2. In certain embodiments, R5represents independently for each occurrence -N(R8)C(O)-(C1-6 alkyl). In certain embodiments, R5represents independently for each occurrence -N(R8)S(O)2-(C1-6 alkyl). In certain embodiments, R5is selected from those depicted in the compounds in Table 1, below.

[0140] As defined generally above, R6and R7each represent independently for each occurrence halo, hydroxyl, C1-6 alkoxyl, C1-6 haloalkoxyl, C1-6 alkyl, C116 haloalkyl, C1-6 hydroxyalkyl, -(C1-6 alkylene)-C1-6 alkoxyl, -(C0-6 alkylene)-(C3-6 cycloalkyl substituted with 0 or 1 -OR8), -(C0-4 alkylene)-cyano, -(C0-4 alkylene)-S(O)2-(halo), -(C0-4 alkylene)-S(O)2-(C1-6 alkyl), -C(O)OR8, -C(O)R8, -C(O)N(R9)2, optionally substituted 3-6 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or -N(R9)2

[0141] In certain embodiments, R6and R7each represent independently for each occurrence halo, hydroxyl, C1-6 alkoxyl, C1-6 haloalkoxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, -(C1-6 alkylene)-C1-6 alkoxyl, -(Co-6 alkylene)-C1-6 cycloalkyl, -(Co-4 alkylene)-cyano, -C(O)OR8, - C(O)N(R9)2, 3-6 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or -N(R9)2.

[0142] In certain embodiments, R6represents independently for each occurrence halo, hydroxyl, C1-6 alkoxyl, C1-6 haloalkoxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, -(Co-4 alkylene)-cyano, -C(O)OR8, -C(O)N(R9)2, or -N(R9)2. In certain embodiments, R6represents independently for each occurrence halo, hydroxyl, C1-6 alkoxyl, C1-6 haloalkoxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, -(Co-4 alkylene)-cyano, or -N(R9)2.

[0143] In certain embodiments, R6represents independently for each occurrence halo, hydroxyl, C1-6 alkoxyl, C1-6 haloalkoxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, cyano, or - N(R9)2. In certain embodiments, R6represents independently for each occurrence halo, hydroxyl, C1-6 alkoxyl, C1-6 haloalkoxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, or -N(R9)2. In certain embodiments, R6represents independently for each occurrence halo, hydroxyl, C1-6 alkoxyl, C1-6 alkyl, or C1-6 haloalkyl. In certain embodiments, R6represents independently for each occurrence halo, C1-6 alkyl, C1-6 haloalkyl, or C3-6 cycloalkyl. In certain embodiments, R6represents independently for each occurrence halo, C1-6 alkyl, or C1-6 haloalkyl. In certain embodiments, R6represents independently for each occurrence halo or C1-6 alkyl. In certain embodiments, R6represents independently for each occurrence fluoro or methyl. In certain embodiments, R6represents independently for each occurrence halo, hydroxyl, or C1-6 alkyl.

[0144] In certain embodiments, R6represents independently for each occurrence halo, hydroxyl, C1-6 alkoxyl, C1-6 haloalkoxyl, or -N(R9)2. In certain embodiments, R6represents independently for each occurrence halo, hydroxyl, or -N(R9)2. In certain embodiments, R6represents independently for each occurrence halo, C1-6 alkoxyl, or C1-6 haloalkoxyl. In certain embodiments, R6represents independently for each occurrence halo, C1-6 alkyl, C1-6 haloalkyl, C1- 6 hydroxyalkyl, or -(C1-4 alkylene)-cyano. In certain embodiments, R6represents independently for each occurrence halo, C1-6 alkyl, C1-6 haloalkyl, or C1-6 hydroxyalkyl. In certain embodiments, R6represents independently for each occurrence C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, or -(C1-4 alkylene)-cyano. In certain embodiments, R6represents independently for each occurrence C1-6 alkyl, C1-6 haloalkyl, or C1-6 hydroxyalkyl. In certain embodiments, R6represents independently for each occurrence C1-6 alkyl or C1-6 haloalkyl.

[0145] In certain embodiments, R6represents independently for each occurrence halo. In certain embodiments, R6represents independently for each occurrence fluoro or chloro. In certain embodiments, R6is fluoro. In certain embodiments, R6is chloro. In certain embodiments, R6is hydroxyl. In certain embodiments, R6represents independently for each occurrence C1-6 alkoxyl. In certain embodiments, R6is methoxy. In certain embodiments, R6represents independently for each occurrence C1-6 haloalkoxyl. In certain embodiments, R6is trifluoromethoxy. In certain embodiments, R6represents independently for each occurrence C1-6 alkyl. In certain embodiments, R6represents independently for each occurrence C1-3 alkyl. In certain embodiments, R6is methyl. In certain embodiments, R6represents independently for each occurrence C1-6 haloalkyl. In certain embodiments, R6is trifluoromethyl. In certain embodiments, R6represents independently for each occurrence C1-6 hydroxyalkyl. In certain embodiments, R6represents independently for each occurrence -(C1-6 alkylene)-C1-6 alkoxyl. In certain embodiments, R6represents independently for each occurrence -(Co-6 alkylene)-(C3-6 cycloalkyl substituted with 0 or 1 -OR8). In certain embodiments, R6is -(Co-4 alkylene)-cyano. In certain embodiments, R6is -(C 1-4 alkylene)-cyano. In certain embodiments, R6is cyano. In certain embodiments, R6represents independently for each occurrence -(C0-4 alkylene)-S(O)2-(halo). In certain embodiments, R6represents independently for each occurrence -(Co-4 alkylene)-S(O)2-(C1-6 alkyl). In certain embodiments, R6represents independently for each occurrence -C(O)OR8. In certain embodiments, R6represents independently for each occurrence -C(O)R8. In certain embodiments, R6represents independently for each occurrence -C(O)N(R9)2. In certain embodiments, R6represents independently for each occurrence -N(R9)2. In certain embodiments, R6represents independently for each occurrence optionally substituted 3-6 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R6is -NH2. In certain embodiments, R6is selected from those depicted in the compounds in Table 1, below.

[0146] In certain embodiments, R7represents independently for each occurrence halo, hydroxyl, C1-6 alkoxyl, C1-6 haloalkoxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, -(C0-4 alkylene)-cyano, or -N(R9)2.

[0147] Tn certain embodiments, R7represents independently for each occurrence halo, hydroxyl, C1-6 alkoxyl, C1-6 alkyl, or C1-6 haloalkyl. In certain embodiments, R7represents independently for each occurrence halo, hydroxyl, C1-6 alkyl, C1-6 hydroxyalkyl, -(C0-4 alkylene)- S(O)2-(halo), or oxiranyl. In certain embodiments, R7represents independently for each occurrence halo, hydroxyl, C1-6 alkyl, C1-6 hydroxyalkyl, -S(O)2-(halo), or oxiranyl. In certain embodiments, R7represents independently for each occurrence halo, hydroxyl, C1-6 alkyl, C1-6 hydroxyalkyl, or oxiranyl. In certain embodiments, R7represents independently for each occurrence halo, hydroxyl, C1-6 alkyl, or C1-6 hydroxyalkyl. In certain embodiments, R7represents independently for each occurrence halo, C1-6 alkyl, or C1-6 haloalkyl. In certain embodiments, R7represents independently for each occurrence halo or C1-6 alkyl. In certain embodiments, R7represents independently for each occurrence halo, hydroxyl, or C1-6 alkyl. In certain embodiments, R7represents independently for each occurrence -(Co-4 alkylene)-S(O)2-(halo) or oxiranyl.

[0148] In certain embodiments, R7represents independently for each occurrence halo, hydroxyl, C1-6 alkoxyl, C1-6 haloalkoxyl, or -N(R9)2. In certain embodiments, R7represents independently for each occurrence halo, hydroxyl, or -N(R9)2. In certain embodiments, R7represents independently for each occurrence halo, C1-6 alkoxyl, or C1-6 haloalkoxyl. In certain embodiments, R7represents independently for each occurrence halo, C1-6 alkyl, C1-6 haloalkyl, or C1-6 hydroxyalkyl. In certain embodiments, R7represents independently for each occurrence C1-6 alkyl, C1-6 haloalkyl, or C1-6 hydroxyalkyl. In certain embodiments, R7represents independently for each occurrence C1-6 alkyl or C1-6 haloalkyl.

[0149] In certain embodiments, R7represents independently for each occurrence fluoro, hydroxyl, methyl, hydroxymethyl, -S(O)2F, or oxiranyl. In certain embodiments, R7represents independently for each occurrence fluoro, hydroxyl, methyl, hydroxymethyl, or oxiranyl. In certain embodiments, R7represents independently for each occurrence fluoro, hydroxyl, methyl, or hydroxymethyl.

[0150] In certain embodiments, at least one occurrence of R7is -S(O)2-(halo) or oxiranyl. In certain embodiments, at least one occurrence of R7is -S(O)2F or oxiranyl. In certain embodiments, R7represents independently for each occurrence -S(O)2-(halo) or oxiranyl. In certain embodiments, R7represents independently for each occurrence -S(O)2F or oxiranyl.

[0151] In certain embodiments, R7represents independently for each occurrence halo. In certain embodiments, R7represents independently for each occurrence fluoro or chloro. In certain embodiments, R7is fluoro. In certain embodiments, R7is chloro. In certain embodiments, R7is hydroxyl. In certain embodiments, R7represents independently for each occurrence C1-6 alkoxyl. In certain embodiments, R7is methoxy. In certain embodiments, R7represents independently for each occurrence C1-6 haloalkoxyl. In certain embodiments, R7is trifluorom ethoxy. In certain embodiments, R7represents independently for each occurrence C1-6 alkyl. In certain embodiments, R7represents independently for each occurrence C1-3 alkyl. In certain embodiments, R7is methyl. In certain embodiments, R7represents independently for each occurrence C1-6 haloalkyl. In certain embodiments, R7is trifluoromethyl. In certain embodiments, R7represents independently for each occurrence C1-6 hydroxyalkyl. In certain embodiments, R7is hydroxymethyl. In certain embodiments, R7represents independently for each occurrence -(C1-6 alkylene)-C1-6 alkoxyl. In certain embodiments, R7represents independently for each occurrence -(Co-6 alkylene)-(C3-6 cycloalkyl substituted with 0 or 1 -OR8). In certain embodiments, R7represents independently for each occurrence C3-6 cycloalkyl. In certain embodiments, R7is cyclopropyl. In certain embodiments, R7represents independently for each occurrence -(Co-4 alkylene)-cyano. In certain embodiments, R7is cyano. In certain embodiments, R7represents independently for each occurrence -(C0-4 alkylene)-S(O)2-(halo). In certain embodiments, at least one occurrence of R7is -(C0-4 alkylene)-S(O)2-(halo). In certain embodiments, at least one occurrence of R7is -S(O)2- (halo). In certain embodiments, at least one occurrence of R7is -S(O)2F. In certain embodiments, R7represents independently for each occurrence -(C0-4 alkylene)-S(O)2-(halo). In certain embodiments, R7represents independently for each occurrence -S(O)2-(halo). In certain embodiments, R7is -S(O)2F. In certain embodiments, R7represents independently for each occurrence -(Co-4 alkylene)-S(O)2-(C1-6 alkyl). In certain embodiments, R7represents independently for each occurrence -C(O)OR8. In certain embodiments, R7represents independently for each occurrence -C(O)R8. In certain embodiments, R7represents independently for each occurrence -C(O)N(R9)2. In certain embodiments, R7represents independently for each occurrence optionally substituted 3-6 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R7represents independently for each occurrence 3-6 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certainembodiments, R7is oxiranyl. In certain embodiments, at least one occurrence of R7is oxiranyl. In certain embodiments, R7represents independently for each occurrence -N(R9)2. In certain embodiments, R7is -NH2. In certain embodiments, R7is selected from those depicted in the compounds in Table 1, below.

[0152] As defined generally above, R8and R9each represent independently for each occurrence hydrogen, optionally substituted C1-6 alkyl, optionally substituted C3-5 cycloalkyl, optionally substituted 3-6 membered saturated or partially unsaturated heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, aryl, -C(O)H, or -C(O)(C1- 4 alkyl); or two occurrences of R9attached to the same nitrogen atom are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring.

[0153] In certain embodiments, R8and R9each represent independently for each occurrence hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C3-5 cycloalkyl, -C(O)H, or -C(O)(C1-4 alkyl); or two occurrences of R9attached to the same nitrogen atom are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring. In certain embodiments, R8and R9each represent independently for each occurrence hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C3-5 cycloalkyl, -C(O)H, or -C(O)(C1-4 alkyl). In certain embodiments, R8and R9each represent independently for each occurrence hydrogen, C1-6 alkyl, or C3-5 cycloalkyl.

[0154] In certain embodiments, R8represents independently for each occurrence hydrogen, optionally substituted C1-6 alkyl, optionally substituted C3-5 cycloalkyl, -C(O)H, or -C(O)(C1-4 alkyl). In certain embodiments, R8represents independently for each occurrence hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C3-5 cycloalkyl, C1.4 alkyl(C3-5 cycloalkyl), C1-4 alkyl(aryl), -C(O)H, or -C(O)(C1-4 alkyl). In certain embodiments, R8represents independently for each occurrence hydrogen, C1-6 alkyl, or C3-5 cycloalkyl.

[0155] In certain embodiments, R8represents independently for each occurrence hydrogen, optionally substituted C1-6 alkyl, or optionally substituted C3-5 cycloalkyl. In certain embodiments, R8represents independently for each occurrence hydrogen or optionally substituted C1-6 alkyl. In certain embodiments, R8represents independently for each occurrence hydrogen or methyl. In certain embodiments, R8represents independently for each occurrence optionally substituted C1-6 alkyl or optionally substituted C3-5 cycloalkyl. In certain embodiments, R8represents independently for each occurrence -C(O)H or -C(O)(C1-4 alkyl).

[0156] Tn certain embodiments, R8is hydrogen. In certain embodiments, R8represents independently for each occurrence optionally substituted C1-6 alkyl. In certain embodiments, R8represents independently for each occurrence C1-6 alkyl, C1-6 haloalkyl, or C1-6 hydroxyalkyl. In certain embodiments, R8represents independently for each occurrence C1-6 alkyl. In certain embodiments, R8is methyl. In certain embodiments, R8represents independently for each occurrence optionally substituted C3-5 cycloalkyl. In certain embodiments, R8represents independently for each occurrence C3-5 cycloalkyl. In certain embodiments, R8is cyclopropyl. In certain embodiments, R8is -C(O)H. In certain embodiments, R8represents independently for each occurrence -C(O)(C1-4 alkyl). In certain embodiments, R8is selected from those depicted in the compounds in Table 1, below.

[0157] As defined generally above, R9represents independently for each occurrence hydrogen, optionally substituted C1-6 alkyl, optionally substituted C3-5 cycloalkyl, -C(O)H, or -C(O)(C1-4 alkyl); or two occurrences of R9attached to the same nitrogen atom are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring.

[0158] In certain embodiments, R9represents independently for each occurrence hydrogen, optionally substituted C1-6 alkyl, or optionally substituted C3-5 cycloalkyl; or two occurrences of R9attached to the same nitrogen atom are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring.

[0159] In certain embodiments, R9represents independently for each occurrence hydrogen, optionally substituted C1-6 alkyl, optionally substituted C3-5 cycloalkyl, -C(O)H, or -C(O)(C1-4 alkyl). In certain embodiments, R9represents independently for each occurrence hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C3-5 cycloalkyl, -C(O)H, or -C(O)(C1-4 alkyl). In certain embodiments, R9represents independently for each occurrence hydrogen, C1-6 alkyl, or C3-5 cycloalkyl.

[0160] In certain embodiments, R9represents independently for each occurrence hydrogen, optionally substituted C1-6 alkyl, optionally substituted C3-5 cycloalkyl, -C(O)H, or -C(O)(C1-4 alkyl). In certain embodiments, R9represents independently for each occurrence hydrogen, optionally substituted C1-6 alkyl, or optionally substituted C3-5 cycloalkyl. In certain embodiments, R9represents independently for each occurrence hydrogen or optionally substituted C1-6 alkyl. In certain embodiments, R9represents independently for each occurrence hydrogen or methyl. In certain embodiments, R9represents independently for each occurrence optionally substituted C1-6alkyl or optionally substituted C3-5 cycloalkyl. In certain embodiments, R9represents independently for each occurrence -C(O)H or -C(O)(C1-4 alkyl).

[0161] In certain embodiments, two occurrences of R9attached to the same nitrogen atom are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring. In certain embodiments, two occurrences of R9attached to the same nitrogen atom are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom.

[0162] In certain embodiments, R9is hydrogen. In certain embodiments, R9represents independently for each occurrence optionally substituted C1-6 alkyl. In certain embodiments, R9represents independently for each occurrence C1-6 alkyl, C1-6 haloalkyl, or C1-6 hydroxyalkyl. In certain embodiments, R9represents independently for each occurrence C1-6 alkyl. In certain embodiments, R9is methyl. In certain embodiments, R9represents independently for each occurrence optionally substituted C3-5 cycloalkyl. In certain embodiments, R9represents independently for each occurrence C3-5 cycloalkyl. In certain embodiments, R9is cyclopropyl. In certain embodiments, R9is -C(O)H. In certain embodiments, R9represents independently for each occurrence -C(O)(C1-4 alkyl). In certain embodiments, R9is selected from those depicted in the compounds in Table 1, below.

[0163] As defined generally above, A1is one of the following: a. a 3-8 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 6-11 membered saturated or partially unsaturated polycyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein each heterocyclyl is substituted with (i) p occurrences of R7, and (ii) 0, 1, or 2 oxo; and wherein said monocyclic heterocyclyl is substituted with 0 or 1 occurrence of -(C0-4 alkyl ene)-(5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), or - (C0-4 alkylene)-phenyl, each of which is optionally substituted; b. C3-10 cycloaliphatic, phenyl, indanyl, a 5- or 6-membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-, 9-, or 10-membered bicyclic heteroaryl having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each ofwhich is substituted with p occurrences of R7; and wherein said monocyclic heteroaryl is substituted with 0 or 1 occurrence of -(Co-4 alkylene)-(5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur) or -(Co-4 alkylene)-phenyl, each of which is optionally substituted; c. -CN, -N(R8)2, or hydroxyl; or

[0164] In certain embodiments, A1is a 4-8 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated ortho -fused heterocyclyl having 1 or 2 nitrogen atoms; a C3-10 cycloaliphatic; or a 5-6 membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with p occurrences of R7.

[0165] In certain embodiments, A1is C3-10 cycloaliphatic, phenyl, indanyl, a 5- or 6-membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-, 9-, or 10-membered bicyclic heteroaryl having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with p occurrences of R7; and wherein said monocyclic heteroaryl is substituted with 0 or 1 occurrence of -(C0-4 alkylene)-(5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur) or -(C0-4 alkylene)-phenyl, each of which is optionally substituted.

[0166] In certain embodiments, A1is C3-10 cycloaliphatic, phenyl, or indanyl, each of which is substituted with p occurrences of R7. In certain embodiments, A1is phenyl substituted with p occurrences of R7. In certain embodiments, A1is phenyl substituted with 1 occurrence of R7. In certain embodiments, A1is 5- or 6-membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with p occurrences of R7; and wherein said monocyclic heteroaryl is substituted with 0 or 1 occurrence of -(C0-4 alkylene)-(5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatomsindependently selected from nitrogen, oxygen, and sulfur) or -(C0-4 alkylene)-phenyl, each of which is optionally substituted. In certain embodiments, A1is pyrazol-4-yl substituted at the 1- position with pyridyl, phenyl, benzyl, cyclopropyl, pyranyl, or piperidinyl; each of which is optionally substituted with methyl, fluoro, or chloro. In certain embodiments, A1is 5- or 6- membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with p occurrences of R7. In certain embodiments, A1is 5- or 6-membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with p occurrences of R7; and wherein said monocyclic heteroaryl is substituted with -(Co-4 alkylene)-(5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur) or -( C0-4 alkylene)-phenyl, each of which is optionally substituted. In certain embodiments, A1is an 8-, 9-, or 10-membered bicyclic heteroaryl having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with p occurrences of R7.

[0167] In certain embodiments, A1is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated ortho -fused heterocyclyl having 1 or 2 nitrogen atoms; or a 5-6 membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with p occurrences of R7.

[0168] In certain embodiments, A1is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 5-6 membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with p occurrences of R7. In certain embodiments, A1is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 5-6 membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0169] In certain embodiments, A1is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated ortho -fused heterocyclyl having 1 or 2 nitrogen atoms;or a 5-6 membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0170] In certain embodiments, A1is a 3-8 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 6-11 membered saturated or partially unsaturated polycyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein each heterocyclyl is substituted with (i) p occurrences of R7, and (ii) 0, 1, or 2 oxo; and wherein said monocyclic heterocyclyl is substituted with 0 or 1 occurrence of -(C0-4 alkylene)-(5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur) or -(C0-4 alkylene)-phenyl, each of which is optionally substituted. In certain embodiments, A1is a 3-8 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 6-11 membered saturated or partially unsaturated polycyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein each heterocyclyl is substituted with (i) p occurrences of R7, and (ii) 0, 1, or 2 oxo.

[0171] In certain embodiments, A1is a 4-8 membered saturated monocyclic heterocyclyl having 1 nitrogen atom; a 4- or 5-membered saturated monocyclic heterocyclyl having 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6- 11 membered saturated ortho -fused heterocyclyl having 1 or 2 nitrogen atoms; each of which is substituted with p occurrences of R7. In certain embodiments, A1is a 4-7 membered saturated monocyclic heterocyclyl having 1 nitrogen atom; a 4- or 5-membered saturated monocyclic heterocyclyl having 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho -fused heterocyclyl having 1 or 2 nitrogen atoms; each of which is substituted with p occurrences of R7.

[0172] In certain embodiments, A1is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho -fused heterocyclyl having 1 or 2 nitrogen atoms; each of which is substituted with p occurrences of R7. In certain embodiments, A1is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho-fused heterocyclyl having 1 or 2 nitrogen atoms.

[0173] Tn certain embodiments, A1is a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho -fused heterocyclyl having 1 or 2 nitrogen atoms; each of which is substituted with p occurrences of R7. In certain embodiments, A1is a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho-fused heterocyclyl having 1 or 2 nitrogen atoms.

[0174] In certain embodiments, A1is a 3-8 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said heterocyclyl is substituted with (i) p occurrences of R7, (ii) 0, 1, or 2 oxo; and (iii) 0 or 1 occurrence of -(C0-4 alkylene)-(5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), or phenyl, each of which is optionally substituted. In certain embodiments, A1is a 3-8 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said heterocyclyl is substituted with (i) p occurrences of R7, (ii) 0, 1, or 2 oxo; and (iii) 0 or 1 occurrence of -(C0-4 alkylene)-(5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), or phenyl.

[0175] In certain embodiments, A1is a 3-8 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with (i) p occurrences of R7, and (ii) 0, 1, or 2 oxo. In certain embodiments, A1is a 3-8 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with (i) p occurrences of R7, and (ii) 1 or 2 oxo. In certain embodiments, A1is a 3-8 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with p occurrences of R7

[0176] In certain embodiments, A1is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with p occurrences of R7. In certain embodiments, A1is a 5- or 6- membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with p occurrences ofR7. In certain embodiments, A1is a 5- or 6-membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0177] In certain embodiments, A1is a 4-8 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R7. In certain embodiments, A1is a 4-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R7. In certain embodiments, A1is a 4-8 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R7.

[0178] In certain embodiments, A1is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R7. In certain embodiments, A1is a 5-6 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R7. In certain embodiments, A1is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms. In certain embodiments, A1is a 5-6 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms.

[0179] In certain embodiments, A1is a 4-8 membered saturated monocyclic heterocyclyl having 1 nitrogen atom; or a 4- or 5-membered saturated monocyclic heterocyclyl having 2 nitrogen atoms; each of which is substituted with p occurrences of R7. In certain embodiments, A1is a 4-7 membered saturated monocyclic heterocyclyl having 1 nitrogen atom; or a 4- or 5- membered saturated monocyclic heterocyclyl having 2 nitrogen atoms; each of which is substituted with p occurrences of R7. In certain embodiments, A1is a 4-7 membered saturated monocyclic heterocyclyl having 1 nitrogen atom; or a 4- or 5-membered saturated monocyclic heterocyclyl having 2 nitrogen atoms.

[0180] In certain embodiments, A1is a 4-8 membered saturated monocyclic heterocyclyl having 1 nitrogen atom; wherein said heterocyclyl is substituted with p occurrences of R7. In certain embodiments, A1is a 4-7 membered saturated monocyclic heterocyclyl having 1 nitrogen atom; wherein said heterocyclyl is substituted with p occurrences of R7. In certain embodiments, A1is a 4- or 5-membered saturated monocyclic heterocyclyl having 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R7.

[0181] In certain embodiments, A1is a 4-8 membered saturated monocyclic heterocyclyl having 1 nitrogen atom. In certain embodiments, A1is a 4-7 membered saturated monocyclic heterocyclyl having 1 nitrogen atom. In certain embodiments, A1is a 4- or 5-membered saturated monocyclic heterocyclyl having 2 nitrogen atoms.

[0182] In certain embodiments, A1is a 4-5 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen; wherein said heterocyclyl is substituted with p occurrences of R7.

[0183] In certain embodiments, A1is 1,4-diazepanyl, piperidinyl, piperazinyl, pyrrolidinyl, or azetidinyl; each of which is substituted with p occurrences of R7. In certain embodiments, A1is piperidinyl, pyrrolidinyl, or azetidinyl; each of which is substituted with p occurrences of R7. In certain embodiments, A1is 1,4-diazepanyl substituted with p occurrences of R7. In certain embodiments, A1is piperidinyl substituted with p occurrences of R7. In certain embodiments, A1is piperazinyl substituted with p occurrences of R7. In certain embodiments, A1is pyrrolidinyl substituted with p occurrences of R7. In certain embodiments, A1is azetidinyl substituted with p occurrences of R7.

[0184] In certain embodiments, A1is 1,4-diazepanyl, piperidinyl, piperazinyl, pyrrolidinyl, or azetidinyl. In certain embodiments, A1is piperidinyl, pyrrolidinyl, or azetidinyl. In certain embodiments, A1is 1,4-diazepanyl. In certain embodiments, A1is piperidinyl. In certain embodiments, A1is piperazinyl. In certain embodiments, A1is pyrrolidinyl. In certain embodiments, A1is azetidinyl.

[0185] In certain embodiments, A1is 1,4-diazepan-l-yl, piperidin-4-yl, piperazin- 1-yl, pyrrolidin-3-yl, or azetidin-3-yl; each of which is substituted with p occurrences of R7In certain embodiments, A1is 1,4-diazepan-l-yl substituted with p occurrences of R7. In certain embodiments, A1is piperidin-4-yl substituted with p occurrences of R7. In certain embodiments, A’ is piperazin- 1-yl substituted with p occurrences of R7. In certain embodiments, A1is pyrrolidin- 3-yl substituted with p occurrences of R7. In certain embodiments, A1is azetidin-3-yl substituted with p occurrences of R7.

[0186] In certain embodiments, A1is 1,4-diazepan-l-yl, piperidin-4-yl, piperazin- 1-yl, pyrrolidin-3-yl, or azetidin-3-yl. In certain embodiments, A1is 1,4-diazepan-l -yl. In certain embodiments, A1is piperidin-4-yl. In certain embodiments, A1is piperazin- 1-yl. In certain embodiments, A1is pyrrolidin-3-yl. In certain embodiments, A1is azetidin-3-yl.

[0187] In certain embodiments, A1is piperidin-l-yl, pyrrolidin-l-yl, or azetidin-l -yl; each of which is substituted with p occurrences of R7. In certain embodiments, A1is piperidin-l-yl substituted with p occurrences of R7. In certain embodiments, A1is pyrrolidin-l-yl substituted with p occurrences of R7. In certain embodiments, A1is azetidin-l-yl substituted with p occurrences of R7.

[0188] In certain embodiments, A1is piperidin-l-yl, pyrrolidin-l-yl, or azetidin-l-yl. In certain embodiments, A1is piperidin-l-yl. In certain embodiments, A1is pyrrolidin-l-yl. In certain embodiments, A1is azetidin-l-yl.

[0189] In certain embodiments, A1is azetidinyl, pyrrolidinyl, or phenyl, each of which is substituted with p occurrences of R7and 0 or 1 occurrence of -(Co-4 alkylene)-(5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), a 4-6 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms, or -(C0-4 alkylene)-phenyl, each of which is optionally substituted. In certain embodiments, A1is azetidinyl, pyrrolidinyl, or phenyl, each of which is substituted with p occurrences of R7, and the azetidinyl and pyrrolidinyl are substituted with 0 or 1 occurrence of -(Co-4 alkylene)-(5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), a 4-6 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms, or -(Co-4 alkylene)-phenyl, each of which is optionally substituted.

[0190] In certain embodiments, A1is a 6-11 membered saturated or partially unsaturated polycyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with (i) p occurrences of R7, and (ii) 0, 1, or 2 oxo.

[0191] In certain embodiments, A1is a 6-11 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with (i) p occurrences of R7, and (ii) 0, 1, or 2 oxo. In certain embodiments, A1is a 6-11 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with (i) p occurrences of R7, and (ii) 1 or 2 oxo. In certain embodiments, A1is a 6-11 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with (i) p occurrences of R7. In certainembodiments, A1is a 6-11 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0192] In certain embodiments, A1is a 6-11 membered saturated bicyclic heterocyclyl having1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with (i) p occurrences of R7, and (ii) 0, 1, or 2 oxo. In certain embodiments, A1is a 6-11 membered saturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with (i) p occurrences of R7, and (ii) 1 or 2 oxo. In certain embodiments, A1is a 6-11 membered saturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with (i) p occurrences of R7. In certain embodiments, A1is a 6-11 membered saturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0193] In certain embodiments, A1is a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R7. In certain embodiments, A1is a 7-10 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R7. In certain embodiments, A1is a 6-11 membered saturated spirocyclic heterocyclyl having 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R7.

[0194] In certain embodiments, A1is a 6-11 membered saturated or partially unsaturated fused heterocyclyl having 1 or 2 nitrogen atoms and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments,

[0195] In certain embodiments, A1is a 4-7 membered saturated or partially unsaturated monocyclic cycloalkyl. In certain embodiments, A1is

[0196] In certain embodiments, A1is a 6-11 membered saturated spirocyclic heterocyclyl having 1 or2 nitrogen atoms. In certain embodiments, A1is a7-10 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms. In certain embodiments, A1is a 6-11 membered

[0197] In certain embodiments, A1is a substituted 7-10 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms. In certain embodiments, A1is

[0198] In certain embodiments, A1is a substituted 3-8 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms. In certain embodiments, A1is

[0201] In certain embodiments, A1is -CN, -N(R8)2, or hydroxyl. In certain embodiments, A1is -CN. In certain embodiments, A1is -N(R8)2. In certain embodiments, A1is hydroxyl.

[0202] In certain embodiments, A1is selected from the following:

[0203] In certain embodiments, -A1is selected from the following:

[0205] Tn certain embodiments, A1is selected from those depicted in the compounds in Table1, below.

[0206] In certain embodiments, -L-A1is selected from the following:

[0207] In certain embodiments, -L1-A1is selected from the following:

[0210] In certain embodiments, -L1-A1is -N(H or C1-6 alkyl)-(Co-3 alkylene)-phenyl, wherein the phenyl is substituted with 1 or 2 occurrences of R7In certain embodiments, -L1-A1is -N(H or C1-6 alkyl)-(Co-3 alkyl ene)-phenyl, wherein the phenyl is substituted with 1 occurrence of R7. In certain embodiments, -L1-A1is selected from those depicted in the compounds in Table 1, below.

[0211] As defined generally above, X1, X2, X3, X4, and X5each represent independently N or CR3.

[0212] In certain embodiments, X1and X2each represent independently N or CH. In certain embodiments X1is CH, and X2is N. In certain embodiments, X1and X2are N. In certain embodiments, X1and X2are CH. In certain embodiments, X1is N. In certain embodiments, X1isCH. Tn certain embodiments, X2is N. In certain embodiments, X2is CH. In certain embodiments, X1and X2each represent independently those depicted in the compounds in Table 1, below.

[0213] In certain embodiments, X3, X4, and X5each represent independently N or CR3. In certain embodiments X3is N, X4is CR3, and X5is N. In certain embodiments, X3, X4, and X5each represent independently N or CH. In certain embodiments, X3, X4, and X5are N. In certain embodiments, X3, X4, and X5are CH.

[0214] In certain embodiments X1, X2, X3, X4, and X5are independently N or CH. In certain embodiments X1is CH, X2is N, X3is N, X4is CR3, and X5is N. In certain embodiments, any one of X1, X2, X3, X4, and X5is N. In certain embodiments, any two of X1, X2, X3, X4, and X5is N. In certain embodiments, any three of X1, X2, X3, X4, and X5is N. In certain embodiments, each of X1, X2, X3, X4, and X5is selected from those depicted in the compounds in Table 1, below.

[0215] As defined generally above, Y1and Y2represent independently a C1-3 bivalent saturated or unsaturated, straight hydrocarbon chain which is substituted with q occurrences of R7. In certain embodiments, Y1is a C1-3 bivalent saturated, straight hydrocarbon chain. In certain embodiments, Y2is a C1-3 bivalent saturated, straight hydrocarbon chain. In certain embodiments, each of Y1and Y2is selected from those depicted in the compounds in Table 1, below.

[0216] As defined generally above, L1, L2, and L3are independently a covalent bond or a C1-4 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -O-, -N(R9)-, -C(O)-, optionally substituted C3-5 cycloalkylene, or a 3-6 membered saturated monocyclic heterocyclyl having 1 heteroatom selected from nitrogen, oxygen, and sulfur.

[0217] In certain embodiments, L1and L2are independently a covalent bond or a C1-4 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -O-, -N(R9)-, -C(O)-, or an optionally substituted C3-5 cycloalkylene.

[0218] In certain embodiments, L1is a covalent bond or a C1-4 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -O-, -N(R9)-, -C(O)-, or an optionally substituted C3-5 cycloalkylene. In certain embodiments, L1is a covalent bond or -N(R9)-(Co-3 alkylene)-, wherein the C0-3 alkylene of L1is attached to A1. In certain embodiments, L1is a covalent bond or -N(Hor C1-6 alkyl)-(Co-3 alkylene)-, wherein the C0-3 alkylene of L1is attached to A1. In certain embodiments, L1is a covalent bond or -N(H or C1-6 alkyl)-.

[0219] In certain embodiments, L1is a covalent bond. In certain embodiments, L1is a C1-4 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -O-, -N(R9)-, -C(O)-, optionally substituted C3-5 cycloalkylene, or a 3-6 membered saturated monocyclic heterocyclyl having 1 heteroatom selected from nitrogen, oxygen, and sulfur. In certain embodiments, L1is a C1-4 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -O-, -N(R9)-, -C(O)-, or an optionally substituted C3-5 cycloalkylene.

[0220] In certain embodiments, L1is -N(R9)-(Co-3 alkylene)-, wherein the C0-3 alkylene of L1is attached to A1. In certain embodiments, L1is -N(R9)-. In certain embodiments, L1is -N(R9)-CH2- or -N(R9)-(CH2)2-, wherein the terminal carbon atom of L1is attached to A1. In certain embodiments, L1is -N(H or C1-6 alkyl)-(Co-3 alkylene)-, wherein the C0-3 alkylene of L1is attached to A1. In certain embodiments, L1is -N(H or C1-6 alkyl)-. In certain embodiments, L1is -N(H or C1-6 alkyl)-CH2- or -N(H or C1-6 alkyl)-(CH2)2-, wherein the terminal carbon atom of L1is attached to A1. In certain embodiments, L1is selected from those depicted in the compounds in Table 1, below.

[0221] In certain embodiments, L2is a covalent bond or a C1-4 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -O-, -N(R9)-, -C(O)-, or optionally substituted C3-5 cycloalkylene. In certain embodiments, L2is a covalent bond or a C2-4 bivalent saturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -O-, -N(R9)-, or cyclopropylene substituted with 0, 1, or 2 fluoro.

[0222] In certain embodiments, L2is a covalent bond. In certain embodiments, L2is a C1-4 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -O-, -N(R9)-, -C(O)-, optionally substituted C3-5 cycloalkylene, or a 3-6 membered saturated monocyclic heterocyclyl having 1 heteroatom selected from nitrogen, oxygen, and sulfur. In certain embodiments, L2is a C1-4 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -O-, -N(R9)-, -C(O)-, oroptionally substituted C3-5 cycloalkylene. In certain embodiments, L2is a C2.4 bivalent saturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -O-, -N(R9)-, or cyclopropylene substituted with 0, 1, or 2 fluoro.

[0223] In certain embodiments, L2is -O-CH2-, -O-(CH2)2-, -N(R9)-CH2-, or -N(R9)-(CH2)2-, wherein the terminal carbon atom of L2is attached to R2. In certain embodiments, L2is -O-CH2-, wherein the terminal carbon atom of L2is attached to R2.

[0225] In certain embodiments, L3is a covalent bond. In certain embodiments, L3is a C1-4 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -O-, -N(R9)-, -C(O)-, optionally substituted C3-5 cycloalkylene, or a 3-6 membered saturated monocyclic heterocyclyl having 1 heteroatom selected from nitrogen, oxygen, and sulfur. In certain embodiments, L3is - O- or -N(R9)-. In certain embodiments, L3is -O-, -N(CH3)-, or -N(H)-. In certain embodiments, L3is -O-. In certain embodiments, L3is -N(CH3)- or -N(H)-. In certain embodiments, L3is selected from those depicted in the compounds in Table 1, below.

[0226] As defined generally above, m is 0, 1, 2, 3, or 4. In certain embodiments, m is 0. In certain embodiments, m is 1. In certain embodiments, m is 2. In certain embodiments, m is 3. In certain embodiments, m is 4. In certain embodiments, m is 0 or 1. In certain embodiments, m is1 or 2. In certain embodiments, m is 2 or 3. In certain embodiments, m is 3 or 4. In certain embodiments, m is 0, 1, or 2. In certain embodiments, m is 1, 2, or 3. In certain embodiments, m is 2, 3, or 4. In certain embodiments, m is 0, 1, 2, or 3. In certain embodiments, m is 1, 2, 3, or 4. In certain embodiments, m is selected from the values represented in the compounds in Table 1, below.

[0227] As defined generally above, n is 0, 1, 2, 3, or 4. In certain embodiments, n is 0. In certain embodiments, n is 1. In certain embodiments, n is 2. In certain embodiments, n is 3. In certain embodiments, n is 4. In certain embodiments, n is 0 or 1. In certain embodiments, n is 1 or 2. In certain embodiments, n is 2 or 3. In certain embodiments, n is 3 or 4. In certain embodiments, n is 0, 1, or 2. In certain embodiments, n is 1, 2, or 3. In certain embodiments, n is 2, 3, or 4. In certain embodiments, n is 0, 1, 2, or 3. In certain embodiments, n is 1, 2, 3, or 4. In certain embodiments, n is selected from the values represented in the compounds in Table 1, below.

[0228] As defined generally above, p is 0, 1, 2, 3, or 4. In certain embodiments, p is 0. In certain embodiments, p is 1. In certain embodiments, p is 2. In certain embodiments, p is 3. In certain embodiments, p is 4. In certain embodiments, p is 0 or 1. In certain embodiments, p is 1 or 2. In certain embodiments, p is 2 or 3. In certain embodiments, p is 3 or 4. In certain embodiments, p is 0, 1, or 2. In certain embodiments, p is 1, 2, or 3. In certain embodiments, p is 2, 3, or 4. In certain embodiments, p is 0, 1, 2, or 3. In certain embodiments, p is 1, 2, 3, or 4. In certain embodiments, p is selected from the values represented in the compounds in Table 1, below.

[0229] As defined generally above, q is 0, 1, 2, 3, or 4. In certain embodiments, q is 0. In certain embodiments, q is 1. In certain embodiments, q is 2. In certain embodiments, q is 3. In certain embodiments, q is 4. In certain embodiments, q is 0 or 1. In certain embodiments, q is 1 or 2. In certain embodiments, q is 2 or 3. In certain embodiments, q is 3 or 4. In certain embodiments, q is 0, 1, or 2. In certain embodiments, q is 1, 2, or 3. In certain embodiments, q is 2, 3, or 4. In certain embodiments, q is 0, 1, 2, or 3. In certain embodiments, q is 1, 2, 3, or 4. In certain embodiments, q is selected from the values represented in the compounds in Table 1, below.

[0230] The description above describes multiple embodiments relating to compounds of Formula (I). The patent application specifically contemplates all combinations of the embodiments.

[0231] Tn certain embodiments, the disclosure provides compounds of Formula la:or a pharmaceutically acceptable salt thereof, wherein each variable is as defined above for Formula I and its embodiments thereof.

[0232] In certain embodiments, the disclosure provides compounds of Formula lb, Ic, or Id:or a pharmaceutically acceptable salt thereof, wherein each variable is as defined above forFormula I and its embodiments thereof.

[0233] In certain embodiments, the disclosure provides compounds of Formula le:or a pharmaceutically acceptable salt thereof, wherein each variable is as defined above for Formula I and its embodiments thereof.

[0234] In certain embodiments, the disclosure provides compounds of Formula If, Ig, or Ih:or a pharmaceutically acceptable salt thereof, wherein each variable is as defined above for Formula I and its embodiments thereof.

[0235] In certain embodiments, the disclosure provides compounds of Formula li:or a pharmaceutically acceptable salt thereof, wherein each variable is as defined above for Formula I and its embodiments thereof.

[0236] In certain embodiments, the disclosure provides compounds of Formula Ij, Ik, or II:or a pharmaceutically acceptable salt thereof, wherein each variable is as defined above for Formula I and its embodiments thereof.

[0237] Another aspect of the disclosure provides a compound represented by Formula (I- 1 ):(1-1) or a pharmaceutically acceptable salt thereof; wherein:R1is naphthyl; an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or phenyl; each of which is substituted with m occurrences of R5;R2is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; phenyl; or C1-6 aliphatic; each of which is substituted with n occurrences of R6;R3represents independently for each occurrence hydrogen, halo, or C1-4 alkyl;R5represents independently for each occurrence 3-6 membered heterocyclyl, C2-6 alkynyl, C2-6 alkenyl, C1-6 alkyl, hydroxyl, C1-6 alkoxyl, halo, amine, or cyano; wherein said C2-6 alkynyl is substituted with 0 or 1 phenyl or 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;R6and R7each represent independently for each occurrence halo, hydroxyl, C1-6 alkoxyl, C1-6 haloalkoxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, -(C1-6 alkylene)-C1-6 alkoxyl, -(Co-6 alkylene)-C1-6 cycloalkyl, -(C0-4 alkylene)-cyano, -C(O)OR8, -C(O)N(R9)2, 3-6 memberedsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or -N(R9)2;R8and R9each represent independently for each occurrence hydrogen, optionally substituted C1-6 alkyl, optionally substituted C3-5 cycloalkyl, optionally substituted C3-6 heterocyclyl, aryl, -C(O)H, or -C(O)(C1-4 alkyl); or two occurrences of R9attached to the same nitrogen atom are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring;A1is one of the following: a. a 3-8 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 6-11 membered saturated or partially unsaturated polycyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein each heterocyclyl is substituted with (i) p occurrences of R7, and (ii) 0, 1, or 2 oxo; and wherein said monocyclic heterocyclyl is substituted with 0 or 1 occurrence of -(C0-4 alkylene)-(5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), a 4-6 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms, or - (C0-4 alkylene)-phenyl, each of which is optionally substituted; b. C3-10 cycloaliphatic, phenyl, indanyl, a 5- or 6-membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-, 9-, or 10-membered bicyclic heteroaryl having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with p occurrences of R7; c. -CN, -N(R8)2, or hydroxyl; orL1and L2are independently a covalent bond or a C1-4 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain areoptionally and independently replaced by -O-, -N(R9)-, -C(O)-, or optionally substituted C3-5 cycloalkylene;X1and X2each represent independently N or CH;X3, X4, and X5each represent independently N or CR3;Y1and Y2represent independently a C1-3 bivalent saturated or unsaturated, straight hydrocarbon chain which is substituted with q occurrences of R7; and m, n, p, and q are each independently 0, 1, 2, 3, or 4.

[0238] The definitions of variables in Formula (1-1) above encompass multiple chemical groups. The application contemplates embodiments where, for example, i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, ii) the definition of a variable is a collection of two or more of the chemical groups selected from those set forth above, and iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii).

[0239] In certain embodiments, the compound is a compound of Formula (1-1).

[0240] As defined generally above, R1is naphthyl; an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or phenyl; each of which is substituted with m occurrences of R5.

[0241] In certain embodiments, R1is naphthyl, an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R5. In certain embodiments, R1is phenyl or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R5.

[0242] In certain embodiments, R1is naphthyl or phenyl; each of which is substituted with m occurrences of R5. In certain embodiments, R1is an 8-10 membered saturated or partiallyunsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R5.

[0243] In certain embodiments, R1is naphthyl or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R5. In certain embodiments, R1is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R5.

[0244] In certain embodiments, R1is naphthyl substituted with m occurrences of R5. In certain embodiments, R1is 1 -naphthyl substituted with m occurrences of R5. In certain embodiments, R1

[0248] In certain embodiments, R1is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with m occurrences of R5. In certain embodiments, R1is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen and oxygen; wherein said heterocyclyl is substituted with m occurrences of R5.

[0250] In certain embodiments, R1is an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with m occurrences of R5. In certain embodiments, R1is an 8-10 membered bicyclic heteroaryl having 1 or 2 heteroatoms independently selected from nitrogen and oxygen, and sulfur; wherein said heteroaryl is substituted with m occurrences of R5

[0251] In certain embodiments, R1is quinolinyl, isoquinolinyl, or indazolyl; each of which is substituted with m occurrences of R5. In certain embodiments, R1is quinolinyl substituted with m occurrences of R5. In certain embodiments, R1is quinoline-4-yl substituted with m occurrences of R5. In certain embodiments, R1is isoquinolinyl substituted with m occurrences of R5. In certainembodiments, R1is isoquinolin-l -yl substituted with m occurrences of R5. In certain embodiments, R1is indazolyl substituted with m occurrences of R5.

[0253] In certain embodiments, R1is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with m occurrences of R5In certain embodiments, R1is a 6-membered monocyclic heteroaryl having 1, 2, or 3 nitrogen atoms; wherein said heteroaryl is substituted with m occurrences of R5. In certain embodiments, R1is a 5-membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with m occurrences of R5. In certain embodiments, R1is selected from those depicted in the compounds in Table 1, below.

[0254] As defined generally above, R2is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; phenyl; or C1-6 aliphatic; each of which is substituted with n occurrences of R6.

[0255] In certain embodiments, R2is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with n occurrences of R6. In certain embodiments, R2is phenyl or C1-6 aliphatic; each of which is substituted with n occurrences of R6.

[0256] In certain embodiments, R2is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with n occurrences of R6. In certain embodiments, R2is an 8-10 membered saturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 3-7 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with n occurrences of R6. In certain embodiments, R2is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with n occurrences of R6.

[0257] In certain embodiments, R2is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; phenyl; or C1-6 aliphatic; each of which is substituted with n occurrences of R6. In certain embodiments, R2is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or C1-6 aliphatic; each of which is substituted with n occurrences of R6. In certain embodiments, R2is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or phenyl; each of which is substituted with n occurrences of R6.

[0258] In certain embodiments, R2is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R6. In certain embodiments, R2is an 8-10 membered saturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R6. In certain embodiments, R2is an 8-10 membered partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R6.

[0259] In certain embodiments, R2is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen and oxygen; wherein said heterocyclyl is substituted with n occurrences of R6. In certain embodiments, R2is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1 nitrogen atom;wherein said heterocyclyl is substituted with n occurrences of R6. In certain embodiments, R2is an 8-10 membered saturated bicyclic heterocyclyl having 1 nitrogen atom; wherein said heterocyclyl is substituted with n occurrences of R6. In certain embodiments, R2is substituted with n occurrences of R6. In certain embodiments, R2is In certainembodiments, R2is or a 3-7 membered saturated monocyclic heterocyclyl having1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0260] In certain embodiments, R2is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R2is an 8-10 membered saturated bicyclic heterocyclyl having1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R2is an 8-10 membered partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0261] In certain embodiments, R2is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen and oxygen. In certain embodiments, R2is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1 nitrogen atom. In certain embodiments, R2is an 8-10 membered saturated bicyclic heterocyclyl having 1 nitrogen atom. In certain embodiments, R2is

[0262] In certain embodiments, R2is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R6. In certain embodiments, R2is a 4-6 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R6. In certain embodiments, R2is a 5-6 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substitutedwith n occurrences of R6. In certain embodiments, R2is a 5-membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R6. In certain embodiments, R2is a 6-membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R6.

[0263] In certain embodiments, R2is a 3-7 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R6. In certain embodiments, R2is a 5-6 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R6. In certain embodiments, R2is a 3-7 membered partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R6. In certain embodiments, R2is a 5-6 membered partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R6.

[0264] In certain embodiments, R2is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R6. In certain embodiments, R2is a 5-6 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen and oxygen; wherein said heterocyclyl is substituted with n occurrences of R6. In certain embodiments, R2is a 5-6 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen and oxygen; wherein said heterocyclyl is substituted with n occurrences of R6.

[0265] In certain embodiments, R2is a 3-7 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0266] In certain embodiments, R2is azetidinyl, pyrrolidinyl, piperidinyl, or morpholinyl; each of which is substituted with n occurrences of R6. In certain embodiments, R2is azetidinyl substituted with n occurrences of R6. In certain embodiments, R2is pyrrolidinyl substituted with n occurrences of R6. In certain embodiments, R2is pyrrolidin-2-yl substituted with n occurrencesof R6. In certain embodiments, R2is pyrrolidin-2-yl substituted with a single occurrence of R6at the 1-position. In certain embodiments, R2is piperidinyl substituted with n occurrences of R6. In certain embodiments, R2is morpholinyl substituted with n occurrences of R6.

[0267] In certain embodiments, R2is azetidinyl, pyrrolidinyl, piperidinyl, or morpholinyl. In certain embodiments, R2is azetidinyl. In certain embodiments, R2is pyrrolidinyl. In certain embodiments, R2is pyrrolidin-2-yl. In certain embodiments, R2is l-methyl-pyrrolidin-2-yl. In certain embodiments, R2is piperidinyl. In certain embodiments, R2is morpholinyl.

[0268] In certain embodiments, R2is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with n occurrences of R6.

[0269] In certain embodiments, R2is phenyl substituted with n occurrences of R6. In certain embodiments, R2is phenyl.

[0270] In certain embodiments, R2is C1-6 aliphatic substituted with n occurrences of R6. In certain embodiments, R2is C3-6 cycloaliphatic substituted with n occurrences of R6. In certain embodiments, R2is a C1-6 aliphatic chain substituted with n occurrences of R6. In certain embodiments, R2is C3-6 cycloalkyl substituted with n occurrences of R6. In certain embodiments, R2is C1-6 alkyl substituted with n occurrences of R6.

[0271] In certain embodiments, R2is C1-6 aliphatic. In certain embodiments, R2is C3-6 cycloaliphatic. In certain embodiments, R2is a C1-6 aliphatic chain. In certain embodiments, R2is C3-6 cycloalkyl. In certain embodiments, R2is C1-6 alkyl. In certain embodiments, R2is selected from those depicted in the compounds in Table 1, below.

[0272] In certain embodiments, In certain embodiments, -L2-R2isselected from those depicted in the compounds in Table 1, below.

[0273] As defined generally above, R3represents independently for each occurrence hydrogen, halo, or C1-4 alkyl. In certain embodiments, R3is hydrogen. In certain embodiments, R3represents independently for each occurrence halo or C1-4 alkyl. In certain embodiments, R3represents independently for each occurrence halo. In certain embodiments, R3is fluoro. In certain embodiments, R3represents independently for each occurrence C1-4 alkyl. In certain embodiments,R3is methyl. Tn certain embodiments, R3represents independently for each occurrence hydrogen or fluoro. In certain embodiments, R3is hydrogen or fluoro. In certain embodiments, R3is selected from those depicted in the compounds in Table 1, below.

[0274] As defined generally above, R5represents independently for each occurrence 3-6 membered heterocycle, C2-6 alkynyl, C2-6 alkenyl, C1-6 alkyl, hydroxyl, C1-6 alkoxyl, halo, amine, or cyano; wherein said C2-6 alkynyl is substituted with 0 or 1 phenyl or 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0275] In certain embodiments, R5represents independently for each occurrence C2-6 alkynyl, C2-6 alkenyl, C1-6 alkyl, hydroxyl, C1-6 alkoxyl, halo, or cyano; wherein said C2-6 alkynyl is substituted with phenyl or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0276] In certain embodiments, R5represents independently for each occurrence C2-6 alkynyl, C2-6 alkenyl, C1-6 alkyl, hydroxyl, C1-6 alkoxyl, halo, or cyano.

[0277] In certain embodiments, R5represents independently for each occurrence C2-6 alkynyl, C2-6 alkenyl, C1-6 alkyl, or hydroxyl. In certain embodiments, R5represents independently for each occurrence ethynyl, ethenyl, C1.3 alkyl, or hydroxyl. In certain embodiments, R5represents independently for each occurrence C2-6 alkynyl or hydroxyl. In certain embodiments, R5represents independently for each occurrence ethynyl or hydroxyl. In certain embodiments, one occurrence of R5is ethynyl. In certain embodiments, one occurrence of R5is hydroxyl.

[0278] In certain embodiments, R5represents independently for each occurrence C2-6 alkynyl, C1-6 alkyl, hydroxyl, or halo. In certain embodiments, R5represents independently for each occurrence -C=CH, methyl, hydroxyl, fluoro, or chloro. In certain embodiments, R5represents independently for each occurrence -C=CH, hydroxyl, or fluoro.

[0279] In certain embodiments, R5represents independently for each occurrence C2-6 alkynyl, C2-6 alkenyl, or C1-6 alkyl. In certain embodiments, R5represents independently for each occurrence ethynyl, ethenyl, or C1-3 alkyl. In certain embodiments, R5represents independently for each occurrence hydroxyl or C 1-6 alkoxyl. In certain embodiments, R5represents independently for each occurrence halo or cyano.

[0280] In certain embodiments, R5represents independently for each occurrence 3-6 membered heterocycle. In certain embodiments, R5represents independently for each occurrence a 3-6 membered saturated or partially unsaturated heterocyclyl having 1, 2, or 3 heteroatomsindependently selected from nitrogen, oxygen, and sulfur. Tn certain embodiments, R5represents independently for each occurrence C2-6 alkynyl. In certain embodiments, R5is ethynyl. In certain embodiments, R5represents C2-6 alkynyl substituted with phenyl or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R5represents independently for each occurrence C2-6 alkenyl. In certain embodiments, R5is ethenyl. In certain embodiments, R5represents independently for each occurrence C1-6 alkyl. In certain embodiments, R5represents independently for each occurrence C1-3 alkyl. In certain embodiments, R5is methyl. In certain embodiments, R5is hydroxyl. In certain embodiments, R5represents independently for each occurrence C1-6 alkoxyl. In certain embodiments, R5represents independently for each occurrence halo. In certain embodiments, R5represents independently for each occurrence fluoro or chloro. In certain embodiments, R5is fluoro. In certain embodiments, R5is chloro. In certain embodiments, R5is -NH2. In certain embodiments, R5is cyano. In certain embodiments, R5is selected from those depicted in the compounds in Table 1, below.

[0281] As defined generally above, R6and R7each represent independently for each occurrence halo, hydroxyl, C1-6 alkoxyl, C1-6 haloalkoxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, -(C1-6 alkylene)-C1-6 alkoxyl, -(C0-6 alkylene)-C1-6 cycloalkyl, -(C0-4 alkylene)-cyano, -C(O)OR8, - C(O)N(R9)2, 3-6 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or -N(R9)2.

[0282] In certain embodiments, R6represents independently for each occurrence halo, hydroxyl, C1-6 alkoxyl, C1-6 haloalkoxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, -(C0-4 alkylene)-cyano, -C(O)OR8, -C(O)N(R9)2, or -N(R9)2. In certain embodiments, R6represents independently for each occurrence halo, hydroxyl, C1-6 alkoxyl, C1-6 haloalkoxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, -(Co-4 alkylene)-cyano, or -N(R9)2.

[0283] In certain embodiments, R6represents independently for each occurrence halo, hydroxyl, C1-6 alkoxyl, C1-6 haloalkoxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, cyano, or - N(R9)2. In certain embodiments, R6represents independently for each occurrence halo, hydroxyl, C1-6 alkoxyl, C1-6 haloalkoxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, or -N(R9)2. In certain embodiments, R6represents independently for each occurrence halo, hydroxyl, C1-6 alkoxyl, C1-6 alkyl, or C1-6 haloalkyl. In certain embodiments, R6represents independently for each occurrence halo, C1-6 alkyl, C1-6 haloalkyl, or C3-6 cycloalkyl. In certain embodiments, R6representsindependently for each occurrence halo, C1-6 alkyl, or C1-6 haloalkyl. In certain embodiments, R6represents independently for each occurrence halo or C1-6 alkyl. In certain embodiments, R6represents independently for each occurrence fluoro or methyl. In certain embodiments, R6represents independently for each occurrence halo, hydroxyl, or C1-6 alkyl.

[0284] In certain embodiments, R6represents independently for each occurrence halo, hydroxyl, C1-6 alkoxyl, C1-6 haloalkoxyl, or -N(R9)2. In certain embodiments, R6represents independently for each occurrence halo, hydroxyl, or -N(R9)2. In certain embodiments, R6represents independently for each occurrence halo, C1-6 alkoxyl, or C1-6 haloalkoxyl. In certain embodiments, R6represents independently for each occurrence halo, C1-6 alkyl, C1-6 haloalkyl, C1- 6 hydroxyalkyl, or -(C1-4 alkylene)-cyano. In certain embodiments, R6represents independently for each occurrence halo, C1-6 alkyl, C1-6 haloalkyl, or C1-6 hydroxyalkyl. In certain embodiments, R6represents independently for each occurrence C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, or - (C1-4 alkylene)-cyano. In certain embodiments, R6represents independently for each occurrence C1-6 alkyl, C1-6 haloalkyl, or C1-6 hydroxyalkyl. In certain embodiments, R6represents independently for each occurrence C1-6 alkyl or C1-6 haloalkyl.

[0285] In certain embodiments, R6represents independently for each occurrence halo. In certain embodiments, R6represents independently for each occurrence fluoro or chloro. In certain embodiments, R6is fluoro. In certain embodiments, R6is chloro. In certain embodiments, R6is hydroxyl. In certain embodiments, R6represents independently for each occurrence C1-6 alkoxyl. In certain embodiments, R6is methoxy. In certain embodiments, R6represents independently for each occurrence C1-6 haloalkoxyl. In certain embodiments, R6is trifluoromethoxy. In certain embodiments, R6represents independently for each occurrence C1-6 alkyl. In certain embodiments, R6represents independently for each occurrence C1-3 alkyl. In certain embodiments, R6is methyl. In certain embodiments, R6represents independently for each occurrence C1-6 haloalkyl. In certain embodiments, R6is trifluoromethyl. In certain embodiments, R6represents independently for each occurrence C1-6 hydroxyalkyl. In certain embodiments, R6represents independently for each occurrence -(C0-6 alkylene)-C3-6 cycloalkyl. In certain embodiments, R6is -(Co-4 alkylene)-cyano. In certain embodiments, R6is -(C 1-4 alkylene)-cyano. In certain embodiments, R6is cyano. In certain embodiments, R6represents independently for each occurrence -C(O)OR8. In certain embodiments, R6represents independently for each occurrence -C(O)N(R9)2. In certain embodiments, R6represents independently for each occurrence -N(R9)2. In certain embodiments,R6represents independently for each occurrence 3-6 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R6is -NH2. In certain embodiments, R6is selected from those depicted in the compounds in Table 1, below.

[0286] In certain embodiments, R7represents independently for each occurrence halo, hydroxyl, C1-6 alkoxyl, C1-6 haloalkoxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, -(C0-4 alkylene)-cyano, or -N(R9)2.

[0287] In certain embodiments, R7represents independently for each occurrence halo, hydroxyl, C1-6 alkoxyl, C1-6 alkyl, or C1-6 haloalkyl. In certain embodiments, R7represents independently for each occurrence halo, hydroxyl, C1-6 alkyl, C1-6 hydroxyalkyl, or oxiranyl. In certain embodiments, R7represents independently for each occurrence halo, hydroxyl, C1-6 alkyl, or C1-6 hydroxyalkyl. In certain embodiments, R7represents independently for each occurrence halo, C1-6 alkyl, or C1-6 haloalkyl. In certain embodiments, R7represents independently for each occurrence halo or C1-6 alkyl. In certain embodiments, R7represents independently for each occurrence halo, hydroxyl, or C1-6 alkyl.

[0288] In certain embodiments, R7represents independently for each occurrence halo, hydroxyl, C1-6 alkoxyl, C1-6 haloalkoxyl, or -N(R9)2. In certain embodiments, R7represents independently for each occurrence halo, hydroxyl, or -N(R9)2. In certain embodiments, R7represents independently for each occurrence halo, C1-6 alkoxyl, or C1-6 haloalkoxyl. In certain embodiments, R7represents independently for each occurrence halo, C1-6 alkyl, C1-6 haloalkyl, or C1-6 hydroxyalkyl. In certain embodiments, R7represents independently for each occurrence C1-6 alkyl, C1-6 haloalkyl, or C1-6 hydroxyalkyl. In certain embodiments, R7represents independently for each occurrence C1-6 alkyl or C1-6 haloalkyl.

[0289] In certain embodiments, R7represents independently for each occurrence fluoro, hydroxyl, methyl, hydroxymethyl, or oxiranyl. In certain embodiments, R7represents independently for each occurrence fluoro, hydroxyl, methyl, or hydroxymethyl.

[0290] In certain embodiments, R7represents independently for each occurrence halo. In certain embodiments, R7represents independently for each occurrence fluoro or chloro. In certain embodiments, R7is fluoro. In certain embodiments, R7is chloro. In certain embodiments, R7is hydroxyl. In certain embodiments, R7represents independently for each occurrence C1-6 alkoxyl. In certain embodiments, R7is methoxy. In certain embodiments, R7represents independently foreach occurrence C1-6 haloalkoxyl. In certain embodiments, R7is trifluoromethoxy. In certain embodiments, R7represents independently for each occurrence C1-6 alkyl. In certain embodiments, R7represents independently for each occurrence C1.3 alkyl. In certain embodiments, R7is methyl. In certain embodiments, R7represents independently for each occurrence C1-6 haloalkyl. In certain embodiments, R7is trifluoromethyl. In certain embodiments, R7represents independently for each occurrence C1-6 hydroxyalkyl. In certain embodiments, R7is hydroxymethyl. In certain embodiments, R7represents independently for each occurrence -(C0-6 alkylene)-C3-6 cycloalkyl. In certain embodiments, R7represents independently for each occurrence C3-6 cycloalkyl. In certain embodiments, R7is cyclopropyl. In certain embodiments, R7represents independently for each occurrence -(Co-4 alkylene)-cyano. In certain embodiments, R7is cyano. In certain embodiments, R7represents independently for each occurrence -C(O)OR8. In certain embodiments, R7represents independently for each occurrence -C(O)N(R9)2. In certain embodiments, R7represents independently for each occurrence 3-6 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R7is oxiranyl. In certain embodiments, at least one occurrence of R7is oxiranyl. In certain embodiments, R7represents independently for each occurrence -N(R9)2. In certain embodiments, R7is -NH2. In certain embodiments, R7is selected from those depicted in the compounds in Table 1, below.

[0291] As defined generally above, R8and R9each represent independently for each occurrence hydrogen, optionally substituted C1-6 alkyl, optionally substituted C3-5 cycloalkyl, optionally substituted C3-6 heterocyclyl, aryl, -C(O)H, or -C(O)(C1-4 alkyl); or two occurrences ofR9attached to the same nitrogen atom are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring.

[0292] In certain embodiments, R8and R9each represent independently for each occurrence hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C3-5 cycloalkyl, -C(O)H, or -C(O)(C1-4 alkyl); or two occurrences of R9attached to the same nitrogen atom are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring. In certain embodiments, R8and R9each represent independently for each occurrence hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C3-5 cycloalkyl, -C(O)H, or -C(O)(C1-4 alkyl). In certain embodiments, R8and R9each represent independently for each occurrence hydrogen, C1-6 alkyl, or C3-5 cycloalkyl.

[0293] Tn certain embodiments, R8represents independently for each occurrence hydrogen, optionally substituted C1-6 alkyl, optionally substituted C3-5 cycloalkyl, -C(O)H, or -C(O)(C1-4 alkyl). In certain embodiments, R8represents independently for each occurrence hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C3-5 cycloalkyl, C1-4 alkyl(C3-5 cycloalkyl), C1-4 alkyl(aryl), -C(O)H, or -C(O)(C1-4 alkyl). In certain embodiments, R8represents independently for each occurrence hydrogen, C1-6 alkyl, or C3-5 cycloalkyl.

[0294] In certain embodiments, R8represents independently for each occurrence hydrogen, optionally substituted C1-6 alkyl, or optionally substituted C3-5 cycloalkyl. In certain embodiments, R8represents independently for each occurrence hydrogen or optionally substituted C1-6 alkyl. In certain embodiments, R8represents independently for each occurrence hydrogen or methyl. In certain embodiments, R8represents independently for each occurrence optionally substituted C1-6 alkyl or optionally substituted C3-5 cycloalkyl. In certain embodiments, R8represents independently for each occurrence -C(O)H or -C(O)(C1-4 alkyl).

[0295] In certain embodiments, R8is hydrogen. In certain embodiments, R8represents independently for each occurrence optionally substituted C1-6 alkyl. In certain embodiments, R8represents independently for each occurrence C1-6 alkyl, C1-6 haloalkyl, or C1-6 hydroxyalkyl. In certain embodiments, R8represents independently for each occurrence C1-6 alkyl. In certain embodiments, R8is methyl. In certain embodiments, R8represents independently for each occurrence optionally substituted C3-5 cycloalkyl. In certain embodiments, R8represents independently for each occurrence C3-5 cycloalkyl. In certain embodiments, R8is cyclopropyl. In certain embodiments, R8is -C(O)H. In certain embodiments, R8represents independently for each occurrence -C(O)(C1-4 alkyl). In certain embodiments, R8is selected from those depicted in the compounds in Table 1, below.

[0296] As defined generally above, R9represents independently for each occurrence hydrogen, optionally substituted C1-6 alkyl, optionally substituted C3-5 cycloalkyl, -C(O)H, or -C(O)(C1-4 alkyl); or two occurrences of R9attached to the same nitrogen atom are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring.

[0297] In certain embodiments, R9represents independently for each occurrence hydrogen, optionally substituted C1-6 alkyl, or optionally substituted C3-5 cycloalkyl; or two occurrences of R9attached to the same nitrogen atom are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring.

[0298] Tn certain embodiments, R9represents independently for each occurrence hydrogen, optionally substituted C1-6 alkyl, optionally substituted C3-5 cycloalkyl, -C(O)H, or -C(O)(C1-4 alkyl). In certain embodiments, R9represents independently for each occurrence hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C3-5 cycloalkyl, -C(O)H, or -C(O)(C1-4 alkyl). In certain embodiments, R9represents independently for each occurrence hydrogen, C1-6 alkyl, or C3-5 cycloalkyl.

[0299] In certain embodiments, R9represents independently for each occurrence hydrogen, optionally substituted C1-6 alkyl, optionally substituted C3-5 cycloalkyl, -C(O)H, or -C(O)(C1-4 alkyl). In certain embodiments, R9represents independently for each occurrence hydrogen, optionally substituted C1-6 alkyl, or optionally substituted C3-5 cycloalkyl. In certain embodiments, R9represents independently for each occurrence hydrogen or optionally substituted C1-6 alkyl. In certain embodiments, R9represents independently for each occurrence hydrogen or methyl. In certain embodiments, R9represents independently for each occurrence optionally substituted C1-6 alkyl or optionally substituted C3-5 cycloalkyl. In certain embodiments, R9represents independently for each occurrence -C(O)H or -C(O)(C1-4 alkyl).

[0300] In certain embodiments, two occurrences of R9attached to the same nitrogen atom are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring. In certain embodiments, two occurrences of R9attached to the same nitrogen atom are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom.

[0301] In certain embodiments, R9is hydrogen. In certain embodiments, R9represents independently for each occurrence optionally substituted C1-6 alkyl. In certain embodiments, R9represents independently for each occurrence C1-6 alkyl, C1-6 haloalkyl, or C1-6 hydroxyalkyl. In certain embodiments, R9represents independently for each occurrence C1-6 alkyl. In certain embodiments, R9is methyl. In certain embodiments, R9represents independently for each occurrence optionally substituted C3-5 cycloalkyl. In certain embodiments, R9represents independently for each occurrence C3-5 cycloalkyl. In certain embodiments, R9is cyclopropyl. In certain embodiments, R9is -C(O)H. In certain embodiments, R9represents independently for each occurrence -C(O)(C1-4 alkyl). In certain embodiments, R9is selected from those depicted in the compounds in Table 1, below.

[0302] As defined generally above, A1is one of the following: a. a 3-8 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 6-11 membered saturated or partially unsaturated polycyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein each heterocyclyl is substituted with (i) p occurrences of R7, and (ii) 0, 1, or 2 oxo; and wherein said monocyclic heterocyclyl is substituted with 0 or 1 occurrence of -(Co-4 alkylene)-(5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), a 4-6 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms, or - (Co-4 alkylene)-phenyl, each of which is optionally substituted; b. C3-10 cycloaliphatic, phenyl, indanyl, a 5- or 6-membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-, 9-, or 10-membered bicyclic heteroaryl having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with p occurrences of R7; c. -CN, -N(R8)2, or hydroxyl; or

[0303] In certain embodiments, A1is a 4-8 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated ortho-fused heterocyclyl having 1 or 2 nitrogen atoms; a C3-10 cycloaliphatic; or a 5-6 membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with p occurrences of R7.

[0304] In certain embodiments, A1is C3-10 cycloaliphatic, phenyl, or indanyl, each of which is substituted with p occurrences of R7. In certain embodiments, A1is phenyl substituted with p occurrences of R7. In certain embodiments, A1is phenyl substituted with 1 occurrence of R7. In certain embodiments, A1is 5- or 6-membered monocyclic heteroaryl having 1, 2, or 3 heteroatomsindependently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with p occurrences of R7. In certain embodiments, A1is an 8-, 9-, or 10-membered bicyclic heteroaryl having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with p occurrences of R7.

[0305] In certain embodiments, A1is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated ortho-fused heterocyclyl having 1 or 2 nitrogen atoms; or a 5-6 membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with p occurrences of R7.

[0306] In certain embodiments, A1is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 5-6 membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with p occurrences of R7. In certain embodiments, A1is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 5-6 membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0307] In certain embodiments, A1is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated ortho-fused heterocyclyl having 1 or 2 nitrogen atoms; or a 5-6 membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0308] In certain embodiments, A1is a 3-8 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 6-11 membered saturated or partially unsaturated polycyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein each heterocyclyl is substituted with (i) p occurrences of R7, and (ii) 0, 1, or 2 oxo; and wherein said monocyclic heterocyclyl is substituted with 0 or 1 occurrence of -(C0-4 alkylene)-(5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), a 4-6 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms, or phenyl, each of which is optionally substituted. In certain embodiments, A1is a 3-8membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 6-11 membered saturated or partially unsaturated polycyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein each heterocyclyl is substituted with (i) p occurrences of R7, and (ii) 0, 1, or 2 oxo.

[0309] In certain embodiments, A1is a 4-8 membered saturated monocyclic heterocyclyl having 1 nitrogen atom; a 4- or 5-membered saturated monocyclic heterocyclyl having 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6- 11 membered saturated ortho-fused heterocyclyl having 1 or 2 nitrogen atoms; each of which is substituted with p occurrences of R7. In certain embodiments, A1is a 4-7 membered saturated monocyclic heterocyclyl having 1 nitrogen atom; a 4- or 5-membered saturated monocyclic heterocyclyl having 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho-fused heterocyclyl having 1 or 2 nitrogen atoms; each of which is substituted with p occurrences of R7.

[0310] In certain embodiments, A1is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho-fused heterocyclyl having 1 or 2 nitrogen atoms; each of which is substituted with p occurrences of R7. In certain embodiments, A1is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho-fused heterocyclyl having 1 or 2 nitrogen atoms.

[0311] In certain embodiments, A1is a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho-fused heterocyclyl having 1 or2 nitrogen atoms; each of which is substituted with p occurrences of R7. In certain embodiments, A1is a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho-fused heterocyclyl having 1 or 2 nitrogen atoms.

[0312] In certain embodiments, A1is a 3-8 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said heterocyclyl is substituted with (i) p occurrences of R7, (ii) 0, 1, or 2 oxo; and (iii) 0 or 1 occurrence of -(Co-4 alkylene)-(5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), a 4-6 memberedsaturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms, or phenyl, each of which is optionally substituted. In certain embodiments, A1is a 3-8 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said heterocyclyl is substituted with (i) p occurrences of R7, (ii) 0, 1, or 2 oxo; and (iii) 0 or 1 occurrence of -(C0-4 alkylene)-(5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), a 4-6 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms, or phenyl.

[0313] In certain embodiments, A1is a 3-8 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with (i) p occurrences of R7, and (ii) 0, 1, or 2 oxo. In certain embodiments, A1is a 3-8 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with (i) p occurrences of R7, and (ii) 1 or 2 oxo. In certain embodiments, A1is a 3-8 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with p occurrences of R7

[0314] In certain embodiments, A1is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with p occurrences of R7. In certain embodiments, A1is a 5- or 6- membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with p occurrences of R7. In certain embodiments, A1is a 5- or 6-membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0315] In certain embodiments, A1is a 4-8 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R7. In certain embodiments, A1is a 4-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R7. In certain embodiments, A1is a 4-8 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R7.

[0316] In certain embodiments, A1is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R7. In certain embodiments, A1is a 5-6 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R7. In certain embodiments, A1is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms. In certain embodiments, A1is a 5-6 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms.

[0317] In certain embodiments, A1is a 4-8 membered saturated monocyclic heterocyclyl having 1 nitrogen atom; or a 4- or 5-membered saturated monocyclic heterocyclyl having 2 nitrogen atoms; each of which is substituted with p occurrences of R7. In certain embodiments, A1is a 4-7 membered saturated monocyclic heterocyclyl having 1 nitrogen atom; or a 4- or 5- membered saturated monocyclic heterocyclyl having 2 nitrogen atoms; each of which is substituted with p occurrences of R7. In certain embodiments, A1is a 4-7 membered saturated monocyclic heterocyclyl having 1 nitrogen atom; or a 4- or 5-membered saturated monocyclic heterocyclyl having 2 nitrogen atoms.

[0318] In certain embodiments, A1is a 4-8 membered saturated monocyclic heterocyclyl having 1 nitrogen atom; wherein said heterocyclyl is substituted with p occurrences of R7. In certain embodiments, A1is a 4-7 membered saturated monocyclic heterocyclyl having 1 nitrogen atom; wherein said heterocyclyl is substituted with p occurrences of R7. In certain embodiments, A1is a 4- or 5-membered saturated monocyclic heterocyclyl having 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R7.

[0319] In certain embodiments, A1is a 4-8 membered saturated monocyclic heterocyclyl having 1 nitrogen atom. In certain embodiments, A1is a 4-7 membered saturated monocyclic heterocyclyl having 1 nitrogen atom. In certain embodiments, A1is a 4- or 5-membered saturated monocyclic heterocyclyl having 2 nitrogen atoms.

[0320] In certain embodiments, A1is a 4-5 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen; wherein said heterocyclyl is substituted with p occurrences of R7.

[0321] In certain embodiments, A1is 1,4-diazepanyl, piperidinyl, piperazinyl, pyrrolidinyl, or azetidinyl; each of which is substituted with p occurrences of R7. In certain embodiments, A1is piperidinyl, pyrrolidinyl, or azetidinyl; each of which is substituted with p occurrences of R7. Incertain embodiments, A1is 1 ,4-diazepanyl substituted with p occurrences of R7. In certain embodiments, A1is piperidinyl substituted with p occurrences of R7. In certain embodiments, A1is piperazinyl substituted with p occurrences of R7. In certain embodiments, A1is pyrrolidinyl substituted with p occurrences of R7. In certain embodiments, A1is azetidinyl substituted with p occurrences of R7.

[0322] In certain embodiments, A1is 1,4-diazepanyl, piperidinyl, piperazinyl, pyrrolidinyl, or azetidinyl. In certain embodiments, A1is piperidinyl, pyrrolidinyl, or azetidinyl. In certain embodiments, A1is 1,4-diazepanyl. In certain embodiments, A1is piperidinyl. In certain embodiments, A1is piperazinyl. In certain embodiments, A1is pyrrolidinyl. In certain embodiments, A1is azetidinyl.

[0323] In certain embodiments, A1is 1,4-diazepan-l-yl, piperidin-4-yl, piperazin- 1-yl, pyrrolidin-3-yl, or azetidin-3-yl; each of which is substituted with p occurrences of R7In certain embodiments, A1is 1,4-diazepan-l-yl substituted with p occurrences of R7. In certain embodiments, A1is piperidin-4-yl substituted with p occurrences of R7. In certain embodiments, A1is piperazin- 1-yl substituted with p occurrences of R7. In certain embodiments, A1is pyrrolidin- 3-yl substituted with p occurrences of R7. In certain embodiments, A1is azetidin-3-yl substituted with p occurrences of R7.

[0324] In certain embodiments, A1is 1,4-diazepan-l-yl, piperidin-4-yl, piperazin- 1-yl, pyrrolidin-3-yl, or azetidin-3-yl. In certain embodiments, A1is 1,4-diazepan-l-yl. In certain embodiments, A1is piperidin-4-yl. In certain embodiments, A1is piperazin- 1-yl. In certain embodiments, A1is pyrrolidin-3-yl. In certain embodiments, A1is azetidin-3-yl.

[0325] In certain embodiments, A1is piperidin-l-yl, pyrrolidin-l-yl, or azetidin-l-yl; each of which is substituted with p occurrences of R7. In certain embodiments, A1is piperidin-l-yl substituted with p occurrences of R7. In certain embodiments, A1is pyrrolidin-l-yl substituted with p occurrences of R7. In certain embodiments, A1is azetidin-l-yl substituted with p occurrences of R7.

[0326] In certain embodiments, A1is piperidin-l-yl, pyrrolidin-l-yl, or azetidin-l-yl. In certain embodiments, A1is piperidin-l-yl. In certain embodiments, A1is pyrrolidin-l-yl. In certain embodiments, A1is azetidin-l-yl.

[0327] In certain embodiments, A1is azetidinyl, pyrrolidinyl, or phenyl, each of which is substituted with p occurrences of R7and 0 or 1 occurrence of -(Co-4 alkylene)-(5-6 memberedmonocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), a 4-6 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms, or -(Co-4 alkylene)-phenyl, each of which is optionally substituted. In certain embodiments, A1is azetidinyl, pyrrolidinyl, or phenyl, each of which is substituted with p occurrences of R7, and the azetidinyl and pyrrolidinyl are substituted with 0 or 1 occurrence of— (Co-4 alkylene)-(5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), a 4-6 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms, or— (Co-4 alkylene)-phenyl, each of which is optionally substituted.

[0328] In certain embodiments, A1is a 6-11 membered saturated or partially unsaturated polycyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with (i) p occurrences of R7, and (ii) 0, 1, or 2 oxo.

[0329] In certain embodiments, A1is a 6-11 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with (i) p occurrences of R7, and (ii) 0, 1, or 2 oxo. In certain embodiments, A1is a 6-11 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with (i) p occurrences of R7, and (ii) 1 or 2 oxo. In certain embodiments, A1is a 6-11 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with (i) p occurrences of R7. In certain embodiments, A1is a 6-11 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0330] In certain embodiments, A1is a 6-11 membered saturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with (i) p occurrences of R7, and (ii) 0, 1, or 2 oxo. In certain embodiments, A1is a 6-11 membered saturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with (i) p occurrences of R7, and (ii) 1 or 2 oxo. In certain embodiments, A1is a 6-11 membered saturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with (i) p occurrences of R7. In certainembodiments, A1is a 6-11 membered saturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0331] In certain embodiments, A1is a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R7. In certain embodiments, A1is a 7-10 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R7. In certain embodiments, A1is a 6-11 membered saturated spirocyclic heterocyclyl having 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R7.

[0332] In certain embodiments, A1is a 6-11 membered saturated or partially unsaturated fused heterocyclyl having 1 or 2 nitrogen atoms and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments,

[0333] In certain embodiments, A1is a 4-7 membered saturated or partially unsaturated monocyclic cycloalkyl. In certain embodiments, A1is

[0334] In certain embodiments, A1is a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms. In certain embodiments, A1is a 7- 10 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms. In certain embodiments, A1is a 6-11 membered saturated spirocyclic heterocyclyl having 2 nitrogen atoms. In certain embodiments,

[0335] In certain embodiments, A1is a substituted 7-10 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms. In certain embodiments, A1is

[0336] In certain embodiments, A1is a substituted 3-8 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms. In certain embodiments, A1is

[0339] In certain embodiments, A1is -CN, -N(R8)2, or hydroxyl. In certain embodiments, A1is -CN. In certain embodiments, A1is -N(R8)2. In certain embodiments, A1is hydroxyl.

[0340] In certain embodiments, A1is selected from the following:

[0341] In certain embodiments, -A1is selected from the following:

[0342] In certain embodiments, A1is selected from those depicted in the compounds in Table1, below.

[0343] Tn certain embodiments, -L1-A1is selected from the following:

[0344] In certain embodiments, -L1-A1is selected from the following:

[0346] In certain embodiments, -L1-A1is -N(H or C1-6 alkyl)-(Co-3 alkylene)-phenyl, wherein the phenyl is substituted with 1 or 2 occurrences of R7. In certain embodiments, -L1-A1is -N(H or C1-6 alkyl)-(Co-3 alkylene)-phenyl, wherein the phenyl is substituted with 1 occurrence of R7. In certain embodiments, -L1-A1is selected from those depicted in the compounds in Table 1, below.

[0347] As defined generally above, X1and X2each represent independently N or CH. In certain embodiments X1is CH, and X2is N. In certain embodiments, X1and X2are N. In certain embodiments, X1and X2are CH. In certain embodiments, X1is N. In certain embodiments, X1is CH. In certain embodiments, X2is N. In certain embodiments, X2is CH. In certain embodiments, X1and X2each represent independently those depicted in the compounds in Table 1, below.

[0348] As defined generally above, X3, X4, and X5each represent independently N or CR3. In certain embodiments X3is N, X4is CR3, and X~ is N. In certain embodiments, X3, X4, and X~ each represent independently N or CH. In certain embodiments, X3, X4, and X5are N. In certain embodiments, X3, X4, and X5are CH.

[0349] In certain embodiments X1, X2, X3, X4, and X5are independently N or CH. In certain embodiments X1is CH, X2is N, X3is N, X4is CR3, and X5is N. In certain embodiments, any one of X1, X2, X3, X4, and X5is N. In certain embodiments, any two of X1, X2, X3, X4, and X5is N. In certain embodiments, any three of X1, X2, X3, X4, and X5is N. In certain embodiments, each of X1, X2, X3, X4, and X5is selected from those depicted in the compounds in Table 1, below.

[0350] As defined generally above, Y1and Y2represent independently a C1-3 bivalent saturated or unsaturated, straight hydrocarbon chain which is substituted with q occurrences of R7. In certain embodiments, Y1is a C1-3 bivalent saturated, straight hydrocarbon chain. In certain embodiments, Y2is a C1-3 bivalent saturated, straight hydrocarbon chain. In certain embodiments, each of Y1and Y2is selected from those depicted in the compounds in Table 1, below.

[0351] As defined generally above, L1and L2are independently a covalent bond or a C1-4 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or twomethylene units of the chain are optionally and independently replaced by -O-, -N(R9)-, -C(O)-, or an optionally substituted C3-5 cycloalkylene. In certain embodiments, L1is selected from those depicted in the compounds in Table 1, below.

[0352] In certain embodiments, L1is a covalent bond or a C1-4 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -O-, -N(R9)-, -C(O)-, or an optionally substituted C3-5 cycloalkylene. In certain embodiments, L1is a covalent bond or -N(R9)-(Co-3 alkylene)-, wherein the C0-3 alkylene of L1is attached to A1. In certain embodiments, L1is a covalent bond or -N(H or C1-6 alkyl)-(Co-3 alkylene)-, wherein the C0-3 alkylene of L1is attached to A1. In certain embodiments, L1is a covalent bond or -N(H or C1-6 alkyl)-.

[0353] In certain embodiments, L1is a covalent bond. In certain embodiments, L1is a C1-4 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -O-, -N(R9)-, -C(O)-, or an optionally substituted C3-5 cycloalkylene.

[0354] In certain embodiments, L1is -N(R9)-(Co-3 alkylene)-, wherein the C0-3 alkylene of L1is attached to A1. In certain embodiments, L1is -N(R9)-. In certain embodiments, L1is -N(R9)-CH2- or -N(R9)-(CH2)2-, wherein the terminal carbon atom of L1is attached to A1. In certain embodiments, L1is -N(H or C1-6 alkyl)-(Co-3 alkylene)-, wherein the C0-3 alkylene of L1is attached to A1. In certain embodiments, L1is -N(H or C1-6 alkyl)-. In certain embodiments, L1is -N(H or C1-6 alkyl)-CH2- or -N(H or C1-6 alkyl)-(CH2)2-, wherein the terminal carbon atom of L1is attached to A1. In certain embodiments, L1is selected from those depicted in the compounds in Table 1, below.

[0355] In certain embodiments, L2is a covalent bond or a C1-4 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -O-, -N(R9)-, -C(O)-, or optionally substituted C3-5 cycloalkylene. In certain embodiments, L2is a covalent bond or a C2-4 bivalent saturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -O-, -N(R9)-, or cyclopropylene substituted with 0, 1, or 2 fluoro.

[0356] In certain embodiments, L2is a covalent bond. In certain embodiments, L2is a C1-4 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -O-, -N(R9)-, -C(O)-, oroptionally substituted C3-5 cycloalkylene. In certain embodiments, L2is a C2-4 bivalent saturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -O-, -N(R9)-, or cyclopropylene substituted with 0, 1, or 2 fluoro.

[0357] In certain embodiments, L2is -O-CH2-, -O-(CH2)2-, -N(R9)-CH2-, or -N(R9)-(CH2)2-, wherein the terminal carbon atom of L2is attached to R2. In certain embodiments, L2is -O-CH2-, wherein the terminal carbon atom of L2is attached to R2.

[0359] In certain embodiments, L2is selected from those depicted in the compounds in Table 1, below.

[0360] As defined generally above, m is 0, 1, 2, 3, or 4. In certain embodiments, m is 0. In certain embodiments, m is 1. In certain embodiments, m is 2. In certain embodiments, m is 3. In certain embodiments, m is 4. In certain embodiments, m is 0 or 1. In certain embodiments, m is 1 or 2. In certain embodiments, m is 2 or 3. In certain embodiments, m is 3 or 4. In certain embodiments, m is 0, 1, or 2. In certain embodiments, m is 1, 2, or 3. In certain embodiments, m is 2, 3, or 4. In certain embodiments, m is 0, 1, 2, or 3. In certain embodiments, m is 1, 2, 3, or 4. In certain embodiments, m is selected from the values represented in the compounds in Table 1, below.

[0361] As defined generally above, n is 0, 1, 2, 3, or 4. In certain embodiments, n is 0. In certain embodiments, n is 1. In certain embodiments, n is 2. In certain embodiments, n is 3. Incertain embodiments, n is 4. In certain embodiments, n is 0 or 1. In certain embodiments, n is 1 or 2. In certain embodiments, n is 2 or 3. In certain embodiments, n is 3 or 4. In certain embodiments, n is 0, 1, or 2. In certain embodiments, n is 1, 2, or 3. In certain embodiments, n is 2, 3, or 4. In certain embodiments, n is 0, 1, 2, or 3. In certain embodiments, n is 1, 2, 3, or 4. In certain embodiments, n is selected from the values represented in the compounds in Table 1, below.

[0362] As defined generally above, p is 0, 1, 2, 3, or 4. In certain embodiments, p is 0. In certain embodiments, p is 1. In certain embodiments, p is 2. In certain embodiments, p is 3. In certain embodiments, p is 4. In certain embodiments, p is 0 or 1. In certain embodiments, p is 1 or 2. In certain embodiments, p is 2 or 3. In certain embodiments, p is 3 or 4. In certain embodiments, p is 0, 1, or 2. In certain embodiments, p is 1, 2, or 3. In certain embodiments, p is 2, 3, or 4. In certain embodiments, p is 0, 1, 2, or 3. In certain embodiments, p is 1, 2, 3, or 4. In certain embodiments, p is selected from the values represented in the compounds in Table 1, below.

[0363] As defined generally above, q is 0, 1, 2, 3, or 4. In certain embodiments, q is 0. In certain embodiments, q is 1. In certain embodiments, q is 2. In certain embodiments, q is 3. In certain embodiments, q is 4. In certain embodiments, q is 0 or 1. In certain embodiments, q is 1 or 2. In certain embodiments, q is 2 or 3. In certain embodiments, q is 3 or 4. In certain embodiments, q is 0, 1, or 2. In certain embodiments, q is 1, 2, or 3. In certain embodiments, q is 2, 3, or 4. In certain embodiments, q is 0, 1, 2, or 3. In certain embodiments, q is 1, 2, 3, or 4. In certain embodiments, q is selected from the values represented in the compounds in Table 1, below.

[0364] The description above describes multiple embodiments relating to compounds of Formula (1-1). The patent application specifically contemplates all combinations of the embodiments.

[0365] In certain embodiments, the disclosure provides compounds of Formula la:or a pharmaceutically acceptable salt thereof, wherein each variable is as defined above for Formula 1-1 and its embodiments thereof.

[0366] In certain embodiments, the disclosure provides compounds of Formula lb, Ic, or Id:or a pharmaceutically acceptable salt thereof, wherein each variable is as defined above for Formula 1-1 and its embodiments thereof.

[0367] In certain embodiments, the disclosure provides compounds of Formula le:or a pharmaceutically acceptable salt thereof, wherein each variable is as defined above for Formula 1-1 and its embodiments thereof.

[0368] In certain embodiments, the disclosure provides compounds of Formula If, Ig, or Ih:or a pharmaceutically acceptable salt thereof, wherein each variable is as defined above for Formula 1-1 and its embodiments thereof.

[0369] Tn certain embodiments, the disclosure provides compounds of Formula li:or a pharmaceutically acceptable salt thereof, wherein each variable is as defined above for Formula 1-1 and its embodiments thereof.or a pharmaceutically acceptable salt thereof, wherein each variable is as defined above forFormula 1-1 and its embodiments thereof.

[0371] Another aspect of the disclosure provides a compound represented by Formula (Im):or a pharmaceutically acceptable salt thereof; wherein:R1is naphthyl substituted with m occurrences of R5;R2is -N(R8)2, or a 3-7 membered saturated monocyclic heterocyclylhaving 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;R3is fluoro or hydrogen;R5represents independently for each occurrence -C=CH, methyl, hydroxyl, fluoro, or chloro;R7represents independently for each occurrence halo, hydroxyl, C1-6 alkyl, C1-6 hydroxyalkyl, -S(O)2-(halo), or oxiranyl;R8represents independently for each occurrence hydrogen, C1-6 alkyl, or C3-5 cycloalkyl;L1is a covalent bond or -N(H or C1-6 alkyl)-(Co-3 alkylene)-, wherein the C0-3 alkylene of L1is attached to A1;wherein the terminal carbon atom of L2is attached to R2; m is 0, 1, 2, 3, or 4; and p is 0, 1, or 2.

[0372] The definitions of variables in Formula (Im) above encompass multiple chemical groups. The application contemplates embodiments where, for example, i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, ii) the definition of a variable is a collection of two or more of the chemical groups selected from those set forth above, and iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii).

[0373] In certain embodiments, the compound is a compound of Formula (Im).

[0374] As defined generally above, R1is naphthyl substituted with m occurrences of R5. In certain embodiments, R1is 1 -naphthyl substituted with m occurrences of R5.In certain embodiments, R2is -N(R8)2 or a 3-7 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certainembodiments, R2isIn certain embodiments, R2is -N(R8)2. In certain embodiments, R2is a 3-7 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0381] As defined generally above, R3is fluoro or hydrogen. In certain embodiments, R3is fluoro. In certain embodiments, R3is hydrogen.

[0382] As defined generally above, R5represents independently for each occurrence -C=CII, methyl, hydroxyl, fluoro, or chloro. In certain embodiments, R5represents independently for each occurrence -C=CH, hydroxyl, or fluoro. In certain embodiments, R5is -C=CH. In certain embodiments, R5is methyl. In certain embodiments, R5is hydroxyl. In certain embodiments, R5is fluoro. In certain embodiments, R5is chloro.

[0383] As defined generally above, R7represents independently for each occurrence halo, hydroxyl, C1-6 alkyl, C1-6 hydroxy alkyl, -S(O)2-(halo), or oxiranyl. In certain embodiments, R7represents independently for each occurrence halo, hydroxyl, C1-6 alkyl, C1-6 hydroxyalkyl, or oxiranyl. In certain embodiments, R7represents independently for each occurrence halo, hydroxyl,C1-6 alkyl, or C1-6 hydroxyalkyl. In certain embodiments, R7represents independently for each occurrence halo or C1-6 alkyl. In certain embodiments, R7represents independently for each occurrence halo, hydroxyl, or C1-6 alkyl. In certain embodiments, R7represents independently for each occurrence -(C0-4 alkylene)-S(O)2-(halo) or oxiranyl.

[0384] In certain embodiments, R7represents independently for each occurrence fluoro, hydroxyl, methyl, hydroxymethyl, -S(O)2F, or oxiranyl. In certain embodiments, R7represents independently for each occurrence fluoro, hydroxyl, methyl, hydroxymethyl, or oxiranyl. In certain embodiments, R7represents independently for each occurrence fluoro, hydroxyl, methyl, or hydroxymethyl.

[0385] In certain embodiments, at least one occurrence of R7is -S(O)2-(halo) or oxiranyl. In certain embodiments, at least one occurrence of R7is -S(O)2F or oxiranyl. In certain embodiments, R7represents independently for each occurrence -S(O)2-(halo) or oxiranyl. In certain embodiments, R7represents independently for each occurrence -S(O)2F or oxiranyl.

[0386] In certain embodiments, R7represents independently for each occurrence halo. In certain embodiments, R7represents independently for each occurrence fluoro or chloro. In certain embodiments, R7is fluoro. In certain embodiments, R7is chloro. In certain embodiments, R7is hydroxyl. In certain embodiments, R7represents independently for each occurrence C1-6 alkyl. In certain embodiments, R7represents independently for each occurrence C1-3 alkyl. In certain embodiments, R7is methyl. In certain embodiments, R7represents independently for each occurrence C1-6 hydroxyalkyl. In certain embodiments, R7is hydroxymethyl. In certain embodiments, at least one occurrence of R7is -S (O)2 -(halo). In certain embodiments, at least one occurrence of R7is -S(O)2F. In certain embodiments, R7represents independently for each occurrence -S(O)2-(halo). In certain embodiments, R7is -S(O)2F. In certain embodiments, R7is oxiranyl. In certain embodiments, at least one occurrence of R7is oxiranyl.

[0387] As defined generally above, R8represents independently for each occurrence hydrogen, C1-6 alkyl, or C3-5 cycloalkyl. In certain embodiments, R8represents independently for each occurrence hydrogen or C1-6 alkyl. In certain embodiments, R8represents independently for each occurrence hydrogen or methyl. In certain embodiments, R8is hydrogen. In certain embodiments, R8represents independently for each occurrence C1-6 alkyl. In certain embodiments, R8is methyl. In certain embodiments, R8represents independently for each occurrence C3-5 cycloalkyl. In certain embodiments, R8is cyclopropyl.embodiments, -L1-A1is -N(H or C1-6 alkyl)-(Co-3 alkylene)-phenyl, wherein the phenyl is substituted with 1 or 2 occurrences of R7. In certain embodiments, -L1-A1is -N(H or C1-6 alkyl)- (C0-3 alkylene)-phenyl, wherein the phenyl is substituted with 1 occurrence of R7.

[0390] As defined generally above, L1is a covalent bond or -N(H or C1-6 alkyl)-(Co-3 alkylene)- , wherein the C0-3 alkylene of L1is attached to A1. In certain embodiments, L1is a covalent bond. In certain embodiments, L1is -N(H or C1-6 alkyl)-(Co-3 alkylene)-, wherein the C0-3 alkylene of L1is attached to A1. In certain embodiments, L1is -N(H or C1-6 alkyl)-. In certain embodiments, L1is -N(H or C1-6 alkyl)-CH2- or -N(H or C1-6 alkyl)-(CH2)2-, wherein the terminal carbon atom of L1is attached to A1.

[0392] As defined generally above, m is 0, 1, 2, 3, or 4. In certain embodiments, m is 0. In certain embodiments, m is 1. In certain embodiments, m is 2. In certain embodiments, m is 3. In certain embodiments, m is 4. In certain embodiments, m is 0 or 1. In certain embodiments, m is 1 or 2. In certain embodiments, m is 2 or 3. In certain embodiments, m is 3 or 4. In certain embodiments, m is 0, 1, or 2. In certain embodiments, m is 1, 2, or 3. In certain embodiments, m is 2, 3, or 4. In certain embodiments, m is 0, 1, 2, or 3. In certain embodiments, m is 1, 2, 3, or 4. In certain embodiments, m is selected from the values represented in the compounds in Table 1, below.

[0393] As defined generally above, p is 0, 1 , or 2. In certain embodiments, p is 0. In certain embodiments, p is 1. In certain embodiments, p is 2. In certain embodiments, p is 0 or 1. In certain embodiments, p is 1 or 2.

[0394] The description above describes multiple embodiments relating to compounds of Formula (Im). The patent application specifically contemplates all combinations of the embodiments.

[0395] In certain embodiments, the disclosure provides a compound in Table 1, below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 1, below.

[0396] In certain embodiments, the disclosure provides a compound selected from Compound 1-1 through 1-88 in Table 1, below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound selected from Compound 1-1 through 1-88 in Table 1, below. In certain embodiments, the disclosure provides a compound selected from Compound I- 1 through 1-91 in Table 1, below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound selected from Compound 1-1 through 1-91 in Table 1, below. In certain embodiments, the disclosure provides a compound selected from Compound I- 1 through 1-110 in Table 1, below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound selected from Compound 1-1 through 1-110 in Table 1, below. In certain embodiments, the disclosure provides a compound selected from Compound 1-254 through 1-258 in Table 1, below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound selected from Compound 1-254 through 1-258 in Table 1, below.TABLE 1.

[0397] Methods for preparing compounds described herein are illustrated in the following synthetic Scheme, and in the Examples below. The Scheme is provided for the purpose of illustrating the invention, and is not intended to limit the scope or spirit of the invention. Starting materials shown in the Scheme can be obtained from commercial sources or can be prepared based on procedures described in the literature. In the Scheme, it is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule should be compatible with the reagents and reactions proposed. Substituents not compatible with the reaction conditions will be apparent to one skilled in the art, and alternate methods are therefore indicated (for example, use of protecting groups or alternative reactions). Protecting groupchemistry and strategy is well known in the art, for example, as described in detail in “Protecting Groups in Organic Synthesis”, T. W. Greene and P. G. M. Wuts, 3rdedition, John Wiley & Sons, 1999, the entire contents of which are hereby incorporated by reference.

[0398] A general synthetic route to preparing substituted pyrido[4,3-d]pyrimidines is provided in Scheme 1 below. Starting from diethyl 3-oxopentanedioate, the substituted dichloro-2- (methylthio)pyrido[4,3-d]pyrimidine is prepared, and then the A-L1group is coupled to it. The R1group can be installed via a palladium coupling reaction, and then lastly the L2-R2group is installed to provide the final compound.SCHEME 1.

[0399] The modular synthetic route illustrated in Scheme 1 can be modified to provide additional naphthyl-substituted pyrido[4,3-d]pyrimidines and related compounds by conducting functional group transformations on the intermediate and final compounds. Functional group transformations are described in, for example, “Comprehensive Organic Synthesis” (B.M. Trost & I. Fleming, eds., 1991-1992).II. Therapeutic Applications of Naphthyl-substituted Pyrido[4,3-d]pyrimidines and Related Compounds

[0400] It is contemplated that the naphthyl-substituted pyrido[4,3-d]pyrimidines and related compounds described herein, such as a compound of Formula (I), Formula (1-1), or other compounds in Section I, provide therapeutic benefits to subjects suffering from cancer and other disorders. Accordingly, one aspect of the disclosure provides a method of treating a disorder mediated by K-Ras in a subject. The method comprises administering a therapeutically effective amount of a compound described herein, such as a compound of Formula (I) or Formula (1-1), to a subject in need thereof to treat the disorder. Another aspect of the disclosure provides a method of treating a disorder mediated by K-Ras G12V in a subject. The method comprises administering a therapeutically effective amount of a compound described herein, such as a compound of Formula (I) or Formula (1-1), to a subject in need thereof to treat the disorder. In certain embodiments, the compound is a compound of Formula (I) or Formula (I-1) defined by one of the embodiments described above.

[0401] Kirsten Rat Sarcoma 2 Viral Oncogene Homolog (“K-Ras”) is a small GTPase and a member of the Ras family of oncogenes. K-Ras has been reported to serve as a molecular switch cycling between inactive (GDP -bound) and active (GTP -bound) states to transduce upstream cellular signals received from multiple tyrosine kinases to downstream effectors to regulate a wide variety of processes, including cellular proliferation (e.g., see Alamgeer et al., (2013) Current Opin Pharmcol .13 : 394-401 ) .

[0402] The role of activated K-Ras in malignancy was observed over thirty years ago (e.g., see Santos et al., (1984) Science 223:661-664). Aberrant expression of K-Ras has been reported to account for up to 20% of all cancers, and oncogenic K-Ras mutations that stabilize GTP binding and lead to constitutive activation of K-Ras and downstream signaling have been reported in 25 - 30% of lung adenocarcinomas, (e.g., see Samatar and Poulikakos (2014) Nat Rev Drug Disc13(12): 928- 942 doi: 10.1038 / nrd428). Single nucleotide substitutions that result in missense mutations at codons 12 and 13 of the K-Ras primary amino acid sequence have been reported to comprise approximately 40% of these K-Ras driver mutations in lung adenocarcinoma. K-Ras G12D mutation has been reported to be present in 25.0% of all pancreatic ductal adenocarcinoma patients, 13.3% of all colorectal carcinoma patients, 10.1% of all rectal carcinoma patients, 4.1% of all non-small cell lung carcinoma patients, and 1.7% of all small cell lung carcinoma patients (e.g., see The AACR Project GENIE Consortium, (2017) Cancer Discovery;7(8): 818-831. Dataset Version 4).

[0403] Despite efforts to develop inhibitors of K-Ras for treating cancer, through year 2020, no K-Ras inhibitor had demonstrated sufficient safety and / or efficacy to obtain regulatory approval from the U.S. FDA (e.g., see McCormick (2015) Clin Cancer Res.21 (8): 1797-1801). Compounds that inhibit K-Ras activity are under investigation, including those that disrupt effectors such as guanine nucleotide exchange factors (e.g., see Sun et al., (2012) Angew Chem Int Ed Engl.51(25):6140-6143 doi: 10.1002 / anie201201358) as well recent advances in the covalent targeting of an allosteric pocket of K-Ras G12C (e.g., see Ostrem et al., (2013) Nature 503:548- 551 and Fell et al., (2018) ACS Med. Chem. Lett.9: 1230-1234).

[0404] Accordingly, the provided compounds are inhibitors of K-Ras and are therefore useful for treating one or more disorders associated with activity of K-Ras. Thus, in certain aspects and embodiments, the present disclosure provides a method for treating a K-Ras-mediated disorder comprising the step of administering to a patient in need thereof a therapeutically effective compound of the present disclosure, or pharmaceutically acceptable composition thereof. As used herein, the term “K-Ras-mediated” disorders, diseases, and / or conditions means any disease or other deleterious condition in which K-Ras, or a variant or mutant thereof, is known to play a role. Accordingly, another aspect of the present disclosure relates to treating or lessening the severity of one or more diseases in which K-Ras is known to play a role.

[0405] In some aspects and embodiments, provided herein are methods of treating, reducing the severity of, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, of a disease or disorder characterized by or associated with increased K-Ras expression and / or increased K-Ras activity, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of the present disclosure, or pharmaceutically acceptable composition thereof. In some aspects and embodiments, providedherein are methods of treating, reducing the severity of, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof of a disease or disorder in which inhibition or antagonizing of K-Ras activity is beneficial, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of the present disclosure, or pharmaceutically acceptable composition thereof.

[0406] Accordingly, in some aspects and embodiments, the present disclosure provides a method for treating one or more disorders, diseases, and / or conditions wherein the disorder, disease, or condition includes, but is not limited to, a cellular proliferative disorder, comprising administering to a patient in need thereof, a K-Ras inhibitor compound as described herein, or a pharmaceutical salt or composition thereof. In certain embodiments, the cellular proliferative disorder is cancer. In certain embodiments, the cancer is characterized by increased K-Ras expression and / or increased K-Ras activity, i.e., “increased activated K-Ras.”

[0407] In certain embodiments, the K-Ras is a mutant K-Ras. In certain embodiments, the K- Ras is an activated mutant K-Ras. In certain embodiments, the K-Ras is K-Ras G12V, K-Ras G12D, K-Ras G12A, K-Ras G12C, K-Ras G12R, K-Ras G12S, and / or K-Ras Q61H. In certain embodiments, the K-Ras is a G12 mutant K-Ras. In certain embodiments, the K-Ras is K-Ras G12V, K-Ras G12D, K-Ras G12A, K-Ras G12C, K-Ras G12R, or K-Ras G12S. In certain embodiments, the K-Ras is K-Ras G12D. In certain embodiments, the K-Ras is K-Ras G12V. In certain embodiments, the K-Ras is K-Ras G12C. In certain embodiments, the K-Ras is K-Ras G12A. In certain embodiments, the K-Ras is K-Ras G12R. In certain embodiments, the K-Ras is K-Ras G12S. In certain embodiments, the K-Ras is K-Ras Q61H.

[0408] Accordingly, the provided compounds are inhibitors of K-Ras and are therefore useful for treating one or more disorders associated with activity of K-Ras, such as K-Ras G12V, K-Ras G12D, K-Ras G12A, K-Ras G12C, K-Ras G12R, K-Ras G12S, and / or K-Ras Q61H. Thus, in certain aspects and embodiments, the present disclosure provides a method for treating a K-Ras- mediated disorder comprising the step of administering to a patient in need thereof a therapeutically effective compound of the present disclosure, or pharmaceutically acceptable composition thereof. As used herein, the term “K-Ras-mediated” disorders, diseases, and / or conditions means any disease or other deleterious condition in which K-Ras or a K-Ras mutation, such as K-Ras G12V, K-Ras G12D, K-Ras G12A, K-Ras G12C, K-Ras G12R, K-Ras G12S, and / or K-Ras Q61H, is known to play a role. Accordingly, another aspect of the present disclosurerelates to treating or lessening the severity of one or more diseases in which K-Ras, such as K-Ras G12V, K-Ras G12D, K-Ras G12A, K-Ras G12C, K-Ras G12R, K-Ras G12S, and / or K-Ras Q61H, is known to play a role.

[0409] Accordingly, in certain embodiments, the provided compounds are inhibitors of K-Ras G12V and are therefore useful for treating one or more disorders associated with activity of K-Ras G12V. Thus, in certain aspects and embodiments, the present disclosure provides a method for treating a K-Ras G12V-mediated disorder comprising the step of administering to a patient in need thereof a therapeutically effective compound of the present disclosure, or pharmaceutically acceptable composition thereof. As used herein, the term “K-Ras G12V-mediated” disorders, diseases, and / or conditions means any disease or other deleterious condition in which K-Ras G12V is known to play a role. Accordingly, another aspect of the present disclosure relates to treating or lessening the severity of one or more diseases in which K-Ras G12V is known to play a role.

[0410] In some aspects and embodiments, provided herein are methods of treating, reducing the severity of, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, of a disease or disorder characterized by or associated with increased mutant K-Ras expression and / or increased mutant K-Ras activity, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of the present disclosure, or pharmaceutically acceptable composition thereof. In some aspects and embodiments, provided herein are methods of treating, reducing the severity of, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof of a disease or disorder in which inhibition or antagonizing of mutant K-Ras activity is beneficial, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of the present disclosure, or pharmaceutically acceptable composition thereof.

[0411] In some aspects and embodiments, provided herein are methods of treating, reducing the severity of, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, of a disease or disorder characterized by or associated with increased K-Ras G12V expression and / or increased K-Ras G12V activity, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of the present disclosure, or pharmaceutically acceptable composition thereof. In some aspects and embodiments, provided herein are methods of treating, reducing the severity of, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof of a diseaseor disorder in which inhibition or antagonizing of K-Ras G12V activity is beneficial, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of the present disclosure, or pharmaceutically acceptable composition thereof.

[0412] Accordingly, in some aspects and embodiments, the present disclosure provides a method for treating one or more disorders, diseases, and / or conditions wherein the disorder, disease, or condition includes, but is not limited to, a cellular proliferative disorder, comprising administering to a patient in need thereof, a mutant K-Ras inhibitor compound as described herein, or a pharmaceutical salt or composition thereof. In certain embodiments, the cellular proliferative disorder is cancer. In certain embodiments, the cancer is characterized by increased mutant K-Ras expression and / or increased mutant K-Ras activity, i.e., “increased activated mutant K-Ras, such as K-Ras G12V, K-Ras G12D, K-Ras G12A, K-Ras G12C, K-Ras G12R, K-Ras G12S, and / or K- Ras Q61H.”

[0413] Accordingly, in some aspects and embodiments, the present disclosure provides a method for treating one or more disorders, diseases, and / or conditions wherein the disorder, disease, or condition includes, but is not limited to, a cellular proliferative disorder, comprising administering to a patient in need thereof, an K-Ras G12V inhibitor compound as described herein, or a pharmaceutical salt or composition thereof. In certain embodiments, the cellular proliferative disorder is cancer. In certain embodiments, the cancer is characterized by increased K-Ras G12V expression and / or increased K-Ras G12V activity, i.e., “increased activated K-Ras G12V.”

[0414] As used herein, the terms "increased," "elevated," or "enhanced," are used interchangeably and encompass any measurable increase in a biological function and / or biological activity and / or a concentration. For example, an increase can be by at least about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, about 2-fold, about 3-fold, about 4- fold, about 5-fold, about 6-fold, about 7-fold, about 8-fold, about 9-fold, about 10-fold, about 20- fold, about 25-fold, about 50-fold, about 100-fold, or higher, relative to a control or baseline amount of a function, or activity, or concentration.

[0415] As used herein, the terms "increased expression" and / or "increased activity" of a substance, such as a mutant K-Ras, in a sample or cancer or patient, refers to an increase in the amount of the substance, such as a mutant K-Ras, of about 5%, about 10%, about 15%, about 20%,about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, about 2-fold, about 3-fold, about 4-fold, about 5- fold, about 6-fold, about 7-fold, about 8-fold, about 9-fold, about 10-fold, about 20-fold, about 25- fold, about 50-fold, about 100-fold, or higher, relative to the amount of the substance, such as a mutant K-Ras, in a control sample or control samples, such as an individual or group of individuals who are not suffering from the disease or disorder (e.g., cancer) or an internal control, as determined by techniques known in the art. A subject can also be determined to have an "increased expression" or "increased activity" of a substance, such as a mutant K-Ras, if the expression and / or activity of the substance, such as the mutant K-Ras, is increased by one standard deviation, two standard deviations, three standard deviations, four standard deviations, five standard deviations, or more, relative to the mean (average) or median amount of the substance, such as mutant K-Ras, in a control group of samples or a baseline group of samples or a retrospective analysis of patient samples. As practiced in the art, such control or baseline expression levels can be previously determined, or measured prior to the measurement in the sample or cancer or subject, or can be obtained from a database of such control samples.

[0416] As used herein, a "proliferative disease" refers to a disease that occurs due to abnormal growth or extension by the multiplication of cells (Walker, Cambridge Dictionary of Biology, Cambridge University Press: Cambridge, UK, 1990). A proliferative disease can be associated with: 1) the pathological proliferation of normally quiescent cells; 2) the pathological migration of cells from their normal location (e.g., metastasis of neoplastic cells); 3) the pathological expression of proteolytic enzymes, such as the matrix metalloproteinases (e.g., collagenases, gelatinases, and elastases); or 4) the pathological angiogenesis, as in proliferative retinopathy and tumor metastasis. Exemplary proliferative diseases include cancers (i.e., "malignant neoplasms"), benign neoplasms, angiogenesis, inflammatory diseases, and autoimmune diseases.

[0417] Accordingly, in certain aspects and embodiments, the disorder is cancer. The cancer or proliferative disorder or tumor to be treated using the compounds and methods and uses described herein include, but are not limited to, a hematological cancer, a lymphoma, a myeloma, a leukemia, a neurological cancer, skin cancer, breast cancer, a prostate cancer, a colorectal cancer, lung cancer, head and neck cancer, a gastrointestinal cancer, a liver cancer, a pancreatic cancer, a genitourinary cancer, a bone cancer, renal cancer, and a vascular cancer.

[0418] In certain embodiments of the methods and uses described herein, a cancer is treated by inhibiting or reducing or decreasing or arresting further growth or spread of the cancer or tumor. In certain embodiments of the methods and uses described herein, a cancer is treated by inhibiting or reducing the size (e.g., volume or mass) of the cancer or tumor by at least 5%, at least 10%, at least 25%, at least 50%, at least 75%, at least 90%, or at least 99% relative to the size of the cancer or tumor prior to treatment. In certain embodiments of the methods and uses described herein, a cancer is treated by reducing the quantity of the cancers or tumors in the patient by at least 5%, at least 10%, at least 25%, at least 50%, at least 75%, at least 90%, or at least 99% relative to the quantity of the cancers or tumors prior to treatment.

[0419] In certain embodiments, the cancer is selected from is non-small cell lung cancer (NSCLC), small cell lung cancer, colorectal cancer, rectal cancer, and pancreatic cancer. In certain embodiments, the cancer is selected from non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer. In certain embodiments, the cancer is non-small cell lung cancer (NSCLC) or pancreatic cancer.

[0420] In certain embodiments, the cancer is a solid tumor. In certain embodiments, the cancer is a melanoma, carcinoma, or blastoma. In certain embodiments, the cancer is a melanoma. In certain embodiments, the cancer is a carcinoma. In certain embodiments, the cancer is an adenocarcinoma. In certain embodiments, the cancer is a blastoma.

[0421] In certain embodiments, the cancer is lung cancer, pancreatic cancer, colorectal cancer, breast cancer, cervical cancer, prostate cancer, gastric cancer, skin cancer, liver cancer, bile duct cancer, or nervous system cancer. In certain embodiments, the cancer is lung cancer. In certain embodiments, the cancer is pancreatic cancer. In certain embodiments, the cancer is colorectal cancer. In certain embodiments, the cancer is breast cancer. In certain embodiments, the cancer is cervical cancer. In certain embodiments, the cancer is prostate cancer. In certain embodiments, the cancer is gastric cancer. In certain embodiments, the cancer is skin cancer. In certain embodiments, the cancer is liver cancer. In certain embodiments, the cancer is bile duct cancer. In certain embodiments, the cancer is nervous system cancer.

[0422] In certain embodiments, the cancer is breast adenocarcinoma, lung adenocarcinoma, pancreatic adenocarcinoma, cervical adenocarcinoma, colorectal adenocarcinoma, prostate adenocarcinoma, gastric adenocarcinoma, melanoma, lung squamous cell carcinoma, hepatocellular carcinoma, cholangiocarcinoma, glioblastoma, or neuroblastoma. In certainembodiments, the cancer is breast adenocarcinoma. In certain embodiments, the cancer is lung adenocarcinoma. In certain embodiments, the cancer is pancreatic adenocarcinoma. In certain embodiments, the cancer is cervical adenocarcinoma. In certain embodiments, the cancer is prostate adenocarcinoma. In certain embodiments, the cancer is gastric adenocarcinoma.

[0423] In certain embodiments, the cancer is melanoma.

[0424] In certain embodiments, the cancer is lung squamous cell carcinoma, hepatocellular carcinoma, or cholangiocarcinoma. In certain embodiments, the cancer is lung squamous cell carcinoma. In certain embodiments, the cancer is hepatocellular carcinoma. In certain embodiments, the cancer is cholangiocarcinoma.

[0425] In certain embodiments, the cancer is glioblastoma or neuroblastoma. In certain embodiments, the cancer is glioblastoma. In certain embodiments, the cancer is neuroblastoma.

[0426] In certain embodiments, the cancer is lung cancer, pancreatic cancer, or colorectal cancer. In certain embodiments, the cancer is non-small cell lung cancer, pancreatic cancer, or colorectal cancer. In certain embodiments, the cancer is lung cancer. In certain embodiments, the cancer is non-small cell lung cancer.

[0427] In certain embodiments, the cancer has elevated K-Ras activity, such as elevated K-Ras G12V, K-Ras G12D, K-Ras G12A, K-Ras G12C, K-Ras G12R, K-Ras G12S, and / or K-Ras Q61H activity. In certain embodiments, the cancer overexpresses K-Ras. In certain embodiments, a subject having a disorder associated with or mediated by K-Ras has been identified or diagnosed as having a cancer having a K-Ras mutation (e.g., as determined using a regulatory agency- approved, e.g., FDA-approved, assay or kit). In certain embodiments, the subject has a tumor that is positive for a K-Ras mutation (e.g., as determined using a regulatory agency -approved assay or kit). The subject can be a subject who has one or more tumor that is positive for a K-Ras mutation (e.g., identified as positive using a regulatory agency-approved, e.g., FDA-approved, assay or kit). The subject can be a subject whose tumor(s) have a K-Ras mutation (e.g., where the tumor is identified as such using a regulatory agency-approved, e.g. , FDA-approved, kit or assay). In certain embodiments, the subject is suspected of having a K-Ras gene-associated cancer. In certain embodiments, the subject has a clinical record indicating that the subject has a tumor that has a K- Ras mutation (and, for example, the clinical record indicates that the subject should be treated with any of the compounds or compositions provided herein).

[0428] In certain embodiments of any of the methods or uses described herein, an assay is used to determine whether the patient has a K-Ras mutation, such as K-Ras G12V, K-Ras G12D, K- Ras G12A, K-Ras G12C, K-Ras G12R, K-Ras G12S, and / or K-Ras Q61H, using a sample (e.g., a biological sample or a biopsy sample (e.g., a paraffin-embedded biopsy sample) from a patient (e.g., a patient suspected of having a K-Ras-associated cancer, a patient having one or more symptoms of a K-Ras-associated cancer, and / or a patient that has an increased risk of developing a K-Ras-associated cancer). Non-limiting examples of such assays that can be used to determine whether a patient or subject has a K-Ras mutation include next generation sequencing (NGS), immunohistochemistry, fluorescence microscopy, break apart FISH analysis, Southern blotting, Western blotting, FACS analysis, Northern blotting, and PCR-based amplification (e.g., RT-PCR and quantitative real-time RT-PCR). As is well-known in the art, the assays are typically performed, e.g., with at least one labelled nucleic acid probe or at least one labelled antibody or antigen-binding fragment thereof. The term “regulatory agency” is a country’s agency for the approval of the medical use of pharmaceutical agents with the country. For example, a non-limiting example of a regulatory agency is the U.S. Food and Drug Administration (FDA).

[0429] In certain embodiments, the K-Ras mutation is a K-Ras G12V, K-Ras G12D, K-Ras G12A, K-Ras G12C, K-Ras G12R, K-Ras G12S, and / or K-Ras Q61H mutation. In certain embodiments, the K-Ras mutation is a G12 mutation. In certain embodiments, the K-Ras mutation is G12D, G12V, G12A, G12C, G12R, and / or G12S. In certain embodiments, the K-Ras mutation is G12V. In certain embodiments, the K-Ras mutation is G12D. In certain embodiments, the K- Ras mutation is G12A. In certain embodiments, the K-Ras mutation is G12C. In certain embodiments, the K-Ras mutation is G12R. In certain embodiments, the K-Ras mutation is G12S. In certain embodiments, the K-Ras mutation is Q61H.

[0430] In certain embodiments, the cancer is aleukemia (e.g., acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, acute erythroleukemia, chronic leukemia, chronic myelocytic leukemia, chronic lymphocytic leukemia), polycythemia vera, lymphoma (e.g., Hodgkin’s disease or non-Hodgkin’s disease), Waldenstrom's macroglobulinemia, multiple myeloma, heavy chain disease, or a solid tumor such as a sarcoma or carcinoma (e.g., fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma,lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing’s tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, uterine cancer, testicular cancer, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, glioblastoma multiforme (GBM, also known as glioblastoma), medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, schwannoma, neurofibrosarcoma, meningioma, melanoma, neuroblastoma, and retinoblastoma).

[0431] In certain embodiments, the cancer is glioma, astrocytoma, glioblastoma multiforme (GBM, also known as glioblastoma), medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, schwannoma, neurofibrosarcoma, meningioma, melanoma, neuroblastoma, or retinoblastoma.

[0432] In certain embodiments, the cancer is acoustic neuroma, astrocytoma (e.g. Grade I - Pilocytic Astrocytoma, Grade II - Low-grade Astrocytoma, Grade III - Anaplastic Astrocytoma, or Grade IV - Glioblastoma (GBM)), chordoma, CNS lymphoma, craniopharyngioma, brain stem glioma, ependymoma, mixed glioma, optic nerve glioma, subependymoma, medulloblastoma, meningioma, metastatic brain tumor, oligodendroglioma, pituitary tumors, primitive neuroectodermal (PNET) tumor, or schwannoma. In certain embodiments, the cancer is a type found more commonly in children than adults, such as brain stem glioma, craniopharyngioma, ependymoma, juvenile pilocytic astrocytoma (JPA), medulloblastoma, optic nerve glioma, pineal tumor, primitive neuroectodermal tumors (PNET), or rhabdoid tumor.

[0433] In certain embodiments, the cancer is mesothelioma, hepatobilliary (hepatic and billiary duct), bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, ovarian cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, gastrointestinal (gastric, colorectal, and duodenal), uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin’s Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroidgland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, testicular cancer, chronic or acute leukemia, chronic myeloid leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, non-Hodgkins’s lymphoma, spinal axis tumors, brain stem glioma, pituitary adenoma, adrenocortical cancer, gall bladder cancer, multiple myeloma, cholangiocarcinoma, fibrosarcoma, neuroblastoma, retinoblastoma, or a combination of one or more of the foregoing cancers.

[0434] In certain embodiments, the cancer is hepatocellular carcinoma, ovarian cancer, ovarian epithelial cancer, fallopian tube cancer, papillary serous cystadenocarcinoma, uterine papillary serous carcinoma (UPSC), prostate cancer, testicular cancer, gallbladder cancer, hepatocholangiocarcinoma, soft tissue and bone synovial sarcoma, rhabdomyosarcoma, osteosarcoma, chondrosarcoma, Ewing sarcoma, anaplastic thyroid cancer, adrenocortical adenoma, pancreatic cancer, pancreatic ductal carcinoma, pancreatic adenocarcinoma, gastrointestinal / stomach (GIST) cancer, lymphoma, squamous cell carcinoma of the head and neck (SCCHN), salivary gland cancer, glioma, or brain cancer, neurofibromatosis- 1 associated malignant peripheral nerve sheath tumors (MPNST), Waldenstrom’s macroglobulinemia, or medulloblastoma.

[0435] In certain embodiments, the cancer is hepatocellular carcinoma (HCC), hepatoblastoma, colon cancer, rectal cancer, ovarian cancer, ovarian epithelial cancer, fallopian tube cancer, papillary serous cystadenocarcinoma, uterine papillary serous carcinoma (UPSC), hepatocholangiocarcinoma, soft tissue and bone synovial sarcoma, rhabdomyosarcoma, osteosarcoma, anaplastic thyroid cancer, adrenocortical adenoma, pancreatic cancer, pancreatic ductal carcinoma, pancreatic adenocarcinoma, glioma, neurofibromatosis- 1 associated malignant peripheral nerve sheath tumors (MPNST), Waldenstrom’s macroglobulinemia, or medulloblastoma.

[0436] In certain embodiments, the cancer is selected from renal cell carcinoma, or kidney cancer; hepatocellular carcinoma (HCC) or hepatoblastoma, or liver cancer; melanoma; breast cancer; colorectal carcinoma, or colorectal cancer; colon cancer; rectal cancer; anal cancer; lung cancer, such as non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC); ovarian cancer, ovarian epithelial cancer, ovarian carcinoma, or fallopian tube cancer; papillary serous cystadenocarcinoma or uterine papillary serous carcinoma (UPSC); prostate cancer; testicularcancer; gallbladder cancer; hepatocholangiocarcinoma; soft tissue and bone synovial sarcoma; rhabdomyosarcoma; osteosarcoma; chondrosarcoma; Ewing sarcoma; anaplastic thyroid cancer; adrenocortical carcinoma; pancreatic cancer; pancreatic ductal carcinoma or pancreatic adenocarcinoma; gastrointestinal / stomach (GIST) cancer; lymphoma; squamous cell carcinoma of the head and neck (SCCHN); salivary gland cancer; glioma, or brain cancer; neurofibromatosis- 1 associated malignant peripheral nerve sheath tumors (MPNST); Waldenstrom’s macroglobulinemia; and medulloblastoma.

[0437] In certain embodiments, the cancer is renal cell carcinoma, hepatocellular carcinoma (HCC), hepatoblastoma, colorectal carcinoma, colorectal cancer, colon cancer, rectal cancer, anal cancer, ovarian cancer, ovarian epithelial cancer, ovarian carcinoma, fallopian tube cancer, papillary serous cystadenocarcinoma, uterine papillary serous carcinoma (UPSC), hepatocholangiocarcinoma, soft tissue and bone synovial sarcoma, rhabdomyosarcoma, osteosarcoma, chondrosarcoma, anaplastic thyroid cancer, adrenocortical carcinoma, pancreatic cancer, pancreatic ductal carcinoma, pancreatic adenocarcinoma, glioma, brain cancer, neurofibromatosis- 1 associated malignant peripheral nerve sheath tumors (MPNST), Waldenstrom’s macroglobulinemia, or medulloblastoma.

[0438] In certain embodiments, the cancer is hepatocellular carcinoma (HCC), hepatoblastoma, colon cancer, rectal cancer, ovarian cancer, ovarian epithelial cancer, ovarian carcinoma, fallopian tube cancer, papillary serous cystadenocarcinoma, uterine papillary serous carcinoma (UPSC), hepatocholangiocarcinoma, soft tissue and bone synovial sarcoma, rhabdomyosarcoma, osteosarcoma, anaplastic thyroid cancer, adrenocortical carcinoma, pancreatic cancer, pancreatic ductal carcinoma, pancreatic adenocarcinoma, glioma, neurofibromatosis- 1 associated malignant peripheral nerve sheath tumors (MPNST), Waldenstrom’s macroglobulinemia, or medulloblastoma.

[0439] In certain embodiments, the cancer is hepatocellular carcinoma (HCC). In certain embodiments, the cancer is hepatoblastoma. In certain embodiments, the cancer is colon cancer. In certain embodiments, the cancer is rectal cancer. In certain embodiments, the cancer is ovarian cancer, or ovarian carcinoma. In certain embodiments, the cancer is ovarian epithelial cancer. In certain embodiments, the cancer is fallopian tube cancer. In certain embodiments, the cancer is papillary serous cystadenocarcinoma. In certain embodiments, the cancer is uterine papillary serous carcinoma (UPSC). In certain embodiments, the cancer is hepatocholangiocarcinoma. Incertain embodiments, the cancer is soft tissue and bone synovial sarcoma. In certain embodiments, the cancer is rhabdomyosarcoma. In certain embodiments, the cancer is osteosarcoma. In certain embodiments, the cancer is anaplastic thyroid cancer. In certain embodiments, the cancer is adrenocortical carcinoma. In certain embodiments, the cancer is pancreatic cancer, or pancreatic ductal carcinoma. In certain embodiments, the cancer is pancreatic adenocarcinoma. In certain embodiments, the cancer is glioma. In certain embodiments, the cancer is malignant peripheral nerve sheath tumors (MPNST). In certain embodiments, the cancer is neurofibromatosis- 1 associated MPNST. In certain embodiments, the cancer is Waldenstrom’s macroglobulinemia. In certain embodiments, the cancer is medulloblastoma.

[0440] In certain embodiments, the subject is a human. In certain embodiments, the subject is an adult human. In certain embodiments, the subject is a pediatric human. In certain embodiments, the subject is a companion animal. In certain embodiments, the subject is a canine, feline, or equine.

[0441] Another aspect of the disclosure provides for the use of a compound described herein (such as a compound of Formula (I), Formula (1-1), or other compounds in Section I) in the manufacture of a medicament. In certain embodiments, the medicament is for treating a disorder described herein, such as cancer.

[0442] Another aspect of the disclosure provides for the use of a compound described herein (such as a compound of Formula (I), Formula (1-1), or other compounds in Section I) for treating a medical disorder, such as a medical disorder described herein (for example, cancer).

[0443] Further, it is contemplated that the compounds described herein, such as a compound of Formula (I), Formula (1-1), or other compounds in Section I, can inhibit K-Ras activity. Accordingly, another aspect of the disclosure provides a method of inhibiting K-Ras activity. The method comprises contacting K-Ras with an effective amount of a naphthyl -substituted pyrido[4,3-d]pyrimidines or related compound described herein, such as a compound of Formula (I), Formula (1-1), or other compounds in Section I, to inhibit K-Ras activity. In certain embodiments, the compound is a compound of Formula (I) or Formula (1-1) defined by one of the embodiments described above.

[0444] In certain embodiments, the K-Ras is a mutant K-Ras. In certain embodiments, the K- Ras is an activated mutant K-Ras. In certain embodiments, the K-Ras is a G12 mutant K-Ras. In certain embodiments, the K-Ras is K-Ras G12D, K-Ras G12V, or K-Ras G12C. In certainembodiments, the K-Ras is K-Ras G12D. In certain embodiments, the K-Ras is K-Ras G12V. In certain embodiments, the K-Ras is K-Ras G12C.

[0445] Further, it is contemplated that the compounds described herein, such as a compound of Formula (I), Formula (1-1), or other compounds in Section I, can inhibit K-Ras activity, such as K-Ras G12V, K-Ras G12D, K-Ras G12A, K-Ras G12C, K-Ras G12R, K-Ras G12S, and / or K- Ras Q61H activity. Accordingly, another aspect of the disclosure provides a method of inhibiting K-Ras activity. The method comprises contacting K-Ras, such as K-Ras G12V, K-Ras G12D, K- Ras G12A, K-Ras G12C, K-Ras G12R, K-Ras G12S, and / or K-Ras Q61H, with an effective amount of a naphthyl-substituted pyrido[4,3-d]pyrimidines or related compound described herein, such as a compound of Formula (I), Formula (1-1), or other compounds in Section I, to inhibit K- Ras activity. In certain embodiments, the compound is a compound of Formula (I) or Formula (I- 1) defined by one of the embodiments described above.

[0446] Compounds may be tested for ability to bind to and / or inhibit K-Ras activity according to any of various assays known in the art, including, for example, surface plasmon resonance binding assays, TR-FRET displacement binding assays, TR-FRET assays that detect Ras-Raf interaction, and cell-based phosphorylation inhibition assays. Compounds may be tested for ability to bind to and / or inhibit K-Ras G12V activity according to any of various assays known in the art, including, for example, surface plasmon resonance binding assays, TR-FRET displacement binding assays, TR-FRET assays that detect Ras-Raf interaction, and cell-based phosphorylation inhibition assays. Such assays are described in, for example, WO 2021 / 041671 and Zhang, Z., et al. “GTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D) Block Its Interaction with Raf,” ACS Cent. Sci. (2020) Vol. 6, No. 10, pp. 1753-1761; the contents of each of which are herein incorporated by reference in their entirety.III. Combination Therapy

[0447] Another aspect of the disclosure provides for combination therapy. Naphthyl-substituted pyrido[4,3-d]pyrimidines or related compounds described herein (e.g., a compound of Formula (I), Formula (I- 1 ), or other compounds in Section I) or their pharmaceutically acceptable salts may be used in combination with additional therapeutic agents to treat medical disorders, such as a cancer.

[0448] In certain embodiments, the present disclosure provides a method of treating a disclosed disease or condition comprising administering to a patient in need thereof an effective amount ofa compound disclosed herein or a pharmaceutically acceptable salt thereof and co-administering simultaneously or sequentially an effective amount of one or more additional therapeutic agents, such as those described herein. In certain embodiments, the method includes co-administering one additional therapeutic agent. In certain embodiments, the method includes co-administering two additional therapeutic agents. In certain embodiments, the combination of the disclosed compound and the additional therapeutic agent or agents acts synergistically.

[0449] One or more other therapeutic agents may be administered separately from a compound or composition of the disclosure, as part of a multiple dosage regimen. Alternatively, one or more other therapeutic agents may be part of a single dosage form, mixed together with a compound of this disclosure in a single composition. If administered as a multiple dosage regime, one or more other therapeutic agent and a compound or composition of the disclosure may be administered simultaneously, sequentially or within a period of time from one another, for example within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 hours from one another. In certain embodiments, one or more other therapeutic agent and a compound or composition of the disclosure are administered as a multiple dosage regimen more than 24 hours apart.

[0450] As used herein, the term “combination,” “combined,” and related terms refers to the simultaneous or sequential administration of therapeutic agents in accordance with this disclosure. For example, a compound of the present disclosure can be administered with one or more other therapeutic agent(s) simultaneously or sequentially in separate unit dosage forms or together in a single unit dosage form. Accordingly, the present disclosure provides a single unit dosage form comprising a compound of the current disclosure, one or more other therapeutic agent(s), and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

[0451] The amount of a compound of the disclosure and one or more other therapeutic agent(s) (in those compositions which comprise an additional therapeutic agent, such as a second anticancer agent, as described above) that can be combined with the carrier materials to produce a single dosage form varies depending upon the host treated and the particular mode of administration. Preferably, a composition of the disclosure should be formulated so that a dosage of between 0.01 - 100 mg / kg body weight / day of a compound of the disclosure can be administered.

[0452] In those compositions which comprise one or more other therapeutic agent(s), the one or more other therapeutic agent(s) and a compound of the disclosure can act synergistically.Therefore, the amount of the one or more other therapeutic agent(s) in such compositions may be less than that required in a monotherapy utilizing only that therapeutic agent. In such compositions a dosage of between 0.01 - 1,000 g / kg body weight / day of the one or more other therapeutic agent(s) can be administered.

[0453] The amount of one or more other therapeutic agent(s) present in the compositions of this disclosure is preferably no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent. Preferably the amount of one or more other therapeutic agent(s) in the presently disclosed compositions ranges from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent. In certain embodiments, one or more other therapeutic agent(s) is administered at a dosage of about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95% of the amount normally administered for that agent. As used herein, the phrase "normally administered" means the amount an FDA-approved therapeutic agent is approved for dosing per the FDA label insert.

[0454] Accordingly, another aspect of the disclosure provides a method of treating cancer in a patient. The method comprises administering to a subject in need thereof (i) a therapeutically effective amount of a naphthyl-substituted pyrido[4,3-d]pyrimidines or related compound described herein and (ii) one or more other therapeutic agents, in order to treat the cancer.A. Exemplary Additional Therapeutic Agents

[0455] In certain embodiments, the one or more other therapeutic agent is a TEAD inhibitor. In certain embodiments, the TEAD inhibitor is selected from those described in WO 2020 / 243415, the contents of which are herein incorporated by reference in their entirety. In certain embodiments, the TEAD inhibitor is selected from those described in WO 2020 / 243423, the contents of which are herein incorporated by reference in their entirety. In certain embodiments, the TEAD inhibitor is selected from those described in US Patent 11,247,082, the contents of which are herein incorporated by reference in their entirety. In certain embodiments, the TEAD inhibitor is selected from those described in WO 2022 / 120353, the contents of which are herein incorporated by reference in their entirety. In certain embodiments, the TEAD inhibitor is selected from those described in WO 2022 / 120354, the contents of which are herein incorporated by reference in their entirety.

[0456] In certain embodiments, the second anti-cancer agent is a TEAD degrader. In certain embodiments, the TEAD degrader is selected from those described in WO 2022 / 120355, the contents of which are herein incorporated by reference in their entirety.

[0457] TEAD inhibitors can be produced by organic synthesis methods known to one of ordinary skill in the art. Additionally, certain TEAD inhibitors can be prepared as described in Pobbati et al., "Targeting the Central Pocket in Human Transcription Factor TEAD as a Potential Cancer Therapeutic Strategy," Structure 2015, 23, 2076-2086; Gibault et al., "Targeting Transcriptional Enhanced Associate Domains (TEADs)," J. Med. Chem. 2018, 61, 5057-5072; Bum-Erdene et al., "Small-Molecule Covalent Modification of Conserved Cysteine Leads to Allosteric Inhibition of the TEADoYap Protein-Protein Interaction," Cell Chemical Biology 2019, 26, 1-12; Holden et al., "Small Molecule Dysregulation of TEAD Lipidation Induces a Dominant-Negative Inhibition of HippoPathway Signaling," Cell Reports 2020, 31, 107809; WO 2017 / 053706, WO 2017 / 111076, WO 2018 / 204532, WO 2018 / 235926, US 20190010136, WO 2019 / 040380, WO 2019 / 113236, WO 2019 / 222431, WO 2019 / 232216, WO 2020 / 051099, WO 2020 / 081572, WO 2020 / 097389, WO 2020 / 190774, WO 2020 / 214734, PCT / US2020 / 35098, and PCT / US2020 / 35111, the contents of each of which are herein incorporated by reference in its entirety.

[0458] In certain embodiments, the one or more other therapeutic agent is an ERK5 inhibitor. In certain embodiments, the ERK5 inhibitor is selected from those described in WO 2022 / 051567, the contents of which are herein incorporated by reference in their entirety. In certain embodiments, the ERK5 inhibitor is selected from those described in WO 2022 / 051565, the contents of which are herein incorporated by reference in their entirety. In certain embodiments, the ERK5 inhibitor is selected from those described in WO 2022 / 051569, the contents of which are herein incorporated by reference in their entirety. In certain embodiments, the ERK5 inhibitor is selected from those described in WO 2022 / 051568, the contents of which are herein incorporated by reference in their entirety.

[0459] In certain embodiments, the one or more other therapeutic agent is an additional KRAS inhibitor, such as a KRAS G12C inhibitor. As used herein, a "KRAS G12C inhibitor" refers to any inhibitor or blocker or antagonist that binds to and / or inhibits signaling through KRAS. In certain embodiments, a KRAS G12C inhibitor is selected from adagrasib (KRAZ ATI®, Mirati Therapeutics), sotorasib (LUMAKRAS® and LUMYKRAS®, Amgen), or a pharmaceutically acceptable salt and / or solvate of any of the foregoing. Other examples of KRAS G12C inhibitorsfor use in the methods and uses described herein include, but are not limited to, JDQ-443 (Novartis AG), D-1553 (Inventisbio Shanghai), GF-105 (GenFleet Therapeutics), GH-35 (Suzhou GenHouse Bio Co.), JAB-21822 (Jacobio Pharmaceuticals), JMKX-001899 (Shanghi Jiyu Pharmaceuticals), TAS-119 (Taiho Pharmaceuticals), XNW-14010 (Suzhou Sinovent Pharmaceuticals), YL-15293 (Shanghai Yingli Pharmaceuticals), ZG-19018 (Suzhou Zelgen Biopharma), BEBT-607 (Guangzhou Bibet Pharmaceuticals), BI-1701963 (Forma Therapeutics Holdings), BI-1823911 (Boehringer Ingelheim Gmbh), BPI-421286 (Betta Pharmaceuticals), D3S-001 (D3 Bio), ERAS-3490 (Regents of the University of California), GEC-255 (GenEros BioPhrma LTD), and JS116 (Shanghai Junshi Biosceinces). Other examples of KRAS G12C inhibitors in the methods and uses described herein include, but are not limited to, those described in international patent publications WO 2021 / 120890 the contents of each of which are herein incorporated by reference in their entireties.

[0460] In certain embodiments, the one or more other therapeutic agent is a pan-RAF inhibitor. As used herein, a “Pan-RAF inhibitor” refers to any inhibitor or blocker or antagonist that binds to all known members of the serine / threonine protein kinase Raf family including A-Raf, B-Raf, and C-Raf protein kinases, with potential antineoplaslic activity. In certain embodiments, a Pan- RAF inhibitor is selected from tovorafenib (TAK580, Day One Biopharmaceuticals), TAK-632 (Takeda Pharmaceuticals), lifirafenib (BGB-283, BeiGene), exarafenib (Kinnate Biopharma), naporafenib (LXH-254, Erasca), or a pharmaceutically acceptable salt and / or solvate of any of the foregoing. In certain embodiments, a Pan-RAF inhibitor is selected from tovorafenib TAK-632, lifirafenib, exarafenib, or a pharmaceutically acceptable salt and / or solvate of any of the foregoing. Other examples of Pan-RAF inhibitors useful with the compositions, methods, and uses described herein include, but are not limited to, those described in international patent publications WO 2015 / 075483, WO 2015 / 075483, and WO 2014 / 151616 the contents of each of which are herein incorporated by reference in their entireties.

[0461] In certain embodiments, one or more other therapeutic agent is a Poly ADP ribose polymerase (PARP) inhibitor. In certain embodiments, a PARP inhibitor is selected from olaparib (LYNPARZA®, AstraZeneca); rucaparib (RUB RAC A®, Clovis Oncology); niraparib (ZEJULA®, Tesaro); talazoparib (MDV3800 / BMN 673 / LT00673, Medivation / Pfizer / Biomarin); veliparib (ABT-888, Abb Vie); and BGB-290 (BeiGene, Inc.).

[0462] In certain embodiments, one or more other therapeutic agent is a histone deacetylase (HDAC) inhibitor. In certain embodiments, an HDAC inhibitor is selected from vorinostat (ZOLINZA®, Merck); romidepsin (ISTODAX®, Celgene); panobinostat (FARYDAK®, Novartis); belinostat (BELEODAQ®, Spectrum Pharmaceuticals); entinostat (SNDX-275, Syndax Pharmaceuticals) (NCT00866333); and chidamide (EPIDAZA®, HBI-8000, Chipscreen Biosciences, China).

[0463] In certain embodiments, one or more other therapeutic agent is a CDK inhibitor, such as a CDK4 / CDK6 inhibitor. In certain embodiments, a CDK 4 / 6 inhibitor is selected from palbociclib (IBRANCE®, Pfizer); ribociclib (KISQALI®, Novartis); abemaciclib (Ly2835219, Eli Lilly); and trilaciclib (G1T28, G1 Therapeutics).

[0464] In certain embodiments, one or more other therapeutic agent is a phosphatidylinositol 3 kinase (PI3K) inhibitor. In certain embodiments, a PI3K inhibitor is selected from idelalisib (ZYDELIG®, Gilead), alpelisib (BYL719, Novartis), taselisib (GDC-0032, Genentech / Roche); pictilisib (GDC-0941, Genentech / Roche); copanlisib (BAY806946, Bayer); duvelisib (formerly IPI-145, Infinity Pharmaceuticals); PQR309 (Piqur Therapeutics, Switzerland); and TGR1202 (formerly RP5230, TG Therapeutics). In certain embodiments, a PI3K inhibitor is selected from inavolisib (GDC-077, Genentech), idelalisib (ZYDELIG®, Gilead), alpelisib (BYL719, Novartis), taselisib (GDC-0032, Genentech / Roche); pictilisib (GDC-0941, Genentech / Roche); copanlisib (BAY806946, Bayer); duvelisib (formerly IPI-145, Infinity Pharmaceuticals); PQR309 (Piqur Therapeutics, Switzerland); and TGR1202 (formerly RP5230, TG Therapeutics).

[0465] In certain embodiments, one or more other therapeutic agent is a platinum-based therapeutic, also referred to as platins. Platins cause cross-linking of DNA, such that they inhibit DNA repair and / or DNA synthesis, mostly in rapidly reproducing cells, such as cancer cells.

[0466] In certain embodiments, a platinum-based therapeutic is selected from cisplatin (PLATINOL®, Bristol-Myers Squibb); carboplatin (PARAPLATIN®, Bristol-Myers Squibb; also, Teva; Pfizer); oxaliplatin (ELOXITIN® Sanofi-Aventis); nedaplatin (AQUPLA®, Shionogi), picoplatin (Poniard Pharmaceuticals); and satraplatin (JM-216, Agennix).

[0467] In certain embodiments, one or more other therapeutic agent is a taxane compound, which causes disruption of microtubules, which are essential for cell division. In certain embodiments, a taxane compound is selected from paclitaxel (TAXOL®, Bristol-Myers Squibb), docetaxel (TAXOTERE®, Sanofi-Aventis; DOCEFREZ®, Sun Pharmaceutical), albumin-boundpaclitaxel (ABRAXANE®; Abraxis / Celgene), cabazitaxel (JEVTANA®, Sanofi -Aventis), and SID530 (SK Chemicals, Co.) (NCT00931008).

[0468] In certain embodiments, one or more other therapeutic agent is a nucleoside inhibitor, or a therapeutic agent that interferes with normal DNA synthesis, protein synthesis, cell replication, or will otherwise inhibit rapidly proliferating cells.

[0469] In certain embodiments, a nucleoside inhibitor is selected from trabectedin (guanidine alkylating agent, YONDELIS®, Janssen Oncology), mechlorethamine (alkylating agent, VALCHLOR®, Aktelion Pharmaceuticals); vincristine (ONCOVIN®, Eli Lilly; VINCASAR®, Teva Pharmaceuticals; MARQIBO®, Talon Therapeutics); temozolomide (prodrug to alkylating agent 5-(3-methyltriazen-l-yl)-imidazole-4-carboxamide (MTIC) TEMODAR®, Merck); cytarabine injection (ara-C, antimetabolic cytidine analog, Pfizer); lomustine (alkylating agent, CEENU®, Bristol-Myers Squibb; GLEOSTINE®, NextSource Biotechnology); azacitidine (pyrimidine nucleoside analog of cytidine, VIDAZA®, Celgene); omacetaxine mepesuccinate (cephalotaxine ester) (protein synthesis inhibitor, SYNRIBO®; Teva Pharmaceuticals); asparaginase Erwinia chrysanthemi (enzyme for depletion of asparagine, ELSPAR®, Lundbeck; ERWINAZE®, EUSA Pharma); eribulin mesylate (microtubule inhibitor, tubulin-based antimitotic, HALAVEN®, Eisai); cabazitaxel (microtubule inhibitor, tubulin-based antimitotic, JEVTANA®, Sanofi-Aventis); capacetrine (thymidylate synthase inhibitor, XELODA®, Genentech); bendamustine (bifunctional mechlorethamine derivative, believed to form interstrand DNA cross-links, TREANDA®, Cephalon / Teva); ixabepilone (semi-synthetic analog of epothilone B, microtubule inhibitor, tubulin-based antimitotic, IXEMPRA®, Bristol-Myers Squibb); nelarabine (prodrug of deoxyguanosine analog, nucleoside metabolic inhibitor, ARRANON®, Novartis); clorafabine (prodrug of ribonucleotide reductase inhibitor, competitive inhibitor of deoxycytidine, CLOLAR®, Sanofi-Aventis); and trifluridine and tipiracil (thymidine- based nucleoside analog and thymidine phosphorylase inhibitor, LONSURF®, Taiho Oncology).

[0470] In certain embodiments, one or more other therapeutic agent is a kinase inhibitor or VEGF-R antagonist. Approved VEGF inhibitors and kinase inhibitors useful in the present disclosure include: bevacizumab (AVASTIN®, Genentech / Roche) an anti-VEGF monoclonal antibody; ramucirumab (CYRAMZA®, Eli Lilly), an anti-VEGFR-2 antibody and ziv-aflibercept, also known as VEGF Trap (ZALTRAP®; Regeneron / Sanofi). VEGFR inhibitors, such as regorafenib (STIVARGA®, Bayer); vandetanib (CAPRELSA®, AstraZeneca); axitinib(INLYTA®, Pfizer); and lenvatinib (LENVIMA®, Eisai); Raf inhibitors, such as sorafenib (NEXAVAR®, Bayer AG and Onyx); dabrafenib (TAFINLAR®, Novartis); and vemurafenib (ZELBORAF®, Genentech / Roche); MEK inhibitors, such as cobimetanib (COTELLIC®, Exelexis / Genentech / Roche); trametinib (MEKINIST®, Novartis); Bcr-Abl tyrosine kinase inhibitors, such as imatinib (GLEEVEC®, Novartis); nilotinib (TASIGNA®, Novartis); dasatinib (SPRYCEL®, BristolMyersSquibb); bosutinib (BOSULIF®, Pfizer); and ponatinib (INCLUSIG®, Ariad Pharmaceuticals); Her2 and EGFR inhibitors, such as gefitinib (IRESSA®, AstraZeneca); erlotinib (TARCEEVA®, Genentech / Roche / Astellas); lapatinib (TYKERB®, Novartis); afatinib (GILOTRIF®, Boehringer Ingelheim); osimertinib (targeting activated EGFR, TAGRISSO®, AstraZeneca); and brigatinib (ALUNBRIG®, Ariad Pharmaceuticals); c-Met and VEGFR2 inhibitors, such as cabozanitib (COMETRIQ®, Exelexis); and multikinase inhibitors, such as sunitinib (SUTENT®, Pfizer); pazopanib (VOTRIENT®, Novartis); ALK inhibitors, such as crizotinib (XALKORI®, Pfizer); ceritinib (ZYKADIA®, Novartis); and alectinib (ALECENZa®, Genentech / Roche); Bruton’s tyrosine kinase inhibitors, such as ibrutinib (IMBRUVICA®, Pharmacyclics / Janssen); and Flt3 receptor inhibitors, such as midostaurin (R YD APT®, Novartis).

[0471] Other kinase inhibitors and VEGF-R antagonists that are in development and may be used in the present disclosure include tivozanib (Aveo Pharmaecuticals); vatalanib (Bayer / Novartis); lucitanib (Clovis Oncology); dovitinib (TKI258, Novartis); Chiauanib (Chipscreen Biosciences); CEP-11981 (Cephalon); linifanib (Abbott Laboratories); neratinib (HKI-272, Puma Biotechnology); radotinib (SUPECT®, IY5511, Il-Yang Pharmaceuticals, S. Korea); ruxolitinib (JAKAFI®, Incyte Corporation); PTC299 (PTC Therapeutics); CP-547,632 (Pfizer); foretinib (Exelexis, GlaxoSmithKline); quizartinib (Daiichi Sankyo) and motesanib ( Amgen / T akeda) .

[0472] In certain embodiments, the one or more other therapeutic agent is an EGFR inhibitor. As used herein, an “EGFR inhibitor” refers to any inhibitor or blocker or antagonist that binds to and / or inhibits epidermal growth factor receptor (EGFR). In certain embodiments, an EGFR inhibitor is selected from those as described in Ayati et al., “A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy,” Bioorganic Chemistry 2020, 99: 103811, the contents of which are incorporated herein by reference in their entirety. In certain embodiments, an EGFR inhibitor is selected from cetuximab,necitumumab, panitumumab, zalutumumab, nimotuzumab, and matuzumab. In certain embodiments, an EGFR inhibitor is cetuximab. In certain embodiments, an EGFR inhibitor is necitumumab. In certain embodiments, an EGFR inhibitor is panitumumab. In certain embodiments, an EGFR inhibitor is zalutumumab. In certain embodiments, an EGFR inhibitor is nimotuzumab. In certain embodiments, an EGFR inhibitor is matuzumab.

[0473] In certain embodiments, an EGFR inhibitor is selected from osimertinib, gefitinib, erlotinib, lapatinib, neratinib, vandetanib, afatinib, brigatinib, dacomitinib, and icotinib. In certain embodiments, an EGFR inhibitor is osimertinib. In certain embodiments, an EGFR inhibitor is gefitinib. In certain embodiments, an EGFR inhibitor is erlotinib. In certain embodiments, an EGFR inhibitor is lapatinib. In certain embodiments, an EGFR inhibitor is neratinib. In certain embodiments, an EGFR inhibitor is vandetanib. In certain embodiments, an EGFR inhibitor is afatinib. In certain embodiments, an EGFR inhibitor is brigatinib. In certain embodiments, an EGFR inhibitor is dacomitinib. In certain embodiments, an EGFR inhibitor is icotinib.

[0474] In certain embodiments, an EGFR inhibitor is a “1st generation EGFR tyrosine kinase inhibitor” (“1st generation TKI”). A 1st generation TKI refers to reversible EGFR inhibitors, such as gefitinib and erlotinib, which are effective in first-line treatment of, for example, NSCLC harboring EGFR activating mutations, such as deletions in exon 19 and exon 21 L858R mutation.

[0475] In certain embodiments, an EGFR inhibitor is a “2nd generation EGFR tyrosine kinase inhibitor” (“2nd generation TKI”). A 2nd generation TKI refers to covalent irreversible EGFR inhibitors, such as afatinib and dacomitib, which are effective in first-line treatment of NSCLC harboring EGFR activating mutations, such as deletions in exon 19 and exon 21 L858R mutation.

[0476] In certain embodiments, an EGFR inhibitor is a “3rd generation EGFR tyrosine kinase inhibitor” (“3rd generation TKI”). A 3rd generation TKI refers to covalent irreversible EGFR inhibitors, such as osimertinib and lazertinib, which are selective to the EGFR activating mutations, such as deletions in exon 19 and exon 21 L858R, alone or in combination with T790M mutation, and have lower inhibitory activity against wild-type EGFR.

[0477] In certain embodiments, one or more other therapeutic agent is an mTOR inhibitor, which inhibits cell proliferation, angiogenesis and glucose uptake. In certain embodiments, an mTOR inhibitor is everolimus (AFINITOR®, Novartis); temsirolimus (TORISEL®, Pfizer); and sirolimus (RAPAMUNE®, Pfizer).

[0478] In certain embodiments, a one or more other therapeutic agent is a SOS1 (son of sevenless 1) inhibitor. In certain embodiments, a S0S1 inhibitor is selected from BI-3406, BAY-293, MRTX0902, and BI- 1701963. Other exemplary S0S1 inhibitors for use with the compositions, methods, and uses described herein include, but are not limited to, those S0S1 inhibitors described in patent publications WO 2020 / 180768 Al, WO 2021 / 130731A1, WO 2022 / 271679A1, WO 2022 / 266248A1, WO 2022 / 058344A1, and WO 2019 / 122129A1, the contents of each of which are herein incorporated by reference in their entireties.

[0479] In certain embodiments, a one or more other therapeutic agent is a SHP2 (Src homology 2 domain-containing protein tyrosine phosphatase) inhibitor. In certain embodiments, a SHP2 inhibitor is selected from RMC-4550, RMC-4630, BBP-398, SHP836, SHP099, SHP394, BPI-442096, and ETS-001. Other exemplary SHP2 inhibitors for use with the compositions, methods, and uses described herein include, but are not limited to, those SHP2 inhibitors described in patent publications WO 2017 / 211303 Al, WO 2017 / 216706A1, WO 2018 / 013597A1, WO2018 / 057884A1, WO 2018 / 172984A1, WO 2018 / 081091A1, WO 2018 / 136265A1, WO2018 / 136264A1, WO 2019 / 051084A1, WO 2019 / 067843A1, WO 2019 / 075265A1, WO2019 / 118909A1, WO 2019 / 165073A1, WO 2019 / 183367A1, WO 2019 / 183364A1, WO2019 / 233810A1, WO 2020 / 022323A1, WO 2020 / 061103A1, WO 2020 / 063760A1, WO 2020 / 108590A1, WO 2020 / 081848A1, WO 2020 / 156242A1, WO 2020 / 156243 Al, WO 2021 / 033153A1, WO 2021 / 061515 Al, WO 2021 / 074227A1, WO 2021 / 110796A1, WO2021 / 143680A1, WO 2021 / 143823A1, WO 2021 / 218752A1, WO 2021 / 218755A1, WO 2021 / 249449A1, WO 2022 / 017444 Al, WO 2022 / 033430A1, WO 2022 / 089389A1, WO2022 / 089406A1, WO 2022 / 161222A1, WO 2023 / 280283A1, and WO 2023 / 282702A1, the contents of each of which are herein incorporated by reference in their entireties.

[0480] In certain embodiments, one or more other therapeutic agent is a proteasome inhibitor. Approved proteasome inhibitors useful in the present disclosure include bortezomib (VELCADE®, Takeda); carfilzomib (KYPROLIS®, Amgen); and ixazomib (NINLARO®, Takeda).

[0481] In certain embodiments, one or more other therapeutic agent is a growth factor antagonist, such as an antagonist of platelet-derived growth factor (PDGF), or epidermal growth factor (EGF) or its receptor (EGFR). Approved PDGF antagonists which may be used in the present disclosure include olaratumab (LARTRUVO®; Eli Lilly). Approved EGFR antagonistswhich may be used in the present disclosure include cetuximab (ERBITUX®, Eli Lilly); necitumumab (PORTRAZZA®, Eli Lilly), panitumumab (VECTIBIX®, Amgen); and osimertinib (targeting activated EGFR, TAGRISSO®, AstraZeneca).

[0482] In certain embodiments, one or more other therapeutic agent is an aromatase inhibitor. In certain embodiments, an aromatase inhibitor is selected from exemestane (AROMASIN®, Pfizer); anastazole (ARIMIDEX®, AstraZeneca) and letrozole (FEMARA®, Novartis).

[0483] In certain embodiments, one or more other therapeutic agent is an antagonist of the hedgehog pathway. Approved hedgehog pathway inhibitors which may be used in the present disclosure include sonidegib (0D0MZ0®, Sun Pharmaceuticals); and vismodegib (ERIVEDGE®, Genentech), both for treatment of basal cell carcinoma.

[0484] In certain embodiments, one or more other therapeutic agent is a folic acid inhibitor. Approved folic acid inhibitors useful in the present disclosure include pemetrexed (ALIMTA®, Eli Lilly).

[0485] In certain embodiments, one or more other therapeutic agent is a CC chemokine receptor 4 (CCR4) inhibitor. CCR4 inhibitors being studied that may be useful in the present disclosure include mogamulizumab (POTELIGEO®, Kyowa Hakko Kirin, Japan).

[0486] In certain embodiments, one or more other therapeutic agent is an isocitrate dehydrogenase (IDH) inhibitor. IDH inhibitors being studied which may be used in the present disclosure include AG120 (Celgene; NCT02677922); AG221 (Celgene, NCT02677922; NCT02577406); BAY1436032 (Bayer, NCT02746081); IDH305 (Novartis, NCT02987010).

[0487] In certain embodiments, one or more other therapeutic agent is an arginase inhibitor. Arginase inhibitors being studied which may be used in the present disclosure include AEB1102 (pegylated recombinant arginase, Aeglea Biotherapeutics), which is being studied in Phase 1 clinical trials for acute myeloid leukemia and myelodysplastic syndrome (NCT02732184) and solid tumors (NCT02561234); and CB-1158 (Calithera Biosciences).

[0488] In certain embodiments, one or more other therapeutic agent is a glutaminase inhibitor. Glutaminase inhibitors being studied which may be used in the present disclosure include CB-839 (Calithera Biosciences).

[0489] In certain embodiments, one or more other therapeutic agent is an antibody that binds to tumor antigens, that is, proteins expressed on the cell surface of tumor cells. Approved antibodies that bind to tumor antigens which may be used in the present disclosure include rituximab(RITUXAN®, Genentech / Biogenldec); ofatumumab (anti-CD20, ARZERRA®, GlaxoSmithKline); obinutuzumab (anti-CD20, GAZYVA®, Genentech), ibritumomab (anti- CD20 and Yttrium-90, ZEVALIN®, Spectrum Pharmaceuticals); daratumumab (anti-CD38, DARZALEX®, Janssen Biotech), dinutuximab (anti-glycolipid GD2, UNITUXIN®, United Therapeutics); trastuzumab (anti-HER2, HERCEPTIN®, Genentech); ado-trastuzumab emtansine (anti-HER2, fused to emtansine, KADCYLA®, Genentech); and pertuzumab (anti-HER2, PERJETA®, Genentech); and brentuximab vedotin (anti-CD30-drug conjugate, ADCETRIS®, Seattle Genetics).

[0490] In certain embodiments, one or more other therapeutic agent is a topoisomerase inhibitor. Approved topoisomerase inhibitors useful in the present disclosure include irinotecan (ONIVYDE®, Merrimack Pharmaceuticals); topotecan (HYCAMTIN®, GlaxoSmithKline). Topoisomerase inhibitors being studied which may be used in the present disclosure include pixantrone (PIXUVRI®, CTI Biopharma).

[0491] In certain embodiments, one or more other therapeutic agent is an inhibitor of anti- apoptotic proteins, such as BCL-2. Approved anti-apoptotics which may be used in the present disclosure include venetoclax (VENCLEXTA®, AbbVie / Genentech); and blinatumomab (BLINCYTO®, Amgen). Other therapeutic agents targeting apoptotic proteins which have undergone clinical testing and may be used in the present disclosure include navitoclax (ABT-263, Abbott), a BCL-2 inhibitor (NCT02079740).

[0492] In certain embodiments, one or more other therapeutic agent is an androgen receptor inhibitor. Approved androgen receptor inhibitors useful in the present disclosure include enzalutamide (XTANDI®, Astellas / Medivation); approved inhibitors of androgen synthesis include abiraterone (ZYTIGA®, Centocor / Ortho); approved antagonist of gonadotropin-releasing hormone (GnRH) receptor (degaralix, FIRMAGON®, Ferring Pharmaceuticals).

[0493] In certain embodiments, one or more other therapeutic agent is a selective estrogen receptor modulator (SERM), which interferes with the synthesis or activity of estrogens. Approved SERMs useful in the present disclosure include raloxifene (EVISTA®, Eli Lilly).

[0494] In certain embodiments, one or more other therapeutic agent is an inhibitor of bone resorption. An approved therapeutic which inhibits bone resorption is Denosumab (XGEVA®, Amgen), an antibody that binds to RANKL, prevents binding to its receptor RANK, found on the surface of osteoclasts, their precursors, and osteoclast-like giant cells, which mediates bonepathology in solid tumors with osseous metastases. Other approved therapeutics that inhibit bone resorption include bisphosphonates, such as zoledronic acid (ZOMETA®, Novartis).

[0495] In certain embodiments, one or more other therapeutic agent is an inhibitor of interaction between the two primary p53 suppressor proteins, MDMX and MDM2. Inhibitors of p53 suppression proteins being studied which may be used in the present disclosure include ALRN- 6924 (Aileron), a stapled peptide that equipotently binds to and disrupts the interaction of MDMX and MDM2 with p53. ALRN-6924 is currently being evaluated in clinical trials for the treatment of AML, advanced myelodysplastic syndrome (MDS) and peripheral T-cell lymphoma (PTCL) (NCT02909972; NCT02264613).

[0496] In certain embodiments, one or more other therapeutic agent is an inhibitor of transforming growth factor-beta (TGF-beta or TGF-0). Inhibitors of TGF-beta proteins being studied which may be used in the present disclosure include NIS793 (Novartis), an anti-TGF-beta antibody being tested in the clinic for treatment of various cancers, including breast, lung, hepatocellular, colorectal, pancreatic, prostate and renal cancer (NCT 02947165). In certain embodiments, the inhibitor of TGF-beta proteins is fresolimumab (GC1008; Sanofi-Genzyme), which is being studied for melanoma (NCT00923169); renal cell carcinoma (NCT00356460); and non-small cell lung cancer (NCT02581787). Additionally, in certain embodiments, the additional therapeutic agent is a TGF-beta trap, such as described in Connolly et al. (2012) IntT J. Biological Sciences 8:964-978. One therapeutic compound currently in clinical trials for treatment of solid tumors is M7824 (Merck KgaA - formerly MSB0011459X), which is a bispecific, anti-PD- L1 / TGF-0 trap compound (NCT02699515); and (NCT02517398). M7824 is comprised of a fully human IgGl antibody against PD-L1 fused to the extracellular domain of human TGF-beta receptor II, which functions as a TGF-0 “trap.”

[0497] In certain embodiments, one or more other therapeutic agent is selected from glembatumumab vedotin-monomethyl auristatin E (MMAE) (Celldex), an anti-glycoprotein NMB (gpNMB) antibody (CR011) linked to the cytotoxic MMAE. gpNMB is a protein overexpressed by multiple tumor types associated with cancer cells’ ability to metastasize.

[0498] In certain embodiments, one or more other therapeutic agents is an antiproliferative compound. Such antiproliferative compounds include, but are not limited to aromatase inhibitors; antiestrogens; topoisomerase I inhibitors; topoisomerase II inhibitors; microtubule active compounds; alkylating compounds; histone deacetylase inhibitors; compounds which induce celldifferentiation processes; cyclooxygenase inhibitors; MMP inhibitors; mTOR inhibitors; antineoplastic antimetabolites; platin compounds; compounds targeting / decreasing a protein or lipid kinase activity and further anti-angiogenic compounds; compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase; gonadorelin agonists; anti -androgens; methionine aminopeptidase inhibitors; matrix metalloproteinase inhibitors; bisphosphonates; biological response modifiers; antiproliferative antibodies; heparanase inhibitors; inhibitors of Ras oncogenic isoforms; telomerase inhibitors; proteasome inhibitors; compounds used in the treatment of hematologic malignancies; compounds which target, decrease or inhibit the activity of Flt-3; Hsp90 inhibitors such as 17-AAG (17-allylaminogeldanamycin, NSC330507), 17- DMAG (17-dimethylaminoethylamino-17-demethoxy-geldanamycin, NSC707545), IPI-504, CNF 1010, CNF2024, CNF 1010 from Conforma Therapeutics; temozolomide (TEMODAL®); kinesin spindle protein inhibitors, such as SB715992 or SB743921 from GlaxoSmithKline, or pentamidine / chlorpromazine from CombinatoRx; MEK inhibitors such as ARRY142886 from Array BioPharma, aZd6244 from AstraZeneca, PD 181461 from Pfizer and leucovorin.

[0499] The term “aromatase inhibitor” as used herein relates to a compound which inhibits estrogen production, for instance, the conversion of the substrates androstenedione and testosterone to estrone and estradiol, respectively. The term includes, but is not limited to steroids, especially atamestane, exemestane and formestane and, in particular, non-steroids, especially aminoglutethimide, roglethimide, pyridoglutethimide, trilostane, testolactone, ketokonazole, vorozole, fadrozole, anastrozole and letrozole. Exemestane is marketed under the trade name AROMASIN™. Formestane is marketed under the trade name LENTARON™. Fadrozole is marketed under the trade name AFEMA™. Anastrozole is marketed under the trade name ARIMIDEX™. Letrozole is marketed under the trade names FEMARA™ or FEMAr™. Aminoglutethimide is marketed under the trade name ORIMETEN™. A combination of the disclosure comprising a chemotherapeutic agent which is an aromatase inhibitor is particularly useful for the treatment of hormone receptor positive tumors, such as breast tumors.

[0500] The term "antiestrogen" as used herein relates to a compound which antagonizes the effect of estrogens at the estrogen receptor level. The term includes, but is not limited to tamoxifen, fulvestrant, raloxifene and raloxifene hydrochloride. Tamoxifen is marketed under the trade name NOLVADEX™. Raloxifene hydrochloride is marketed under the trade name EVISTA™. Fulvestrant can be administered under the trade name FASLODEX™. Fulvestrant can beadministered under the trade name Faslodex™. A combination of the disclosure comprising a chemotherapeutic agent which is an anti estrogen is particularly useful for the treatment of estrogen receptor positive tumors, such as breast tumors.

[0501] The term "anti-androgen" as used herein relates to any substance which is capable of inhibiting the biological effects of androgenic hormones and includes, but is not limited to, bicalutamide (CASODEX™). The term "gonadorelin agonist" as used herein includes, but is not limited to abarelix, goserelin, and goserelin acetate. Goserelin can be administered under the trade name ZOLADEX™.

[0502] The term "topoisomerase I inhibitor" as used herein includes, but is not limited to topotecan, gimatecan, irinotecan, camptothecian and its analogues, 9-nitrocamptothecin and the macromolecular camptothecin conjugate PNU-166148. Irinotecan can be administered, e.g., in the form as it is marketed, e.g., under the trademark CAMPTOSAR™. Topotecan is marketed under the trade name HYCAMPTIN™.

[0503] The term "topoisomerase II inhibitor" as used herein includes, but is not limited to the anthracyclines such as doxorubicin (including liposomal formulation, such as CAELYX™), daunorubicin, epirubicin, idarubicin and nemorubicin, the anthraquinones mitoxantrone and losoxantrone, and the podophillotoxines etoposide and teniposide. Etoposide is marketed under the trade name ETOPOPHOS™. Teniposide is marketed under the trade name VM 26-Bristol Doxorubicin is marketed under the trade name ACRIBLASTIN™ or ADRIAMYCIN™. Epirubicin is marketed under the trade name FARMORUBICIN™. Idarubicin is marketed, under the trade name ZAVEDOS™. Mitoxantrone is marketed under the trade name NOVANTRON™.

[0504] The term "microtubule active agent" relates to microtubule stabilizing, microtubule destabilizing compounds and microtublin polymerization inhibitors including, but not limited to taxanes, such as paclitaxel and docetaxel; vinca alkaloids, such as vinblastine or vinblastine sulfate, vincristine or vincristine sulfate, and vinorelbine; discodermolides; cochicine and epothilones and derivatives thereof. Paclitaxel is marketed under the trade name TAXOL™. Docetaxel is marketed under the trade name TAXOTERE™. Vinblastine sulfate is marketed under the trade name VINBLASTIN R.P™. Vincristine sulfate is marketed under the trade name FARMISTIN™.

[0505] The term "alkylating agent" as used herein includes, but is not limited to, cyclophosphamide, ifosfamide, melphalan or nitrosourea (BCNU or Gliadel). Cyclophosphamideis marketed under the trade name CYCLOSTIN™. Tfosfamide is marketed under the trade name HOLOXAN™.

[0506] The term "histone deacetylase inhibitors" or "HDAC inhibitors" relates to compounds which inhibit the histone deacetylase and which possess antiproliferative activity. This includes, but is not limited to, suberoylanilide hydroxamic acid (SAHA).

[0507] The term "anti neoplastic antimetabolite" includes, but is not limited to, 5 -fluorouracil or 5-FU, capecitabine, gemcitabine, DNA demethylating compounds, such as 5-azacytidine and decitabine, methotrexate and edatrexate, and folic acid antagonists such as pemetrexed. Capecitabine is marketed under the trade name XELODA™. Gemcitabine is marketed under the trade name GEMZAR™.

[0508] The term "platin compound" as used herein includes, but is not limited to, carboplatin, cis-platin, cisplatinum and oxaliplatin. Carboplatin can be administered, e.g., in the form as it is marketed, e.g., under the trademark CARBOPLAT™. Oxaliplatin can be administered, e.g., in the form as it is marketed, e.g. under the trademark ELOXATIN™.

[0509] The term "compounds targeting / decreasing a protein or lipid kinase activity; or a protein or lipid phosphatase activity; or further anti-angiogenic compounds" as used herein includes, but is not limited to, protein tyrosine kinase and / or serine and / or threonine kinase inhibitors or lipid kinase inhibitors, such as a) compounds targeting, decreasing or inhibiting the activity of the platelet-derived growth factor-receptors (PDGFR), such as compounds which target, decrease or inhibit the activity of PDGFR, especially compounds which inhibit the PDGF receptor, such as an N-phenyl-2-pyrimidine-amine derivative, such as imatinib, SU101, SU6668 and GFB-111; b) compounds targeting, decreasing or inhibiting the activity of the fibroblast growth factor-receptors (FGFR); c) compounds targeting, decreasing or inhibiting the activity of the insulin-like growth factor receptor I (IGF-IR), such as compounds which target, decrease or inhibit the activity of IGF - IR, especially compounds which inhibit the kinase activity of IGF-I receptor, or antibodies that target the extracellular domain of IGF-I receptor or its growth factors; d) compounds targeting, decreasing or inhibiting the activity of the Trk receptor tyrosine kinase family, or ephrin B4 inhibitors; e) compounds targeting, decreasing or inhibiting the activity of the Axl receptor tyrosine kinase family; f) compounds targeting, decreasing or inhibiting the activity of the Ret receptor tyrosine kinase; g) compounds targeting, decreasing or inhibiting the activity of the Kit / SCFR receptor tyrosine kinase, such as imatinib; h) compounds targeting, decreasing orinhibiting the activity of the C-kit receptor tyrosine kinases, which are part of the PDGFR family, such as compounds which target, decrease or inhibit the activity of the c-Kit receptor tyrosine kinase family, especially compounds which inhibit the c-Kit receptor, such as imatinib; i) compounds targeting, decreasing or inhibiting the activity of members of the c-Abl family, their gene-fusion products (e.g., BCR-Abl kinase) and mutants, such as compounds which target decrease or inhibit the activity of c-Abl family members and their gene fusion products, such as an N-phenyl-2-pyrimidine-amine derivative, such as imatinib or nilotinib (AMN107); PD180970; AG957; NSC 680410; PD173955 from ParkeDavis; or dasatinib (BMS-354825); j) compounds targeting, decreasing or inhibiting the activity of members of the protein kinase C (PKC) and Raf family of serine / threonine kinases, members of the MEK, SRC, JAK / pan-JAK, FAK, PDK1, PKB / Akt, Ras / MAPK, PI3K, SYK, TYK2, BTK and TEC family, and / or members of the cyclin- dependent kinase family (CDK) including staurosporine derivatives, such as midostaurin; examples of further compounds include UCN-01, safingol, BAY 43-9006, Bryostatin 1, Perifosine; llmofosine; RO 318220 and RO 320432; GO 6976; Isis 3521; LY333531 / LY379196; isochinoline compounds; FTIs; PD184352 or QAN697 (a P13K inhibitor) or AT7519 (CDK inhibitor); k) compounds targeting, decreasing or inhibiting the activity of protein-tyrosine kinase inhibitors, such as compounds which target, decrease or inhibit the activity of protein-tyrosine kinase inhibitors include imatinib mesylate (GLEEVEC™) or tyrphostin such as Tyrphostin A23 / RG-50810; AG 99; Tyrphostin AG 213; Tyrphostin AG 1748; Tyrphostin AG 490; Tyrphostin B44; Tyrphostin B44 (+) enantiomer; Tyrphostin AG 555; AG 494; Tyrphostin AG 556, AG957 and adaphostin (4-{[(2,5- dihydroxyphenyl)methyl]amino}-benzoic acid adamantyl ester; NSC 680410, adaphostin); 1) compounds targeting, decreasing or inhibiting the activity of the epidermal growth factor family of receptor tyrosine kinases (EGFRi ErbB2, ErbB3, ErbB4 as homo- or heterodimers) and their mutants, such as compounds which target, decrease or inhibit the activity of the epidermal growth factor receptor family are especially compounds, proteins or antibodies which inhibit members of the EGF receptor tyrosine kinase family, such as EGF receptor, ErbB2, ErbB3 and ErbB4 or bind to EGF or EGF related ligands, CP 358774, ZD 1839, ZM 105180; trastuzumab (HERCEPTIN™), cetuximab (ERBITUX™), Iressa, Tarceva, OSI-774, Cl-1033, EKB-569, GW-2016, El.l, E2.4, E2.5, E6.2, E6.4, E2.l l, E6.3 or E7.6.3, and 7H- pyrrolo-[2,3-d]pyrimidine derivatives; m) compounds targeting, decreasing or inhibiting the activity of the c-Met receptor, such as compounds which target, decrease or inhibit the activity ofc-Met, especially compounds which inhibit the kinase activity of c-Met receptor, or antibodies that target the extracellular domain of c-Met or bind to HGF, n) compounds targeting, decreasing or inhibiting the kinase activity of one or more JAK family members (JAK1 / JAK2 / JAK3 / TYK2 and / or pan-JAK), including but not limited to PRT-062070, SB-1578, baricitinib, pacritinib, momelotinib, VX-509, AZD-1480, TG-101348, tofacitinib, and ruxolitinib; o) compounds targeting, decreasing or inhibiting the kinase activity of PI3 kinase (PI3K) including but not limited to ATU-027, SF-1126, DS-7423, PBI-05204, GSK-2126458, ZSTK-474, buparlisib, pictrelisib, PF-4691502, BYL-719, dactolisib, XL-147, XL-765, and idelalisib; and; and q) compounds targeting, decreasing or inhibiting the signaling effects of hedgehog protein (Hh) or smoothened receptor (SMO) pathways, including but not limited to cyclopamine, vismodegib, itraconazole, erismodegib, and IPI-926 (saridegib).

[0510] The term “PI3K inhibitor” as used herein includes, but is not limited to compounds having inhibitory activity against one or more enzymes in the phosphatidylinositol-3 -kinase family, including, but not limited to PI3Kα, PI3Kγ, PI3K5, PI3Kβ, PI3K-C2α, PI3K-C2β, PI3K- C2γ, Vps34, p110-α, p110-β, p110-γ, pl 10-δ, p85-α, p85-β, p55-γ, p150, p101, and p87. Examples of PI3K inhibitors useful in this disclosure include but are not limited to ATU-027, SF-1126, DS- 7423, PBI-05204, GSK-2126458, ZSTK-474, buparlisib, pictrelisib, PF-4691502, BYL-719, dactolisib, XL-147, XL-765, and idelalisib.

[0511] The term “Bcl-2 inhibitor” as used herein includes, but is not limited to compounds having inhibitory activity against B-cell lymphoma 2 protein (Bcl-2), including but not limited to ABT-199, ABT-731, ABT-737, apogossypol, Ascenta’s pan-Bcl-2 inhibitors, curcumin (and analogs thereof), dual Bcl-2 / Bcl-xL inhibitors (Infinity Pharmaceuticals / Novartis Pharmaceuticals), Genasense (G3139), HA14-1 (and analogs thereof; see WO 2008 / 118802), navitoclax (and analogs thereof, see US Patent 7,390,799), NH-1 (Shenayng Pharmaceutical University), obatoclax (and analogs thereof, see WO 2004 / 106328), S-001 (Gloria Pharmaceuticals), TW series compounds (Univ, of Michigan), and venetoclax. In certain embodiments the Bcl-2 inhibitor is a small molecule therapeutic. In certain embodiments the Bcl- 2 inhibitor is a peptidomimetic.

[0512] The term “BTK inhibitor” as used herein includes, but is not limited to compounds having inhibitory activity against Bruton’s Tyrosine Kinase (BTK), including, but not limited to AVL-292 and ibrutinib.

[0513] The term “SYK inhibitor” as used herein includes, but is not limited to compounds having inhibitory activity against spleen tyrosine kinase (SYK), including but not limited to PRT- 062070, R-343, R-333, Excellair, PRT-062607, and fostamatinib.

[0514] Further examples of BTK inhibitory compounds, and conditions treatable by such compounds in combination with compounds of this disclosure can be found in WO 2008 / 039218 and WO 2011 / 090760, the entirety of which are incorporated herein by reference.

[0515] Further examples of SYK inhibitory compounds, and conditions treatable by such compounds in combination with compounds of this disclosure can be found in WO 2003 / 063794, WO 2005 / 007623, and WO 2006 / 078846, the entirety of which are incorporated herein by reference.

[0516] Further examples of PI3K inhibitory compounds, and conditions treatable by such compounds in combination with compounds of this disclosure can be found in WO 2004 / 019973, WO 2004 / 089925, WO 2007 / 016176, US Patent 8,138,347, WO 2002 / 088112, WO 2007 / 084786, WO 2007 / 129161, WO 2006 / 122806, WO 2005 / 113554, and WO 2007 / 044729 the entirety of which are incorporated herein by reference.

[0517] Further examples of JAK inhibitory compounds, and conditions treatable by such compounds in combination with compounds of this disclosure can be found in WO 2009 / 114512, WO 2008 / 109943, WO 2007 / 053452, WO 2000 / 142246, and WO 2007 / 070514, the entirety of which are incorporated herein by reference.

[0518] Further anti -angiogenic compounds include compounds having another mechanism for their activity, e.g. , unrelated to protein or lipid kinase inhibition e.g. , thalidomide (THALOMID™) and TNP-470.

[0519] Examples of proteasome inhibitors useful for use in combination with compounds of the disclosure include, but are not limited to bortezomib, disulfiram, epigallocatechin-3-gallate (EGCG), salinosporamide A, carfilzomib, ONX-0912, CEP-18770, and MLN9708.

[0520] Compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase are e.g., inhibitors of phosphatase 1, phosphatase 2A, or CDC25, such as okadaic acid or a derivative thereof.

[0521] Compounds which induce cell differentiation processes include, but are not limited to, retinoic acid, α- γ- or 8- tocopherol or α- γ- or 8-tocotrienol.

[0522] The term cyclooxygenase inhibitor as used herein includes, but is not limited to, Cox-2 inhibitors, 5-alkyl substituted 2-arylaminophenylacetic acid and derivatives, such as celecoxib (CELEBREX™), rofecoxib (VIOXX™), etoricoxib, valdecoxib or a 5-alkyl-2- aryl...

Claims

Claims:

1. A compound represented by Formula (I):or a pharmaceutically acceptable salt thereof; wherein:R1is naphthyl; an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl or oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or phenyl; each of which is substituted with m occurrences of R5;R2is a 6-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; phenyl; or C1-6 aliphatic; each of which is substituted with n occurrences of R6; or R2is - N(R8)2or -OR8;R3represents independently for each occurrence hydrogen, halo, or C1-4 alkyl;R5represents independently for each occurrence a 3-6 membered saturated or partially unsaturated heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, C2-6 alkynyl, C2-6 alkenyl, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, hydroxyl, C1-6 alkoxyl, C1-6 haloalkoxyl, halo, -N(R8)2, cyano, - (Co-6 alkylene)-C(O)N(R9)2, -OC(O)-(C1-6 aliphatic substituted with 0 or 1 -N(R9)2), -OC(O)-(3-6membered heterocycle substituted with 0, 1, or 2 C1-6 alkyl), -S(O)2N(R9)2, -N(R8)C(O)-(CI-6 alkyl), or -N(R8)S(O)2-(CI-6 alkyl); wherein said C2-6 alkynyl is substituted with 0 or 1 phenyl or 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and wherein said 5-6 membered heteroaryl is substituted with 0, 1, or 2 C1-6 alkyl;R6and R7each represent independently for each occurrence halo, hydroxyl, C1-6 alkoxyl, C1-6 haloalkoxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, -(C1-6 alkylene)-C1-6 alkoxyl, -(Co- 6 alkylene)-(C3-6 cycloalkyl substituted with 0 or 1 -OR8), -(C0-4 alkylene)-cyano, -(C0-4 alkylene)-S(O)2-(halo), -(C0-4 alkylene)-S(O)2-(C1-6alkyl), -C(O)OR8, -C(O)R8, -C(O)N(R9)2, optionally substituted 3-6 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or -N(R9)2;R8and R9each represent independently for each occurrence hydrogen, optionally substituted C1-6 alkyl, optionally substituted C3-5 cycloalkyl, optionally substituted 3-6 membered saturated or partially unsaturated heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, aryl, -C(O)H, or -C(O)(C1-4 alkyl); or two occurrences of R9attached to the same nitrogen atom are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring;A1is one of the following: a. a 3-8 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 6-11 membered saturated or partially unsaturated polycyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein each heterocyclyl is substituted with (i) p occurrences of R7, and (ii) 0, 1, or 2 oxo; and wherein said monocyclic heterocyclyl is substituted with 0 or 1 occurrence of -(Co-4 alkylene)-(5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur) or - (C0-4 alkylene)-phenyl, each of which is optionally substituted; b. C3-10 cycloaliphatic, phenyl, indanyl, a 5- or 6-membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-, 9-, or 10-membered bicyclic heteroaryl having 1, 2, 3, or 4heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with p occurrences of R7; and wherein said monocyclic heteroaryl is substituted with 0 or 1 occurrence of -(Co-4 alkylene)-(5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur) or -(Co-4 alkylene)-phenyl, each of which is optionally substituted; c. -CN, -N(R8)2, or hydroxyl; orL1, L2, and L3are independently a covalent bond or a C1-4 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -O-, -N(R9)-, -C(O)-, optionally substituted C3-5 cycloalkylene, or a 3-6 membered saturated monocyclic heterocyclyl having 1 heteroatom selected from nitrogen, oxygen, and sulfur;X1, X2, X3, X4, and X5each represent independently N or CR3;Y1and Y2represent independently a C1-3 bivalent saturated or unsaturated, straight hydrocarbon chain which is substituted with q occurrences of R7; and m, n, p, and q are each independently 0, 1, 2, 3, or 4.

2. The compound of claim 1, wherein the compound is a compound of Formula (I).

3. The compound of claim 1 or 2, wherein L3is a covalent bond.

4. The compound of any one of claims 1 to 3, wherein X1and X2each represent independently N or CH.

5. A compound represented by Formula (1-1):or a pharmaceutically acceptable salt thereof; wherein:R1is naphthyl; an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or phenyl; each of which is substituted with m occurrences of R5;R2is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; phenyl; or C1-6 aliphatic; each of which is substituted with n occurrences of R6;R3represents independently for each occurrence hydrogen, halo, or C1-4 alkyl;R5represents independently for each occurrence 3-6 membered heterocycle, C2-6 alkynyl, C2-6 alkenyl, C1-6 alkyl, hydroxyl, C1-6 alkoxyl, halo, amine, or cyano; wherein said C2-6 alkynyl is substituted with 0 or 1 phenyl or 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;R6and R7each represent independently for each occurrence halo, hydroxyl, C1-6 alkoxyl, C1-6 haloalkoxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, -(C1-6 alkylene)-C1-6 alkoxyl, -(Co- 6 alkylene)-C3-6 cycloalkyl, -(C0-4 alkylene)-cyano, -C(O)OR8, -C(O)N(R9)2, 3-6 memberedsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or -N(R9)2;R8and R9each represent independently for each occurrence hydrogen, optionally substituted C1-6 alkyl, optionally substituted C3-5 cycloalkyl, optionally substituted C3-6 heterocyclyl, aryl, -C(O)H, or -C(O)(C1-4 alkyl); or two occurrences of R9attached to the same nitrogen atom are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring;A1is one of the following: a. a 3-8 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 6-11 membered saturated or partially unsaturated polycyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein each heterocyclyl is substituted with (i) p occurrences of R7, and (ii) 0, 1, or 2 oxo; and wherein said monocyclic heterocyclyl is substituted with 0 or 1 occurrence of -(C0-4 alkylene)-(5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), a 4-6 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms, or - (C0-4 alkylene)-phenyl, each of which is optionally substituted; b. C3-10 cycloaliphatic, phenyl, indanyl, a 5- or 6-membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-, 9-, or 10-membered bicyclic heteroaryl having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with p occurrences of R7; c. -CN, -N(R8)2, or hydroxyl; orL1and L2are independently a covalent bond or a C1-4 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain areoptionally and independently replaced by -O-, -N(R9)-, -C(O)-, or optionally substituted C3-5 cycloalkylene;X1and X2each represent independently N or CH;X3, X4, and X5each represent independently N or CR3;Y1and Y2represent independently a C1-3 bivalent saturated or unsaturated, straight hydrocarbon chain which is substituted with q occurrences of R7; and m, n, p, and q are each independently 0, 1, 2, 3, or 4.

6. The compound of claim 5, wherein the compound is a compound of Formula (1-1).

7. The compound of any one of claims 1 to 6, wherein X1, X2, X3, X4, and X5are independently N or CH.

8. The compound of claim 1 or 5, wherein the compound has Formula la:or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 or 5, wherein the compound has Formula lb, Ic, or Id:or a pharmaceutically acceptable salt thereof.

10. The compound of any one of claims 1 to 9, wherein R1is naphthyl substituted with m occurrences of R5.

11. The compound of any one of claims 1 to 9, wherein12. The compound of any one of claims 1 to 9, wherein R1is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with m occurrences of R5.

13. The compound of any one of claims 1 to 9, wherein R1is an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with m occurrences of R5.

14. The compound of any one of claims 1 to 13, wherein R5represents independently for each occurrence -C=CH, methyl, hydroxyl, fluoro, or chloro.

15. The compound of claim 1 or 5, wherein the compound has Formula le:or a pharmaceutically acceptable salt thereof.

16. The compound of claim 1 or 5, wherein the compound has Formula If, Ig, or Ih:or a pharmaceutically acceptable salt thereof.

17. The compound of any one of claims 1 to 16, wherein R2is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R6.

18. The compound of any one of claims 1 to 16, wherein R2is substituted with n occurrences of R6.

19. The compound of any one of claims 1 to 16, wherein R2is20. The compound of any one of claims 1 to 16, wherein R2is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R6.

21. The compound of any one of claims 1 to 16, wherein R2is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with n occurrences of R6.

22. The compound of any one of claims 1 to 18, 20, or 21, wherein R6represents independently for each occurrence halo, C1-6 alkyl, or C1-6 haloalkyl.

23. The compound of any one of claims 1 to 22, wherein L2is -O-CH2-, -O-(CH2)2-, -N(R9)- CH2-, or -N(R9)-(CH2)2-, wherein the terminal carbon atom of L2is attached to R2.

24. The compound of any one of claims 1 to 22, wherein L2is -O-CH2-, wherein the terminal carbon atom of L2is attached to R2.

25. The compound of any one of claims 1 to 22, wherein L isor wherein the terminal carbon atom of L2is attached to R2.

26. The compound of any one of claims 1 to 25, wherein R3represents independently for each occurrence hydrogen or fluoro.

27. The compound of any one of claims 1 to 25, wherein R3is hydrogen.

28. The compound of any one of claims 1 to 25, wherein R3is fluoro.

29. The compound of any one of claims 1 to 28, wherein L1is a covalent bond.

30. The compound of any one of claims 1 to 28, wherein L1is -N(R9)-.

31. The compound of any one of claims 1 to 28, wherein L1is -N(H or C1-6 alkyl)-(Co-3 alkylene)-, wherein the C0-3 alkylene of L1is attached to A1.

32. The compound of claim 1 or 5, wherein the compound has Formula li:or a pharmaceutically acceptable salt thereof.

33. The compound of claim 1 or 5, wherein the compound has Formula Ij, Ik, or II:or a pharmaceutically acceptable salt thereof.

34. The compound of any one of claims 1 to 33, wherein A1is a 3-8 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with (i) p occurrences of R7, and (ii) 0, 1, or 2 oxo.

35. The compound of any one of claims 1 to 33, wherein A1is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with p occurrences of R7.

36. The compound of any one of claims 1 to 33, wherein A1is a 6-11 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with (i) p occurrences of R7, and (ii) 0, 1, or 2 oxo.

37. The compound of any one of claims 1 to 33, wherein A1is C3-10 cycloaliphatic, phenyl, or indanyl, each of which is substituted with p occurrences of R7.

38. The compound of any one of claims 1 to 33, wherein A1is phenyl substituted with p occurrences of R7.

39. The compound of any one of claims 1 to 33, wherein A1is a 5- or 6-membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with p occurrences of R7.

40. The compound of any one of claims 1 to 33, wherein A1is an 8-, 9-, or 10-membered bicyclic heteroaryl having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with p occurrences of R7.

41. The compound of any one of claims 1 to 33, wherein A1is a 4-5 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen; wherein said heterocyclyl is substituted with p occurrences of R7.

42. The compound of any one of claims 1 to 33, wherein A1is azetidinyl, pyrrolidinyl, or phenyl, each of which is substituted with p occurrences of R7and 0 or 1 occurrence of -(C0-4 alkylene)-(5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), a 4-6 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms, or -(Co-4 alkylene)-phenyl, each of which is optionally substituted.

43. The compound of any one of claims 1 to 33, wherein A1is44. The compound of any one of claims 1 to 33, wherein A1is -CN, -N(R8)2, or hydroxyl.

45. The compound of any one of claims 1 to 28, wherein -L'-A1is selected from the46. The compound of any one of claims 1 to 28, wherein -L1-A1is selected from the following:

47. The compound of any one of claims 1 to 33, wherein A1is selected from the following:

48. The compound of any one of claims 1 to 43, wherein R7represents independently for each occurrence halo, hydroxyl, C1-6 alkyl, C1-6 hydroxyalkyl, or oxiranyl.

49. The compound of any one of claims 1 to 44, wherein R8and R9each represent independently for each occurrence hydrogen, C1-6 alkyl, or C3-5 cycloalkyl.

50. The compound of any one of claims 1 to 44, 48, or 49, wherein p is 0, 1, or 2.

51. The compound of any one of claims 1 to 44, 48, or 49, wherein p is 1 or 2.

52. The compound of any one of claims 1 to 4, wherein the compound has Formula Im:or a pharmaceutically acceptable salt thereof; wherein:R1is naphthyl substituted with m occurrences of R5;R2is -N(R8)2, or a 3-7 membered saturated monocyclic heterocyclylhaving 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;R3is fluoro or hydrogen;R5represents independently for each occurrence -C≡CH, methyl, hydroxyl, fluoro, or chloro;R7represents independently for each occurrence halo, hydroxyl, C1-6 alkyl, C1-6 hydroxyalkyl, -S(O)2-(halo), or oxiranyl;R8represents independently for each occurrence hydrogen, C1-6 alkyl, or C3-5 cycloalkyl;L1is a covalent bond or -N(H or C1-6 alkyl)-(Co-3 alkylene)-, wherein the C0-3 alkylene of L1is attached to A1; wherein the terminal carbon atomof L2is attached to R2;m is 0, 1, 2, 3, or 4; and p is 0, 1, or 2.

53. The compound of claim 52, wherein the compound is a compound of Formula Im.

54. The compound of claim 52 or 53, wherein55. The compound of any one of claims 52 to 54, wherein L is orwherein the terminal carbon atom of L2is attached to R2.

56. The compound of any one of claims 52 to 55, wherein57. The compound of any one of claims 52 to 55, wherein R2is -N(R8)2.

58. The compound of any one of claims 52 to 57, wherein R3is fluoro.

59. The compound of any one of claims 52 to 58, wherein -L1-A1is60. The compound of any one of claims 52 to 58, wherein -L1-A1is -N(H or C1-6 alkyl)-(Co-3 alkylene)-phenyl, wherein the phenyl is substituted with 1 or 2 occurrences of R7.

61. The compound of any one of claims 52 to 60, wherein R7is methyl.

62. The compound of any one of claims 52 to 60, wherein at least one occurrence of R7is - S(O)2-(halo) or oxiranyl.

63. A compound in Table 1 herein, or a pharmaceutically acceptable salt thereof.

64. The compound of claim 63, wherein the compound is selected from I-1 through 1-110, or a pharmaceutically acceptable salt thereof.

65. The compound of claim 63, wherein the compound is selected from I-1 through 1-88, or a pharmaceutically acceptable salt thereof.

66. A pharmaceutical composition comprising a compound of any one of claims 1 to 65 and a pharmaceutically acceptable carrier.

67. A method of treating a disorder mediated by K-Ras, comprising administering a therapeutically effective amount of a compound of any one of claims 1 to 65, or a pharmaceutical composition of claim 66, to a subject in need thereof to treat the disorder.

68. The method of claim 67, wherein the disorder is cancer.

69. The method of claim 68, wherein the cancer is lung cancer, pancreatic cancer, colorectal cancer, breast cancer, cervical cancer, prostate cancer, gastric cancer, skin cancer, liver cancer, bile duct cancer, or nervous system cancer.

70. The method of claim 68, wherein the cancer is non-small cell lung cancer (NSCLC) or pancreatic cancer.

71. The method of any one of claims 67 to 70, wherein the subject is a human.

72. A method of inhibiting K-Ras activity, comprising contacting K-Ras with an effective amount of a compound of any one of claims 1 to 65, or a pharmaceutical composition of claim 66, to inhibit K-Ras activity.

Citation Information

Patent Citations

  • Aza-naphthalene derivative, synthesis method and electronic device thereof

    CN111533736A

  • Therapeutic compounds and related methods of use

    EP3056207A1

  • Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof

    US20130109697A1

  • Quinazoline derivatives as medicaments

    US6476031B1

  • Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof

    US8022077B2

Cited By

  • KRAS G12D modulating compounds

    US12448400B2

  • KRAS inhibitors

    US12624033B2

  • Ras inhibitors

    WO2025240847A1

  • Methods of treating a ras protein-related disease or disorder

    WO2025255438A1

  • Therapeutic compositions and methods for managing treatment-related effects

    WO2025265060A1